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AB trial comparing treatment A and treatment B - here a direct
comparison
AC trial comparing treatment A and treatment C - here an indirect
comparison
AgD aggregated data
AIS acute ischemic stroke
AML acute myeloid leukemia
ASPECTS Alberta Stroke Program Early CT score
BFGS Broyden-Fletcher-Goldfarb-Shanno
CB trial comparing treatment C and treatment B - here a direct
comparison
CI confidence interval




2 Abbreviations and Symbols
EP endpoint
ESS effective sample size
H0 null hypothesis
H1 alternative hypothesis
HTA health technology assessment
HR hazard ratio
IPD individual patient data
IQWiG Institute for Quality and Efficiency in Healthcare
KEEP SIMPLEST KEep Evaluating Protocol Simplification In Managing
Periinterventional Light Sedation for Endovascular Stroke Treatment
LL lower left corner
LR lower right corner
MAIC Matching Adjusted Indirect Comparison
mRS modified Rankin Scale
NICE National Institute for Health and Care Excellence
NIHSS National Institutes of Health Stroke Scale
OR odds ratio
RCT randomized controlled trial
RMSE root mean squared error
sd standard deviation
SIESTA Sedation vs. Intubation for Endovascular Stroke Treatment
Abbreviations and Symbols 3
SOP system operating procedure
STC simulated treatment comparison
TTE time-to-event
UL upper left corner
UR upper right corner
Var variance
α significance level
b number of resampling steps
b∗ binary variable
β∗ regression coefficient for variable ∗, in case of β0 it describes the
model intercept
β vector containing the regression coefficients
β̂ vector containing the estimates of the regression coefficients
Bin(·) probability mass function of the binomial distribution
c continuous variable
δ effect estimate comparing two treatments
e(·) propensity score function
g(·) link function
λ baseline hazard rate of the Weibull distribution
l lower limit of the confidence interval
M number of matching partners
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Mmax maximal number of matching partners
mr matching rate
mr mean matching rate
max.time maximal follow-up time for time to event endpoints
µ mean of a probability distribution (e.g. normal distribution)
n∗ sample size, the index indicates the trial or group
N∗ number of trials, the index indicates the considered treatment
comparison
N probability mass function of the normal distribution
ν shape parameter of the Weibull distribution
Φ probability distribution function of the standard normal distribution
π (binary) response/event rate
P (·) probability function
s number of patients recruited for the interim analysis, referred to as
time point of interim analysis
σ standard deviation of a probability distribution (e.g. normal
distribution)




τ tolerance in iterative matching procedure (maximal difference to 1:1
matching rate)
Abbreviations and Symbols 5
ω vector of weights (ωi the weight for patient i)
X data matrix containing the patient characteristics
xi vector containing the patient characteristics of patient i
xij value of patient characteristic j of patient i
x vector containing the mean patient characteristics of a trial
Y vector of outcome variable
yi outcome for patient i
Z group variable
zi group assignment for patient i
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In clinical research, blinded randomized controlled trials (RCTs) are the gold-standard for
evaluating the efficacy of a medical intervention. The random allocation of patients to treat-
ment and control group ensures the comparability of patient cohorts. However, there are
situations that do not achieve comparability despite a randomized trial design was chosen,
e.g., in oncological trials where group sizes are small or, patient cohorts are heterogeneous
(Harrison, 2016; Gan et al., 2010). An alternative design to an RCT is a larger single-arm
trial comparing the treatment effect to a predefined value, which often fails since they ig-
nore variety in patient characteristics influencing the treatment effect. Beside unsuccessful
randomization, it is not always feasible to randomize a clinical trial due to ethical concerns
or practical reasons (Frakt, 2015; Faraoni and Schaefer, 2016; Goodman et al., 2017), but
circumstances may allow for an observational trial. If furthermore, it is not practicable to
observe the treatment and the control group at the same time, an observational single-arm
study might remain the only option. Single-arm studies have the disadvantage that a direct
comparison to placebo or the standard therapy is not possible. When historical individual
patient data (IPD) for the control group recruited within an earlier study or a registry is
available, an alternative strategy would be to use this external control group for comparison.
A naïve approach, which does not adjust for confounders, to compare patient groups of dif-
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ferent trials, may lead to severe bias due to potential differences in patient characteristics.
The lack of comparability can be addressed by matching procedures that aim to balance the
patient groups concerning chosen matching variables. So far, matching is applied after all
patients are recruited, and the study database is closed. While performing the matching
procedure, one may observe that some patients cannot find an appropriate matching partner
and thus are dropped from subsequent analysis. This failure to identify suitable matching
partners may cause the power to decrease. In practice, it cannot be expected to match all
patients in the control group to an intervention patient when recruiting just the same number
of patients as in the control group. Thus, published prospective matched case-control trials,
defined as a prospective single-arm study compared with an external control group under the
usage of a matching approach, prespecified an additional percentage of intervention patients.
Or, for example, the trial of Charpentier et al. (2001) applied an algorithm that directly tries
to find a matching partner for an intervention patient, which results in recruiting 30% more
treated patients than the number of control patients. In case a lower or higher number of
patients can be matched to one of the controls than expected, the sample size would be too
small or more patients than needed are recruited. The fraction of patients matched to one of
the controls, the matching rate, is, therefore, an important statistical measure of such trials
aimed to be as high as possible. Additionally, if the number of control patients allows to iden-
tify more than one suitable matching partner per treated patient, power can be increased.
So far, the designs for prospective matched case control trials are limited which offers scope
for development.
Until now, the methods for matching are used for the generation of evidence. The second
part of this work covers a situation in evidence synthesis, where the comparability of patient
groups might not be given. In medical practice, physicians frequently face circumstances
where various therapy options exist. It would be desirable that all these therapies were
previously compared at once in one or several clinical trials. However, multi-arm trials are
seldom available, and two-arm trials were conducted comparing just a subset of all possible
therapies, whereas some comparisons are covered by multiple studies. In situations where
a so-called head-to-head comparison (a trial directly comparing two treatments) is missing,
the question arises whether and how reliable and valid conclusions on the choice of the best
treatment option can be drawn without initiating a new trial. In recent years, the so-called
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indirect comparisons attracted considerable attention (Signorovitch et al., 2013; Nash et al.,
2018; Veroniki et al., 2016). In particular, indirect comparisons are of increasing interest in
the field of health technology assessments (HTAs) (IQWiG, 2017, 2019; Phillippo et al., 2018).
For early benefit assessment in the framework of HTAs, the valid comparator treatment is
predefined, and frequently, there is a lack of direct comparisons with this valid comparator
(Kühnast et al., 2017). Imprudently combining the results from different trials to get an
estimate for the unavailable comparison of interest can cause severe bias due to cross-trial
differences, such as differences in effect modifier distributions or worse baseline disease status
of patients in one of the trials, which may mean that the treatment is more or less effec-
tive (Signorovitch et al., 2010). Additionally, published results in the form of aggregated
data (AgD) are usually employed, because access to IPD is seldom available for all relevant
studies. In case IPD is available, its usage may increase the reliability of the results and
may reduce the uncertainty in treatment effects compared to situations where only AgD is
available. Indirect comparisons taking the potential imbalance between trials into account
are called adjusted indirect comparisons. The method of Bucher (Bucher et al., 1997) and
the Matching Adjusted Indirect Comparison (MAIC) (Signorovitch et al., 2010) address this
setting of an anchored adjusted indirect comparison. There are published simulation studies
in the context of indirect comparisons which show unsatisfactory performance in terms of
power, meaning it is hard to demonstrate an existing treatment effect by an indirect com-
parison (Mills et al., 2011; Kühnast et al., 2017). Furthermore, the sample size needed for an
indirect comparison is always higher than for the underlying direct comparison (Snapinn and
Jiang, 2011). Despite there are simulation results on indirect comparisons available, their
performance is not sufficiently studied in situations where effect modifications are present,
assumptions of the methods for indirect comparisons are violated, or when cross-trial dif-
ferences exist, such as differences in patient population or different confounder adjustment
of regression models for evaluating the treatment effect. Moreover, the power provided by
the sample size calculation for the head-to-head trials may have a substantial impact on the
power of the indirect comparison which is not sufficiently quantified, yet. This is of particular
interest for investigators when designing a head-to-head trial, which is already planned to
be included in a later indirect comparison. To examine those situations, simulation studies
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covering a variety of practically relevant scenarios are needed (Phillippo et al., 2018; Song
et al., 2009; Glenny et al., 2005; Petto et al., 2019).
The major weakness of established methods for indirect comparisons is the limitation for
considering only one study per treatment comparison. However, often more studies and,
therefore, more evidence is available, which should all be considered. Mainly because not
using all available evidence may introduce additional bias when selecting one of the various
available trials for the indirect comparison. So far, Belger et al. (2015) presented some
solutions for the use of multiple studies in a frequentist framework at a conference, and
some are stated in the guideline of National Institute for Health and Care Excellence (NICE)
(Phillippo et al., 2016); Leahy and Walsh (2019) evaluated the situation of multiple IPD trials
in a Bayesian framework. But, no published paper that includes a systematic comparison
of such methods in a frequentist setting is available. Especially for numerous IPD and AgD
trials, there is no recommendation. Therefore, methods for indirect comparisons need further
development to enhance power and reduce bias under the usage of all available evidence and
they need to be compared in practically relevant scenarios.
1.2 Objectives and Structure of the Present Work
The overall objective of this thesis is to examine matching procedures for the generation
and synthesis of evidence in clinically relevant situations and to further develop the existing
methods. The part about generation of evidence pursue the aim to develop methods that take
the study-specific matching rate already in the planning stage into account, e.g., in the form
of a sample size recalculation for a prospective matched case-control trial. The synthesis of
evidence aims in answering the question whether and in which settings indirect comparisons
produce valid treatment effects under the usage of matching procedures. Throughout this
thesis, a simulation study is designed with the purpose to compare the method of Bucher
(Bucher et al., 1997) and the MAIC (Signorovitch et al., 2010) in a wide range of practically
relevant scenarios where assumptions are violated, and cross-trial differences exist. As a
second aim of this simulation study, the influence of the planned power for the corresponding
head-to-head trials on the power of the indirect comparison is examined. Furthermore this
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thesis has the objective of refining those methods to include multiple studies in indirect
comparisons.
The presented thesis is structured as follows. The second chapter focuses on the methods,
Section 2.1 explains the methods for the generation of evidence, including new approaches for
considering the matching rate already in the planning stage. The second part (Section 2.2)
covers the tools for the synthesis of evidence. The results in Chapter 3 are split according
to the simulation studies. Each section includes the data simulation process, the evaluation
measures, the simulation scenarios, and the simulation results. One of the new approaches
for the generation of evidence is applied to a real data example which is included in the
results chapter (Section 3.1.3). The discussion is again structured according to the two parts,
generation and synthesis of evidence. It contains a discussion of the results, its contribution
to research, as well as limitations and directions for further research. Appendix A includes
additional tables, Appendix B supplementary methodological background, and Appendix C
implementations of essential functions in R.
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Chapter 2
Methods
The methods described in this chapter are divided into methods applied for the generation
of evidence (Section 2.1) and tools needed for the synthesis of evidence (Section 2.2).
2.1 Generation of Evidence
When imbalances in important patient characteristics between study arms are observed
matching procedures can address this issue, Optimal Matching or Propensity Score Matching
are frequently applied methods (Gu and Rosenbaum, 1993; Rosenbaum and Rubin, 1985).
Throughout this thesis, the evaluation of developed approaches which use a matching proce-
dure for the generation of evidence is based on the propensity score method by Rosenbaum
and Rubin (Rosenbaum and Rubin, 1983, 1984; Rubin and Thomas, 1996) which is explained
before the details of the new approaches are given. Nevertheless, the new approaches can be
combined with any matching algorithm and are not limited to the propensity score.
In nonrandomized studies, a direct comparison of treatment and control group may give
misleading results because of systematic differences between groups. Matching approaches
aim to find appropriate pairs of treated and control patients, which can be used for a more
reasonable comparison. It is assumed that there are ntreated patients in the intervention group
and ncontrol patients in the control group. In natural settings ncontrol > ntreated is assumed.
Propensity score matching purposes to minimize the influence of observed and considered
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baseline characteristics on the treatment effect (Austin, 2011). The propensity score e(X)
is a function depending on the given (relevant) confounders X such that the conditional
distribution of being assigned to the treated study arm (Z = 1) and the control arm (Z = 0)
is the same (Austin, 2011). Assuming that there are ncontrol + ntreated patients included, the
propensity score is defined as the conditional probability of being assigned to the treatment
group, given the vector of considered confounders xi
e(xi) = P (Zi = 1 | xi) i = 1, . . . , ncontrol + ntreated,
where Zi ∈ {0, 1} represents the group assignment. Here independence is assumed which
means




The propensity score function is unknown in the case of nonrandomized studies. To generate
an estimate of the propensity score function, for example, a logistic regression model with
treatment status as outcome variable and the relevant baseline characteristics as covariates
can be considered (Rosenbaum and Rubin, 1984)
logit(zi) = β0 + β1xi1 + β2xi2 + . . . (2.1)
This logistic model provides the propensity scores; in other words, the probability of being
assigned to the treatment group. To form pairs, the treatment and control patients are
matched according to the logit of the estimated propensity score
ln e(xi)1− e(xi)
by using some caliper width of these estimates (Rosenbaum and Rubin, 1985). The caliper
width is a predefined amount, which is the maximal difference in propensity scores between
treated and control patients. The choice of the caliper width follows a bias-variance trade-
off; small calipers reduce bias but also may reduce sample size, which increases variance of
the estimated treatment effect. Austin recommends a caliper width of 0.2 of the standard
deviation of the logit of the propensity score (Austin, 2011). According to Austin et al.
(2007), variables that influence the outcome or both treatment assignment or selection and
outcome should be considered in the propensity score estimation.
2.1. Generation of Evidence 21
Beside finding matched pairs, the propensity score can be used for adjustment in the analysis
of observational data to reduce potential bias in the estimated treatment effect (Rosenbaum
and Rubin, 1985).
Assumed is a situation where an RCT is not feasible. Therefore, a prospective matched case-
control trial design is intended. This means the control group already exist because it was part
of an earlier randomized controlled trial, and the treatment group will be newly recruited.
One essential part of the planning stage of a clinical trial is the sample size calculation, which
is usually based on 80% to 90% power and 5% type I error rate. The sample size calculation
has the aim of securing that a clinically relevant treatment effect can be detected. In a
prospective matched case-control trial, the sample size calculation is not straightforward.
In the following, two methods for sample size recalculation in prospective matched case-
control trials are introduced. It is assumed that a historical control group already exists.
Section 2.1.1 covers the situation of a historical control, which was part of an earlier study,
including a sample size which was based on a sample size calculation. Subsequently, Section
2.1.2 comprises a procedure for a large historical control group, for example a registry.
For the first setting, the sample size in the already recruited study arm is fixed and was usually
based on a clinically relevant effect considered in the sample size calculation. Therefore, the
objective is to find an appropriate matching partner for as many patients of the control
group as possible. The matching rate is unknown and as in most practical situations likely
to be less than 100%. This means that recruiting just the same number of patients as in
the external control arm will not result in a situation where a matching partner is found for
all patients in the control group. A possible step to address this uncertainty concerning the
matching rate could be to include an interim analysis. This interim analysis is set after a
predefined number of treated patients are recruited and used to estimate the actual matching
rate. At the same time, information about the primary endpoint is not needed. The results
of the interim analysis can then be used to recalculate the sample size for the treatment
group, which makes it possible to find a matching partner to all control patients in the final
analysis. Thus one receives an adaptive matched case-control design.
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A first approach might be to use all available treated and control patients for estimating
the matching rate at interim analysis. The sample size recalculation is then based on this
estimate of the matching rate. In the following, this strategy will be referred to as the naïve
method. In practice, a potential overestimation of the matching rate may occur when all
patients are used at interim analysis. In consequence, a smaller number of patients than
necessary is recruited after interim analysis and therefore, a lower matching rate is achieved
at the final analysis. To avoid this overestimation, the naïve method is refined.
Comment: Parts of the following Chapter (Section 2.1.1) have already been published in
Weber et al. (2019). The manuscript has been written by myself but may contain comments
and corrections from the co-authors.
2.1.1 Resampling CI Method
A resampling approach and two propensity score matching steps are the core parts of the
proposed adaptive design for recalculating the sample size in a prospective matched case-
control trial.
The adaptive design includes two matching steps. At the interim analysis, the matching
rate is determined and is used for recalculation of the sample size needed to reach a high
matching rate for the final analysis. The matching procedure at interim analysis is solely
used for calculating the matching rate, and pairs are not fixed for the final analysis. For
estimating the treatment effect in the final analysis, the second matching step produces the
final 1:1 matches.
The control study arm includes ncontrol patients. Initially, the number of treated patients is
set to ntreated = ncontrol. A number of ntreated,interim patients are recruited in the treatment
group, which is a predefined proportion of ntreated. Conducting the matching step using all
ncontrol controls may lead to an overestimation in the matching rate. To avoid this potential
overestimation, equally sized groups are used for the matching procedure at interim analysis.
To achieve equal-sized groups, a sample of ncontrol,interim is taken from the ncontrol controls
without replacement with ncontrol,interim = ntreated,interim. The sampled controls and all
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ntreated,interim treated patients are used to perform the matching step and to calculate the
matching rate. To avoid bias due to the random sampling, the resampling and the matching
step, including the calculation of the matching rate (mr) at the interim analysis, are repeated
b times.






The lower limit of the 100 · (1− αCI) % confidence interval (CI) is given by
lmr = mr − Φ(1− αCI) ·
√
mr ∗ (1−mr)/ncontrol,matched (2.2)
with the maximal number of ncontrol,matched matched pairs and Φ() the probability distribu-
tion function of the standard normal distribution. The lower limit of the confidence interval
is then used for recalculating the sample size.





In practice, the maximal number of ntreated may be limited due to practical or temporal
reasons. This number ntreated,max is fixed beforehand and leads to the following final number








In the following, this approach is called resampling CI method. The pseudocode of the steps
are given in Table 1.
Besides the lower limit of the 100 ·(1−αCI)% CI, there are other values that could be used for
the recalculation of sample size. One could use the mean resampling matching rate directly
or a quantile of the distribution of the resampling matching rates. Using mr directly may
overestimate the true matching rate. Quantiles are independent of the number of patients
in the control group. But, in trials with a large control arm, a higher diversity of patients
may be represented; therefore, one would expect to observe a higher matching rate. Hence,
taking the number of control patients into account has the advantage of a smaller confidence
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interval for a larger number of control patients. Consequently, the proposed definition of the
100 · (1 − αCI)% CI is used hereafter. The resampling CI method is here combined with
propensity score matching, but the fundamental idea of this method can be combined with
any matching algorithm.
Table 1: Steps of the resampling CI method at interim analysis (adapted from Weber et al.
(2019)).
Given entities:
b the number of resampling steps.
ncontrol the number of control patients in already recruited study arm.
ntreated,interim the number of treated patients at interim analysis.
ntreated,max the maximal number of treated patients if applicable.
1. Repeat (a) - (d) b times:
(a) Sample ncontrol,interim = ntreated,interim patients without replacement out of the control
group.
(b) Calculate propensity scores for sampled control patients and treated patients.
(c) Conduct a 1:1 matching according to the logit of the propensity scores.
(d) Calculate the matching rate mr.
2. Calculate the mean matching rate mr of the b matching rates calculated in step 1.
3. Calculate the lower limit of the 100 · (1− αCI)% confidence interval using formula (2.2).
4. Calculate the total number of treated patients needed for analysis as in formula (2.3 or 2.4).
So far, the available historical data have contained a limited number of patients. When a
large historical control exist, it might be possible to find more than one matching partner to
the majority of control patients and the resampling CI method may not give satisfying results.
Including more controls may enhance power or one can reduce the number of treated patients.
Therefore, the question of how many control patients could be matched per intervention
patient arises. The procedure introduced in Section 2.1.2 address this setting of a large
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control group and makes it possible to iteratively determine the number of matching partners
under the trial-specific matching rate.
Comment: Parts of the following Chapter (Section 2.1.2) find application in the Matched
Threshold Crossing Design by Krisam et al. (2020), which is already submitted. The part
of the manuscript describing the iterative determination of the number of matching partners
has been written by myself but may contain comments and corrections from the co-authors.
2.1.2 Iterative Matching Procedure
In the proposed design, a sample size calculation determines the number of treated patients
ntreated for a balanced design. Thereof, an initial number of ntreated,interim treated patients
are recruited (a fixed number or a proportion of ntreated) and a large data set including
ncontrol control patients is available. As before, a matching procedure is conducted twice
in the considered adaptive design. In the interim analysis, the matching determines the
number of matching partners M by an iterative process (compare Table 2); furthermore,
the matching rate is calculated at interim analysis to extrapolate the matching rate for
recalculating the sample size in the treated group. In the final analysis, the matching is
performed to find the fixed number of matching partners M for the treated patients. It
is obvious that higher numbers of matching partners M will lead to a more powerful trial.
However, when increasingM the matching rate may decrease because it gets more challenging
to find suitable matching partners. The statistical analysis is only based on the matched
patients; therefore the matching rate should also be sufficiently high to avoid a power loss
of the trial. Thus, the interim analysis aims to select a suitable number of matched controls
M , which also guarantee an adequately high matching rate. The iterative procedure at
interim analysis starts by a 1:1 propensity score matching and is followed by calculating the
corresponding matching rate. In the next step, a 1:2 propensity score matching (M = 2) is
performed and the matching rate is calculated, respectively. The number of matching partners
M is increased as long as the matching rate is equal or higher than the 1:1 matching rate
minus a predefined tolerance criterion τ . This tolerance parameter τ defines the maximally
tolerated deviation from the 1:1 matching rate. If e.g., τ = 0, the 1:2 matching rate is not
allowed to be smaller than the 1:1 matching rate, otherwise M will be set to 1. Choosing
a value of τ = 0 ensures that the maximum number of treated patients is included into the
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analysis, but may ignore that a larger control group could be built; this corresponds to the
most conservative approach. If τ = 0.05 is predefined and suppose the 1:1 matching rate
is 0.95 at the interim analysis, so the iterative procedure will increase M as long as the
calculated 1:M matching rate does not fall below 0.95− 0.05 = 0.9. The pseudocode for the
iterative process is given in Table 2.
Table 2: Pseudocode for the setup of the iterative matching procedure (Krisam et al. (2020)).
step 1:
M = 1
perform 1:1 propensity score matching
calculate matching rate mr1:1
set M = 2
step 2:
perform 1: M propensity score matching
calculate matching rate mr1:M
if (mr1:1 − τ ) 6 mr1:M
increase M to M + 1 and perform step 2
else
stop
For the number of patients in the treatment group, the following holds ntreated,interim 6
ntreated. To ensure that M suitable matching partners per intervention patient can still be
found in the final analysis, the maximum number of control patients per intervention patient
Mmax needs to be predefined. To determine an estimate of Mmax, the number of patients
needed for a balanced design complying 80% power and 5% type I error rate can be used
for estimating the number of treated patients in the trial. This number ntreated,planned can
be calculated by established sample size formulas depending on the outcome and the trial
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The iterative matching procedure can be combined with two-stage designs including an in-
terim analysis allowing for a sample size recalculation, a stop for futility, or a stop for efficacy
based on the treatment effect observed at the interim analysis, for example, the matched
threshold crossing design (Krisam et al., 2018). The test statistics of the two stages (interim
and final analysis, respectively) in such designs need to be independent in order to ensure
type I error rate control. Therefore, one has to note that in case of such designs, the controls
matched to patients at interim analysis are not reassigned to keep the independence. On the
other hand, if the interim analysis is just used for estimating the matching rate and deter-
mine the number of matching partners, the final matching partners can be found at the final
analysis. Assigning the matching partners at final analysis may have the advantage that the
optimal partners are found under consideration of all patients considered in the analysis.
2.2 Synthesis of Evidence
The situation considered throughout the part about the synthesis of evidence in this thesis
is the following: two treatments A and C are compared to a common comparator B in head-
to-head trials. For trial A versus B (AB), IPD is available, for the trial C versus B (CB),
only AgD is accessible from published results (see Figure 1).
Figure 1: The plot shows the situation of the indirect comparison A versus C considered
in this simulation study. To illustrate that cross-trial differences may exist, treatment B is
described as B1 for the individual patient data (IPD) trial and B2 for the aggregated data
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The aim is to demonstrate a treatment effect between treatment A and C (AC); this is called
an indirect comparison. This thesis deals with a frequentist setting, so all the methods are
explained accordingly.
In the current Section 2.2 the established methods for indirect comparisons (MAIC and
the method of Bucher) are explained, followed by subsections about meta-analysis and the
approximate adjustment which are needed for the ways to include multiple studies in indirect
comparisons (Subsection 2.2.4).
2.2.1 Indirect Comparisons
There are several established methods addressing the situation of an indirect comparison,
such that the method of Bucher (Bucher et al., 1997), MAIC (Signorovitch et al., 2010,
2012), simulated treatment comparison (STC) (Caro and Ishak, 2010; Ishak et al., 2015a),
cross-design synthesis (Droitcour et al., 1993), or likelihood reweighting methods (Nie et al.,
2013). This thesis focus on the widely used and accepted method of Bucher and the MAIC;
the latter includes a matching step. Later on, the methods will be compared and extended
for the use of multiple studies.
2.2.1.1 Method of Bucher
To perform the method of Bucher, the treatment effects and the corresponding variances
on aggregated data level of the two studies AB and CB are sufficient; IPD is not needed.
The method of Bucher preserves the within-study randomization since the treatment effects
are calculated for each trial separately. This calculation takes the randomization within
the respective trial into consideration. Furthermore, a common comparator is needed for
calculating this indirect comparison; assuming head-to-head trials AB and CB are available
treatment B is the common comparator between trials AB and CB. The assumptions made
are comparable study populations for essential effect modifiers. If the treatment effect differs
according to another variable, this variable is an effect modifier, whereas the presence of a
confounder variable introduces bias in the estimated treatment effect.
Following the method of Bucher, the effect estimate δAC for the indirect comparison AC is
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given by
δAC = δAB − δCB, (2.5)
with δAB and δCB denoting the respective effect estimate reported in trial AB and CB. The
variance of the indirect effect estimate δAC is given by
V ar(δAC) = V ar(δAB) + V ar(δCB).
Insufficient comparability of studies according to important effect modifiers leads to a viola-
tion of assumptions for the method of Bucher. MAIC addresses this issue of differing patient
populations by a matching procedure. However, IPD needs to be available for one trial and
AgD for the other trial to conduct an indirect comparison by MAIC. When IPD is available
for both trials, a propensity score matching or outcome regression approach might be more
appropriate for estimating a treatment effect (Phillippo et al., 2016).
2.2.1.2 MAIC
Without loss of generality, it is assumed that IPD is available for the comparison AB and
solely AgD for the trial comparing CB. The MAIC approach addresses this situation and
makes use of the IPD data. The aim is to match the IPD to the AgD of the other trial
to reach balance in summary measures of the baseline characteristics of the two trials. The
matching procedure selects a weight ωi for each patient in trial AB (IPD available), which
follows the idea of propensity score matching (Rosenbaum and Rubin, 1983, 1984). The
variable T denotes the trial, here T = 0 corresponds to trial AB and T = 1 to trial CB,
respectively. The outcome is described by Y and X includes the baseline covariates, which
will be considered within the matching procedure. In the case of T = 1 there are no individual
values available, but the means or proportions of baseline covariates xCB and the outcome







with n the number of patients in AB and CB together (n = nAB+nCB, with nAB the number
of patients in trial AB and nCB the number of patients in trial CB, respectively), ti the trial
affiliation of patient i (ti = 0 for AB, ti = 1 for CB), and ωi = P (Ti=1|xi)P (Ti=0|xi) the weight for
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patient i (for i = 1, . . . , nAB), which is the odds between being a patient in trial AB versus
belonging to trial CB given the baseline covariates xi. These weights achieve that patients
who better fit in the CB than the AB trial (according to the observed baseline characteristics)
will be up-weighted to balance between the trials. Before calculating the estimated treatment
effect, one has to estimate the weight ωi. As frequently in propensity score matching, it is
assumed that the weights for the correspondence to one of the trials AB or CB follow a
logistic regression model
ωi = exp(α+ x′iβ),
where xi includes the baseline covariates of patient i (for i = 1, . . . , nAB). Because IPD of
baseline characteristics is only available for one of the trials, the maximum likelihood method
cannot be applied. Instead, the method of moments addresses this setting and allows to
estimate β̂ for the coefficients β (details see Appendix B). In order to determine the estimates
β̂ , the following equation needs to be solved
0 =
∑




where ti = 0 the trial affiliation of patient i to trial AB for i = 1, . . . , nAB. The optimization
with respect to β is done using the Broyden-Fletcher-Goldfarb-Shanno (BFGS) algorithm
(Broyden, 1970). The effect estimate δ̂AC is determined by using the before calculated weights








The standard errors of δ̂AC are calculated using a robust sandwich estimator (Huber, 1967;
White, 1980).
Weighting patients in the calculation of a treatment effect to balance populations reduces
the effective sample size (ESS). For MAIC, the ESS is calculated to measure the differences
in baseline characteristics between the trials. The set of estimated weights ω̂ contains the







where nAB describes the sample size of trial AB and ω̂i the estimated weight for patient i
(Phillippo et al., 2018).
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In practice, it is likely that two or even more studies compare the same treatments. Combining
evidence from different studies is done by meta-analysis.
2.2.2 Meta-analysis
Before technically a meta-analysis is performed, an intensive literature search according to
clear rules is conducted, which identifies several independent studies comparing the same
treatments. This is called a systematic review which aims to find, summarize, and rate the
quality of all available evidence. Then one may be interested in the common treatment effect
over the chosen studies. The results in terms of treatment effects and the corresponding vari-
ance of individual studies can be combined by mathematical considerations, which are then
called a meta-analysis (Borenstein et al., 2011). Trials are not merely combined to increase
sample size; methods for meta-analysis adjust for differences in sample size, variability in
treatment effects and heterogeneity between trials. Appropriately conducted meta-analyses
make a more objective evaluation of treatment effects possible (Egger and Smith, 1997).
Facing a frequentist setting, the most commonly used approaches are the fixed and random-
effects models. The fixed-effects model assumes that the trials are based on the same (true)
treatment effect, which means they are comparable in terms of the target population and the
definition of dependent and independent variables. The only source of error in the treatment
effect is, therefore, within the study. The inverse of the study variance then provides the
weights for the included studies. That those treatment effects are the same is a strong as-
sumption which may be violated in practice even if the studies are similar enough to fulfill the
literature search criteria. The random-effects model allows for such variations by assuming
a distribution for the true effect size. The weights are again calculated by the inverse of the
variance, but two sources of error apply in this setting, the within-study variance and the
between-study variance, which are included in the weight calculation (Sutton et al., 2000).
2.2.3 Approximate Adjustment
In some of the approaches which will be introduced in Section 2.2.4, trials are included in
several indirect comparisons. To correct for this multiple use, the approximate adjustment,
according to Rücker et al. (2017) is applied. This method was originally proposed for the
inclusion of multi-arm trials in a generic inverse variance meta-analysis to avoid unit-of-
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analysis errors. The idea is to increase the standard error of a comparison when using the
full data set several times instead of splitting the data. In the setting of an indirect comparison
having several AgD studies, one could split IPD to avoid multiple uses, which addresses a
situation closely related to Rücker et al. (2017). The standard deviation of each indirect
comparison ACij (sd(δACij )) is adjusted by
sd(δACij ) = NCB · sd(δABi) +NAB · sd(δCBj )
with NAB denoting the number of AB trials, NCB the number of CB trials, i = 1, . . . , NAB,
and j = 1, . . . , NCB.
Until now, the methods for adjusted indirect comparisons are designed to include one study
per direct comparison. The following section consists of the proposed solutions for incorporat-
ing multiple studies within MAIC under a frequentist setting. Methods like IPD meta-analysis
cover situations where IPD is available on both sides. The same holds true for cases where
only AgD can be used (Sutton et al., 2000; Stewart et al., 2012).
Comment: Parts of the following Chapter (Section 2.2.4) are already included in the submit-
ted manuscript Weber et al. (2020b). The manuscript has been written by myself but may
contain comments and corrections from the co-authors.
2.2.4 Inclusion of Multiple Studies in Indirect Comparisons
Different situations of multiple studies may occur. There could be one IPD trial and multiple
AgD trials (A.), multiple IPD trials and one AgD trial (B.), or multiple IPD and AgD trials
(C.). The underlying situation includes IPD for the AB trial(s) and AgD for the CB trial(s).
A. One IPD trial (AB) and multiple AgD trials (CB)
A.1. Pool AgD:
• The AgD trials are pooled by a meta-analysis. The meta-analysis results
(treatment effect and the corresponding standard error) are used for the indi-
rect comparison.
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• A weighted average of the aggregated data according to the standard error of
the relevant treatment effect is calculated.
• The IPD within the MAIC is matched to the weighted average of the aggre-
gated data.
• The indirect comparison is conducted using the results of the steps before.
A.2. All indirect comparisons:
• All indirect comparisons are conducted separately, applying the variance cor-
rection (see the adjusted standard deviation in Section 2.2.3).
• A meta-analysis is used to combine the effect estimates calculated by the
indirect comparisons.
B. Multiple IPD trials (AB) and one AgD trial (CB)
B.1. Pool IPD:
• The IPD trials are pooled into one data set.
• One indirect comparison is conducted using the pooled IPD data.
B.2. All indirect comparisons:
• All indirect comparisons are conducted separately applying the variance cor-
rection (see the adjusted standard deviation in Section 2.2.3).
• A meta-analysis is used to combine the effect estimates calculated by the
indirect comparisons.
C. Multiple IPD trials (AB) and multiple AgD trials (CB)
C.1. Pool IPD, pool AgD:
• The IPD trials are pooled into one data set.
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• The AgD trials are pooled by a meta-analysis. The meta-analysis results
(treatment effect and the corresponding standard error) are used for the indi-
rect comparison.
• A weighted average of the aggregated data according to the standard error of
the relevant treatment effect is calculated.
• The IPD within the MAIC is matched to the weighted average of the aggre-
gated data.
• One indirect comparison is conducted using the results of the steps before.
C.2. Pool IPD:
• The IPD trials are pooled into one data set.
• The AgD trials are considered separately.
• All indirect comparisons are conducted using the pooled IPD data set and ap-
plying the variance correction (see the adjusted standard deviation in Section
2.2.3).
• A meta-analysis is used to combine the effect estimates calculated by the
indirect comparisons.
C.3. All indirect comparisons:
• All indirect comparisons are conducted separately applying the variance cor-
rection (see the adjusted standard deviation in Section 2.2.3).
• A meta-analysis is used to combine the effect estimates calculated by the
indirect comparisons.
When IPD trials are pooled and a common effect estimate is calculated, one needs to take
the clustered structure into account. For example, this can be done by including a random
intercept for the trial in a mixed-effects regression model for estimating the treatment effect
over all the IPD trials.
Chapter 3
Results
In this chapter, the methods introduced in Chapter 2 are evaluated using simulation studies.
For each simulation study, the data generating process, the simulation scenarios, and the
corresponding results are presented.
Comment: Parts of the following Section 3.1 have already been published in Weber et al.
(2019). The manuscript has been written by myself but may contain comments and corrections
from the co-authors.
3.1 Generation of Evidence - Resampling CI Method
3.1.1 Data Simulation
For the evaluation of the resampling CI method and its comparison to the naïve approach,
a simulation study using 10,000 runs is performed. The distribution parameters for the
involved baseline variables are chosen motivated by a clinical example (Section 3.1.3), which
deals with patients suffering from acute cerebral infarction. Simplifications like distribution
assumptions for baseline variables and fewer variables within the matching procedure were
made within the simulation study.
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The outcome variable is assumed to be binary indicating some favourable event. The corre-
sponding hypotheses are formulated in terms of rates
H0 : πcontrol > πtreated
H1 : πcontrol < πtreated,
with πcontrol and πtreated are the true event rates in the control and the treatment group,
respectively.
The simulated data include three binary variables (X1, X2, and the group variable Z), one
categorical variable (X4), and two continuous variables (X3, X5). The variables are used
to simulate group assignment and the outcome variable (Y ), as well as they are considered
within the matching procedure.
First, two binary (X1, X2) and one continuous variable (X3) are independently sampled,
which describe, for example, gender, diabetes (yes/no), and age. The binary variables are
assumed to follow a binomial distribution; the continuous variable is sampled out of a normal
distribution.
X1 ∼ Bin(1; 0.5)
X2 ∼ Bin(1; 0.2)
X3 ∼ N (70; 15)
The assignment to the treatment or the control group depends on the variables X1 and X3.
In the subsequent step, the group variable is simulated based on a logistic regression model




P (Z = 1)
1− P (Z = 1)
)
= −0.6 + 0.35X1 − 0.01X3
Based on the group allocation, two additional variables, X4 and X5, are simulated. The
variable X4 is an ordinal variable assumed to follow a binomial distribution with ten levels
which may represent the Alberta Stroke Program Early CT score (ASPECTS) here. The
ASPECTS is a tool for detecting early ischemic changes on non-contrast computed tomog-
raphy (CT) scans (Barber et al., 2000). The variable X5 follows a normal distribution and
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describes here the National Institutes of Health Stroke Scale (NIHSS). The NIHSS is a tool
to assess stroke severity (Lyden et al., 2001). These two additional variables are sampled out
of different distributions (according to the group).
X4,control ∼ Bin(10; 0.8)
X4,treated ∼ Bin(10; 0.75)
X5,control ∼ N (17; 5)
X5,treated ∼ N (16; 4)
Under the alternative hypothesis the outcome is then sampled out of a logistic regression
model using variables X4 and Z as covariates
YH1 = logit
(
P (Y = 1)
1− P (Y = 1)
)
= −0.5 + Z + 0.2X4.
In this outcome model, the coefficient for the group variable Z is chosen to be βZ,outcome = 1.
Under the null hypothesis treatment and control are assumed to perform equally, so the
outcome is assumed to follow a binomial distribution:
YH0 ∼ Bin(1; 0.5).
Intending to simplify the simulation study, the baseline variables X1 to X5 are assumed to be
independent. However, in practice, correlations are likely to occur and should be taken into
account when selecting the matching variables. By using a logistic regression model for the
group allocation and sampling clinical variables out of different distributions for treatment
and control patients, differences between the groups are included, which can be balanced by
the matching procedure.
The propensity score estimation is done by using a logistic regression model for the group as
outcome variable (Z) and the baseline variables X2, X3, and X5 as covariates. This model
includes baseline variable X2, which was not used for group assignment. Considering X2
in the propensity score model leads to misspecification. However, the true model is usually
not known, and therefore, this setting avoids to get over-optimistic results in the simulation
study.
A set of confidence levels is considered with αCI ∈ {0.01, 0.05, 0.1}, and hence the resampling
CI method is evaluated for 99%, 95%, and 90% confidence intervals in this simulation study.
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When all patients are recruited according to the recalculated sample size, the null-hypothesis
is tested by the McNemar test for paired data. An approach for paired data is used to account
for the matched design. In practice, an alternative option to adjust for matching variables
and additional confounders may a generalized mixed effects model considering the matching
ID as random effect.
Fixed Time Point - Varying Number of Control Patients
The number of patients in the control group ncontrol and a fixed fraction t of patients for the
interim analysis are needed to start a prospective observational trial including an adaptive
matching approach. To evaluate the new approach by its power, type I error rate, matching
rate, and sample size, the time point for the interim analysis needs to be fixed. It is set to
s = 0.5 · ncontrol, with
ncontrol ∈{25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300},
because this might be the most intuitive time point. In a fixed design, a number of 142 patients
per group would have been needed to show the simulated treatment effect with a power of
80% at a type I error rate of 5%. Underpowered, less than 142 patients per group, as well
as overpowered scenarios, more than 142 patients per group, are investigated. Underpowered
situations may occur when the expected effect in the existing trial, where the control group of
the prospective observational trial is taken from, was higher than expected in the new trial.
When the existing trial was planned based on a smaller expected effect or included multiple
primary hypothesis, this may result in a greater control group than needed for a fixed design
and leads to an overpowered scenario. At the interim analysis, the matching rate on b = 200
resampling sets of size ntreated,interim is calculated. By using the simulated data as described
in Section 3.1.1 and performing the steps in Table 1, the proposed method is compared with
the naïve approach. The properties of the two approaches are evaluated according to the
matching rate at the final analysis, the recruited sample size ntreated,final, as well as the type
I error rate and power at final analysis. To calculate the power, the number of correct test
decisions under the alternative hypothesis is counted. To assess the type I error rate, the rate
of rejected hypotheses under the null hypothesis is determined.
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Time Point of Interim Analysis
Now, the aim is to assess the time point for the interim analysis. A fixed number of patients
ncontrol in the control group for a prospective observational trial is given. The confidence level
for the resampling CI method is set to 99%, corresponding to an alpha-level of αCI = 0.01.




















For recalculation of the sample size, the resampling CI method, as well as the naïve approach,
is used. The conclusion and recommendation will be based on the evaluation of the matching
rate, the recruited sample size ntreated, as well as the type I error rate and power at the final
analysis.
The time point of interim analysis may be influenced by the size of the control group. There-
fore, a small (ncontrol = 50), medium (ncontrol = 150), and a large (ncontrol = 500) sample size
in the control group is considered. To obtain 80% power within each scenario, the regression
coefficient for the group variable βZ,outcome varies between the considered sample sizes:
small: βZ,outcome = 2
medium: βZ,outcome = 1
large: βZ,outcome = 0.55
Due to problems in finding matching partners if fewer than 15 patients are included in the
matching procedure at the interim analysis step, if a small sample size in the control group
is assumed, the considered time points of interim analysis start at 13 · ncontrol and for the
medium sample size at 14 · ncontrol.
All simulations in Section 3.1.2 were done in R version 3.4.3 under the usage of the packages
Matching (by using the function Match) and boot (by using the function inv.logit) (R Core
Team, 2017; Sekhon, 2011; Canty and Ripley, 2017).
3.1.2 Simulation Results
First, the results varying the number of control patients under the usage of a fixed time
point for the interim analysis are described and visualized. The subsequent paragraph deals
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with the results for the time point of interim analysis, which is evaluated for both considered
methods.
Fixed Time Point - Varying Number of Control Patients
The main evaluation measure in this setting is the matching rate. The matching rates de-
pending on the number of patients in the control group are plotted in Figure 2 upper right
corner (UR). Comparing the matching rate curves of the naïve approach at interim and final
analysis, it can be observed that for all scenarios, the matching rate at interim analysis is
higher than the matching rate for the final analysis. This means that the matching rate at
interim analysis overestimates the true matching rate and results in undersized recruitment of
patients for the final analysis. The consequence of a lower matching rate at the final analysis,
caused by an overestimation of the matching rate at the interim analysis, is a loss in power
(Figure 2 upper left corner (UL)).
The proposed method counteracts this overestimation by using equal sample sizes for the
matching procedure at the interim analysis, which leads more likely to an underestimation of
the true matching rate. Therefore, more treated patients are recruited (Figure 2 lower right
corner (LR)), which achieves a higher matching rate at the final analysis. Hence, a higher
number of matched pairs are included in the final analysis, which increases power.
When considering the naïve method, a dependency between the number of patients in the
control group and the matching rate is observed: the matching rate increases with the number
of patients in the control group. In contrast, for the resampling CI method the matching
rate at final analysis stays on a constant level. The mean matching rate is around 92% for
αCI = 0.01 applying the resampling CI method, whereas the mean matching rate of the naïve
approach (αCI = 0.01) lies between 79 - 86% (Figure 2 UR and Table 3).
In this simulation study, the fixed design, based on 80% power, 5% type I error rate, and
the Chi-squared test, would have required a number of n = 142 patients per group. For the
proposed design, 80% power is reached for ncontrol ≈ 150. Thus, the always intended power
of 80% is achieved, requiring only slightly more patients in the control group than would have
been needed in a fixed randomized design (Figure 2 UL). The number of required control
patients is higher, because the observed matching rate is lower than 100% (Figure 2 UR).
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In all scenarios, as well as for both considered methods, the type I error rate is approximately
5% (between 4.37% and 5.72%). As expected, a difference between the two methods according
to the type I error is not observed (Figure 2 lower left corner (LL)).
Varying the confidence level within the resampling CI method results in small differences in
the mean lower CI limit of the matching rate. The mean lower CI limit of the matching rate
at interim analysis increases slightly for increasing αCI or decreasing the confidence level,
respectively (Table 3). This increase leads to a slightly lower number of recruited patients
for lower confidence levels. For αCI = 0.05, the mean recruited sample size in the treatment
group is around 4 patients higher than for αCI = 0.1, and for αCI = 0.01 is for another 8
patients higher, for details, see Table 4.
Time Point of Interim Analysis
The focus of this section is the results for a medium sample size in the control arm (ncontrol =
150), as the simulations for small and large sample sizes show comparable results.
Using the naïve method, for early time points of the interim analysis, a matching rate close
to 100% is observed, but in the final analysis, it is less than 85% (Figure 3 UR). Even for
later time points, the matching rate is below 90%, and as a consequence, the power is less
than 80% for all considered time points (Figure 3 UL). The total sample size is lowest for
the early time point (Figure 3 LR) because the matching rate at interim analysis is highest
for this time point and indicates the lowest power value. As expected, the type 1 error rate
is around 5% (Figure 3 LL).
The resampling CI method uses equal-sized groups at the interim analysis. When performing
an early interim analysis, the matching rate is poor, and a high number of patients need to
be additionally recruited for the final analysis. Comparing the matching rate at the final
analysis between the different time points, the gain in the matching rate and, therefore, in
power is small when performing an early interim analysis. With an increasing number of
patients at interim analysis, the matching rate seems to converge and the observed changes
are tiny (in the matching rate) when increasing the number of patients in the control group
used at interim analysis above 50% (Figure 3 UR). Taking also the recruited sample size into
account, it seems that a time point between 12 and
2
3 of the control patients is a good choice
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as a trade-off between matching rate and sample size (Figure 3 LR). The matching rate lies
between 90.7% and 93.4% for all considered time points. In all scenarios, the achieved power
is around 80% and the type I error rate around 5% (Figure 3 UL, 3 LL).
For small sample sizes (ncontrol = 50) in the control group, it is observed that a later interim
analysis could be a good choice, because sample size decreases and matching rate as well
as power do not decrease in a considerable amount. Using only 50% of the control patients
at the interim analysis in small trials leads to a low absolute number of patients, which
underestimates the matching rate. For large sample sizes, an earlier time point seems to be
the right choice since the matching rate converges already for early time points of the interim
analysis. For large sample sizes, it is observed that a smaller absolute number of control
patients leads to a good estimate of the matching rate. The results are shown in Appendix
A.1 (Figure 11 and 12).
Table 3: Mean matching rate/mean lower CI limit of the matching rate at interim and final
analysis for the naïve approach and the resampling CI method for different numbers of patients
in the control group. The resampling CI method is applied for different confidence levels
(αCI ∈ {0.01, 0.05, 0.1}) (adapted from Weber et al. (2019)).
ncontrol Naïve 99%-CI 95%-CI 90%-CI
interim final interim final interim final interim final
50 0.89 0.79 0.49 0.92 0.54 0.91 0.56 0.90
75 0.93 0.81 0.58 0.92 0.62 0.91 0.64 0.90
100 0.95 0.82 0.64 0.92 0.67 0.91 0.68 0.91
125 0.96 0.83 0.67 0.92 0.70 0.91 0.71 0.91
150 0.97 0.84 0.70 0.92 0.72 0.91 0.73 0.91
175 0.98 0.84 0.72 0.92 0.74 0.91 0.75 0.91
200 0.98 0.84 0.73 0.92 0.75 0.91 0.76 0.91
225 0.98 0.85 0.74 0.92 0.76 0.91 0.77 0.91
250 0.99 0.85 0.76 0.92 0.77 0.91 0.78 0.91
275 0.99 0.85 0.76 0.92 0.78 0.91 0.79 0.91
300 0.99 0.86 0.77 0.92 0.79 0.91 0.80 0.91
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Table 4: Mean total number of recruited patients in the treatment group for the naïve ap-
proach and the resampling CI method for different numbers of patients in the control group.
The resampling CI method is applied for different confidence levels (αCI ∈ {0.01, 0.05, 0.1})
(adapted from Weber et al. (2019)).
ncontrol Naïve 99%-CI 95%-CI 90%-CI
50 57.20 103.05 94.11 89.97
75 81.88 130.51 122.83 119.10
100 106.24 158.13 150.99 147.45
125 130.73 187.46 180.42 176.88
150 155.34 215.80 208.85 205.32
175 179.98 245.10 238.09 234.52
200 204.84 273.86 266.81 263.19
225 229.42 303.28 296.11 292.42
250 254.39 331.75 324.53 320.80
275 279.19 361.06 353.69 349.90

























































































Figure 2: Power, type I error rate, mean matching rate, and mean sample size in treated group for different sample sizes in the control



































































































Figure 3: Power, type I error rate, mean matching rate, and mean sample size in treated group for different time points of the interim
analysis (ncontrol = 150) (adapted from Weber et al. (2019)).
46 Chapter 3. Results
Comment: Parts of the following Section 3.1.3 have already been published in Schönenberger
et al. (2019). The statistical analysis of this trial has been carried out by myself and the
manuscript part about the statistical analysis has been written by myself, but may contain
comments and corrections from the co-authors.
The following section 3.1.3 covers the application of the resampling CI method to a real
data set, the KEep Evaluating Protocol Simplification In Managing Periinterventional Light
Sedation for Endovascular Stroke Treatment (KEEP SIMPLEST) trial.
3.1.3 Real Data Example
The KEEP SIMPLEST trial (Schönenberger et al., 2019) had the objective to compare dif-
ferent aspects of peri-interventional management in patients with acute cerebral infarction
treated according to a new system operating procedure (SOP) with patients having been ran-
domized into the conscious sedation (CS) group of the SIESTA trial (Sedation vs. Intubation
for Endovascular Stroke Treatment) (Schönenberger et al., 2016). The aim is to evaluate
if the new SOP yields benefit in terms of patient outcome due to smooth, fast, clear, and
effective processes compared to the early implementation stages of conscious sedation. The
primary endpoint was early neurological improvement at 24 hours measured by the NIHSS.
The CS group of the Sedation vs. Intubation for Endovascular Stroke Treatment (SIESTA)
trial includes 77 patients, but four were excluded before the matching analysis due to missing
values in at least one of the matching variables. The study protocol of the KEEP SIMPLEST
trial intended an interim analysis after 50 patients to estimate the matching rate and to per-
form a possible recalculation of the sample size. The actually recruited number of treated
patients at interim analysis was 51. The conducted simulation study gave promising re-
sults using the resampling CI method. Therefore, the resampling CI method is used for the
recalculation of the sample size using 200 resampling steps. Additionally, for reasons of com-
parability, the analysis is done using the naïve method, but this was not part of the medical
publication (Schönenberger et al., 2019).
Within the matching procedure, four baseline variables were considered: Age, NIHSS on ad-
mission, premorbid modified Rankin Scale (mRS), and the ASPECTS score. The propensity
score was estimated by a logistic regression model for group affiliation. For the matching on
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the propensity score, a caliper width of 0.2 of the standard deviation of the propensity score
was used. The interim analysis results in the following matching rates:
mrnaiv =0.607
mr =0.461
The same pattern as in the simulation study is observed, the matching rate at interim analysis
using the naïve method is substantially higher than the matching rate of the resampling CI
method.
The extrapolation of mr = 0.461 (resampling CI method) leads to a total sample size of 161.
The evaluable KEEP SIMPLEST data set consists of 154 patients with complete data, seven
of 161 included patients who had a missing ASPECTS score. The ASPECTS score is consid-
ered as matching variable; therefore, those patients who had a missing ASPECTS score were
excluded from the trial. The matching procedure using the resampling CI method reached a
matching rate of 94.5% in the final analysis; hence 69 pairs were found and analyzed. The
naïve approach would result in a total sample size of 122. In case just 122 patients would have
been used for the second matching procedure in the treated group, this would have resulted
in 63 matched pairs and hence a matching rate of 86.3%. Thus, in the KEEP SIMPLEST
trial, the resampling CI method achieves an 8.2% higher matching rate in the final analysis
compared to the naïve approach.
The patient characteristics addressed in the propensity score matching are given in Table 5 for
the SIESTA and the KEEP SIMPLEST trial before and after matching. One can recognize
that patient characteristics are balanced after matching.
The KEEP SIMPLEST trial could not find a difference in early neurological improvement
(NIHSS after 24 hours) and mRS at three months. Differences in secondary endpoints like
the door-to-recanalization time with mean time in minutes of 128.6 (sd=69.47) versus 156.8
minutes (sd=75.91), mean duration of mechanical thrombectomy of 92.01 minutes (sd=52)
versus 131.9 (sd=64.03), door-to-first angiographic image with mean time in minutes of 51.61
(sd=31.7) versus 64.23 minutes (sd=21.53), and computed tomography-to-first angiographic
image time with a mean of 31.61 minutes (sd=20.6) versus 44.61 minutes (sd=19.3) were
shorter in the group treated under the new SOP.
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Further details and results of the KEEP SIMPLEST trial can be found in Schönenberger
et al. (2019).
Table 5: Patient characteristics of the SIESTA and the KEEP SIMPLEST trial before and
after matching.
Before Matching After Matching
KEEP KEEP
SIESTA SIMPLEST SIESTA SIMPLEST
(n=73) (n=154) (n=69) (n=69)
Age, mean (sd) 71.1 (14.9) 76.1 (11.0) 72 (14.7) 72.7 (12.4)
NIHSS on admission,
mean (sd) 17.4 (3.7) 14.3 (7.7) 17.2 (3.7) 16.9 (6.8)
premorbid mRS, n(%)
0 36 (49.3) 48 (31.2) 32 (46.4) 32 (46.4)
1 18 (24.7) 40 (26.0) 18 (26.1) 17 (24.6)
2 13 (17.8) 22 (14.3) 13 (18.8) 15 (21.7)
> 2 6 (8.2) 44 (28.6) 6 (8.7) 5 (7.2)
ASPECTS, n(%)
10-8 42 (57.5) 103 (66.9) 42 (60.8) 39 (56.5)
7-6 23 (31.5) 34 (22.1) 21 (30.4) 21 (30.4)
<6 8 (11.0) 17 (11.0) 6 (8.6) 9 (13)
Median (Q1-Q3) 8 (6-9) 9 (7-10) 8 (7-9) 8 (6.25-9)
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Comment: Parts of the following Section 3.2 find application in the Matched Threshold Cross-
ing Design by Krisam et al. (2020), which is already submitted. The part of the manuscript
describing the iterative determination of the number of matching partners has been written
by myself but may contain comments and corrections from the co-authors.
3.2 Generation of Evidence - Iterative Matching Procedure
Simulations investigate the characteristics of the iterative matching procedure. The simula-
tions involve 10,000 runs for each data scenario which are described in Section 3.2.1. The
maximal number of matching partners is set to M = 10, and a caliper of 0.2 is used within
the propensity score matching. The tolerance is set to τ ∈ {0, 0.05, 0.1}.
3.2.1 Data Simulation
The data for the iterative matching procedure is motivated by refractory acute myeloid
leukemia (AML) patients. It is assumed that there exists a cohort of 1000 refractory AML
patients treated with the current standard of care. To investigate a novel treatment for AML
a single-arm phase II trial including 25 patients (at interim analysis) using the historical data
as the control group is planned. The response rate under standard treatment is assumed to
be πcontrol = 0.3; for the new therapy, a response rate of πtreated = 0.5 is assumed. The data
consist of three baseline variables, two binary variables that may represent the prevalence of
high-risk cytogenetics and the presence of a FLT3 mutation, as well as one continuous repre-
senting the patients’ age. Two data scenarios are considered. First, patient characteristics in
the treatment and control group are assumed to follow the same distributions. Age follows a
normal distribution with µ = 55 and σ = 15. The contingency table of the binary variables
given in Table 6 is assumed for both cohorts.
Differences in baseline characteristics characterize the second scenario. In the control group
the normally distributed age variable has µ = 60 and σ = 5, whereas in the treatment group
µ = 55 and σ = 15. For the binary variable, the contingency tables given in Table 7 are
assumed.
The response variable Y can be modelled by a logistic regression model conditioned on both
binary and the continuous baseline variable, as well as including the treatment affiliation with
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Table 6: Contingency table of the binary variables (high-risk cytogenetics and FLT3 mutation)







Table 7: Contingency table of the binary variables (high-risk cytogenetics and FLT3 muta-




yes no yes no
FLT3
yes 0.04 0.2 0.02 0.18
no 0.24 0.52 0.32 0.48










logit(y) = β0 + δxtr + βFLT3xFLT3 + βCytoxCyto + βAgexAge.
The coefficients of this model are set to β0 = 2, βFLT3 = −0.2, βCyto = −0.5, and βAge =
−0.05. Because the response distribution depends on these three baseline variables, all of
them are considered within the matching procedure.
3.2.2 Simulation Results
For equal patient characteristic distributions in the control and the treatment group, most
of the simulation runs reach M = 10 matching partners for τ = 0.1. Decreasing τ leads to a
shift towards less matching partners. The mean matching rate, its standard deviation (sd),
and the distribution of the number of matching partners is given in Table 8 for equal patient
characteristics. The mean matching rate is close to 1 in case τ = 0 and all numbers of
matching partners and decreases with increasing τ (which is not surprising because of the
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design of the tolerance criterion). For τ = 0.05 it is observed that the mean matching rate
is similar for M ∈ [2, 9] and is higher for M = 1 and M = 10. In case τ = 0.1 the matching
rate is around 92% for M ∈ [3, 9]; for M = 10 a matching rate of 97.7% is observed. When
the predefined maximal number of matching partners is not reached, the mean matching rate
reflects approximately the tolerance criterion τ .
In case the populations differ in regard to distribution parameters of baseline characteristics
(9), the highest matching rate mr = 0.867 is reached for M = 10 and τ = 0. Using higher
tolerance values results in a lower matching rate, even if the maximal number of matching
partners is reached. The maximal number of matching partners can be reached for less than
3% for τ = 0, 10% and 25% for τ = 0.05 and τ = 0.1, respectively. The mean matching
rate for τ = 0 and M ∈ [1, 9] is between 76% and 81%. For τ = 0.05 it is around 75% and
for τ = 0.1 around 70%, respectively. When the number of matching partners is compared
to the scenario with equal populations, there is a shift towards smaller numbers of matching
partners, which is stronger for τ = 0 compared to higher values of τ .
The distribution of matching partners is displayed in Figure 4 for both data scenarios and
the considered tolerance values.
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Table 8: Mean and standard deviation of the matching rate split by the number of matching
partners (M). The columns entitled n include the number of simulation runs ending with
this number of matching partners. Values are given for a tolerance of τ ∈ (0, 0.05, 0.1).
Populations of the control and intervention group are sampled from equal distributions.
τ = 0 τ = 0.05 τ = 0.1
M mean sd n mean sd n mean sd n
1 0.997 0.011 380 1.000 0.000 6 0
2 0.998 0.008 424 0.963 0.021 50 0
3 0.999 0.006 453 0.962 0.016 85 0.914 0.028 7
4 0.999 0.007 479 0.962 0.013 126 0.925 0.014 24
5 0.998 0.009 510 0.961 0.010 160 0.921 0.017 38
6 0.999 0.008 481 0.961 0.011 184 0.921 0.016 64
7 0.998 0.009 542 0.961 0.013 290 0.925 0.016 104
8 0.999 0.008 615 0.961 0.013 323 0.923 0.013 113
9 0.999 0.007 600 0.961 0.011 450 0.922 0.014 193
10 0.999 0.007 5516 0.985 0.021 8326 0.977 0.029 9457
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Table 9: Mean and standard deviation of the matching rate split by the number of matching
partners (M). The columns entitled n include the number of simulation runs ending with
this number of matching partners. Values are given for a tolerance of τ ∈ (0, 0.05, 0.1).
Populations of the control and intervention group are sampled from different distributions.
τ = 0 τ = 0.05 τ = 0.1
M mean sd n mean sd n mean sd n
1 0.763 0.106 6395 0.762 0.099 2416 0.770 0.093 604
2 0.781 0.116 1493 0.730 0.106 2306 0.700 0.098 1506
3 0.787 0.121 745 0.739 0.109 1323 0.696 0.103 1284
4 0.787 0.130 425 0.739 0.116 972 0.696 0.108 1104
5 0.807 0.138 271 0.736 0.121 648 0.699 0.106 824
6 0.814 0.132 160 0.748 0.121 482 0.698 0.114 756
7 0.833 0.133 111 0.750 0.134 378 0.699 0.121 602
8 0.837 0.152 98 0.740 0.135 295 0.705 0.119 509
9 0.810 0.155 78 0.757 0.131 226 0.697 0.127 423
10 0.867 0.145 224 0.777 0.154 954 0.722 0.146 2388
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Figure 4: The plot shows the distribution of the number of matching partners (10,000
simulation runs) for equal and different patient populations including tolerance values of
τ ∈ (0, 0.05, 0.1).
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Comment: Parts of the following Section 3.3 are already included in the accepted manuscript
Weber et al. (2020a). The manuscript has been written by myself but may contain comments
and corrections from the co-authors.
3.3 Synthesis of Evidence - Method Comparison
A simulation study covering a wide range of practically relevant scenarios in medical context
is performed. The aim is to investigate the method of Bucher and the MAIC for indirect
comparisons considering time-to-event (TTE) and binary endpoints. The evaluated methods
and scenarios are transferable to continuous endpoints. The statistical properties of the
methods are assessed and compared. The main evaluation measures used in the comparison
are the bias in the estimated therapy effects, root mean squared error (RMSE), coverage, type
I error rates, and power. The simulation comprises nsim = 10, 000 runs for each scenario. In
case the method of Bucher is applied one has to assume that no differences between trial AB
and CB are observed with respect to effect modifiers. Nonetheless, this assumption needs to
be evaluated for each situation in practice. All simulations were done using R version 3.3.3 (R
Core Team, 2017) using the packages corpcor (Schafer et al., 2017) and survival (Therneau,
2015).
3.3.1 Data Simulation
The simulation setting comprises two studies; one study covers the comparison between
treatment A and B (AB) and another study compares treatment C versus B (CB). It is
assumed that a study comparing A versus C is not available (Figure 1). The true treatment
effects of treatment AB, BC, and AC are expressed on the log hazard ratio (HR) scale
for a time-to-event setting and on the log odds ratio (OR) scale for a binary endpoint,
respectively. In the data generating process of the full data set, beyond the treatment variable,
one continuous and three binary variables are involved. A covariance matrix for the error term
is considered which leads to correlations between the four variables (Table 10). Subsequently,
the term “similar populations” refers to the situation where data for the trials AB and CB
follows the same distribution, when divergence in the distribution parameters are assumed
they are called “different”. The event and the censoring times are sampled from a Weibull
distribution (λevent = 0.0002, νevent = 1.8, λcensoring = 0.00012, νcensoring = 2, max.time =
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100) for the generation of the TTE endpoint. The endpoint is then generated by a Cox
proportional hazard model using the simulated event times, event statuses, and the patient
characteristics as covariates. The binary endpoint is generated by a logistic regression model
that considers the patient characteristics as covariates. The included covariates are called
confounders. The outcome generation model with the link function g(·) looks as follows
g(yi) = β0 + βtrxtr,i + βb1xb1,i + βb2xb2,i + βb3xb3,i + βcxc,i
where b1, b2, and b3 refer to the binary variables, c to the continuous variable, and tr
indicates the treatment variable. For TTE endpoints the link function between the log-
hazard function and covariates is assumed to be linear and for binary endpoints the logit-link
is used g(yi) = logit(yi) = log yi1−yi . The values for log HR and log OR of the confounders in
the models with respect to the assumed true treatment effect (Table 12) are given in Table
11. In addition, some of the simulation scenarios cover an interaction term between a binary
variable and the treatment assignment. In this case, the variable is called effect modifier. The
inclusion of the interaction between binary variable 1 (xb1) and treatment (binary variable 1
is an effect modifier for treatment) in the outcome generation model is shown in the following
equation:
g(yi) = β0 + βtrxtr,i + βtr·b1xtr,i · xb1,i + βb1xb1,i + βb2xb2,i + βb3xb3,i + βcxc,i
In Table 11 the corresponding log HR and log OR for the interaction term can be found.
Note, that in case the interaction term is only included in one of the trials, the shared effect
modifier assumption is violated which is assumed for the method of Bucher. The simulation
study is limited to the described clinically inspired data because the aim is not to examine the
influence of the number of confounders or distributions of patient characteristics itself, but
rather the violation of assumptions and occurrence of cross-trial differences. The population
in trial CB defines the target population where the treatment effect between A and C is
estimated for. The true effect size of the trial AC is simulated as high, moderate, low, and
no effect, the exact values for HRs and ORs are given in Table 12. The classification of effect
sizes in terms of log HRs for TTE endpoints is done according to Skipka et al. (2015); for
the ease of comparability, the log ORs for binary endpoints are set to comparable values.
This classification of treatment effects is traced back to the benefit assessment of new drugs,
which aims to test whether a new drug achieves an added benefit compared to the current
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standard of practice. Sample size calculations for balanced designs in trials AB and CB are
based on established formulas (Schoenfeld, 1983; Cohen, 1988) assuming the effects given in
Table 12, 5% type I error rate, and 80% power.
Table 10: Patient characteristics and covariance matrices used for the data generating process
for the two trials (AB and CB) (adapted from Weber et al. (2020a)).
population
similar different
Variable AB/CB AB1 CB2
continuous, mean (sd) 55 (15) 55 (15) 65 (10)
binary 1 (xb1 = 1), % 0.7 0.7 0.5
binary 2 (xb2 = 1), % 0.8 0.8 0.6
binary 3 (xb3 = 1), % 0.4 0.4 0.45
Covariance matrix for AB/CB similar and AB1:
225 0.25 0.05 0.01
0.25 0.2 0.01 0
0.05 0.01 0.15 0.05
0.01 0 0.05 0.1

Covariance matrix for CB2:
100 0 0.05 0.01
0 0.25 −0.01 0
0.05 −0.01 0.1 0.05
0.01 0 0.05 0.15

3.3.2 Evaluation Measures
The main evaluation measures to assess the performance of the two methods are the bias of the
effect estimate (the difference to the true treatment effect as given in Table 12), the RMSE,
the power, the type I error rate, and the two-sided 95% CI coverage. Where the calculated
CIs for the effect estimates in the regression models are based on a normal approximation.
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Table 11: Regression coefficients in terms of log hazard ratio for Cox proportional hazards
models and log odds ratio for logistic regression models considered for simulation of outcomes
in trials AB and CB (adapted from Weber et al. (2020a)).
Time to event Binary
Variable log HR log OR
continuous -0.0051 0.06
binary 1 (b1 = 1) -0.2 -1.76
binary 2 (b2 = 1) 0.18 1.26
binary 3 (b3 = 1) -0.14 -0.2
interaction:
treatment and binary 1 (=1) 0.02 0.04
The power is assessed by the proportion of simulation runs where 0 (no effect) is not included
in the two-sided 95% CI of the effect estimate of the indirect comparison AC when in fact
an effect exists. The power is divided into the categories high, moderate, and low effect. In
case of no effect, one is interested in the type I error rate which is based on the proportion
of simulation runs where again 0 (no effect) is not covered by the two-sided 95% CI of the





δ̂AC,i − δAC (3.1)






(δ̂AC,i − δAC)2 (3.2)
where nsim the number of simulation runs and δAC denotes the true treatment effect and
δ̂AC,i its estimate in simulation run i (Morris et al., 2019). The aim is to minimize bias and
RMSE, whereas power ought to reach high values, the type I error rate should be around
5%, and the CI coverage around 95%. All evaluation measures are calculated for the indirect
comparison AC and correspond to the main treatment effect even if an interaction term is
included in the regression model, because its effect cannot be assessed by the marginal effect
(Norton et al., 2004).
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Table 12: True effect sizes in terms of log odds ratios for binary endpoints including the
binary event rates (π1, π2) and log hazard ratios for time-to-event endpoints for different
effect classes. The column AC is the difference between the effects in columns AB and CB
(adapted from Weber et al. (2020a)).
Time to event Binary
AC AB CB AC AB (π1, π2) CB (π1, π2)
high -0.69 -0.91 -0.22 -0.48 -0.7 (0.45, 0.62) -0.22 (0.45, 0.51)
moderate -0.22 -0.44 -0.22 -0.23 -0.45 (0.45, 0.56) -0.22 (0.45, 0.51)
low -0.05 -0.27 -0.22 -0.06 -0.28 (0.45, 0.52) -0.22 (0.45, 0.51)
no 0 -0.22 -0.22 0 -0.22 (0.45, 0.51) -0.22 (0.45, 0.51)
3.3.3 Simulation Scenarios
The definition of simulation scenarios aims to introduce cross-trial differences between the
trials AB and CB. They are characterized by the following four aspects
• similar or different distributions of patient characteristics (proportions of categorical
variables, mean and variance in distributions of continuous variables substantially dif-
fer), but note that the cut-off between similar and different (as in Table 10) depends
on the variable and the objective of the comparison,
• inclusion of effect modification (interaction term between a binary variable and treat-
ment),
• similar or different confounder variables included in data generating process (trial CB
does not include the variable binary 3 (xb3)),
• differences in the presence of the interaction (trial AB does not include an interaction
term).
The simulation scenarios are given in Table 13 where the distribution of patient characteristics
is considered within each scenario.
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Additionally, the influence of the true power considered in the sample size calculation of the
head-to-head trials (AB and CB) on the performance, in particular, the power of the indirect
comparison (AC) is investigated. The sample size calculations are based on established
formulas (Schoenfeld, 1983; Cohen, 1988) by assuming the effects given in Table 12, a type I
error rate of 5%, and a power of 80%, 90%, 95%, or 99%. The scenarios are again evaluated
using characteristics such as the power, type I error rate, 95% CI coverage, and bias of the
effect estimate in the indirect comparison.
All scenarios for the indirect comparisons are analyzed for a binary and a TTE endpoint.
Table 13: Considered simulation scenarios (adapted from Weber et al. (2020a)).
Scenario Population Confounders Interactions

















This section includes a paragraph for each of the evaluation measures introduced in Section
3.3.2, followed by a paragraph focusing on the influence of the planned power, which is
considered in the sample size calculation of the individual trials, to the indirect comparison.
For the method comparison, the underlying assumptions for the sample size calculation for
trials AB and CB evaluated under scenarios I to V are 80% power, 5% type I error rate,
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and the treatment effect or proportions given in Table 12. Three different settings for the
calculation of direct effect estimates are considered:
1. The regression models for trials AB and CB are adjusted for all relevant effect modifiers
(in terms of an interaction) and confounders.
2. The regression models in trials AB and CB are only adjusted for confounders (effect
modifiers are treated as confounders).
3. The regression models for trials CB are not adjusted for effect modifiers or confounders.
The scenarios are evaluated in all three settings if procurable. When effect modification is
present, MAIC is applied twice: First, considering all confounders and effect modifiers as
matching variables; and second, considering only effect modifiers as matching variables.
Each paragraph covers the results for TTE and binary endpoints. Initially, the results for
setting 1 are described, when differences between the settings are observed they are mentioned
in the corresponding paragraph. The detailed results of the different scenarios and endpoints
based on the described evaluation measures when regression models (trials AB and CB)
are adjusted for all effect modifiers and confounders (setting 1) can be found in Tables 14
to 18. All other results are given in Appendix A.2 (Tables 27 to 35). The differences in
distributions of variables considered in the MAIC procedure influence the ESS. That means
the ESS (neffective) is independent of interactions or adjustment of regression models. Hence,
ESS differs when the assumed set of effect modifiers differs, but the results are comparable
for all considered settings considered for calculating the direct treatment effect (see Table
19 and Appendix A.2 Tables 36 to 39). A performance summary of the methods over all
scenarios is given in Table 20 for TTE endpoints and in Table 21 for binary endpoints.
Power
In scenario I (Table 14), the method of Bucher and MAIC produce equal results, but adjusting
MAIC for all confounders leads to a loss in power when patient characteristics differ. Scenario
II is characterized by an interaction that makes MAIC reach higher power values in case
there are differences in the confounder and effect modifier distributions for TTE endpoints
(Table 15). When adjusting MAIC only for the effect modifiers, power is slightly decreasing.
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For binary endpoints and when characteristics are similar, MAIC results in higher power
values. Additionally, a small increase is observed when MAIC adjusts for effect modifiers
only. In case confounder overlap differs (scenario III, Table 16), similar results as for scenario
II are observed. In scenario IV (Table 17), the power values are relatively high and are
comparable for both methods when populations are similar. When population distributions
differ, adjusting MAIC for all confounders leads to power loss compared to only adjusting for
effect modifiers. In case the effect modification is not considered within the regression models
(setting 2, Appendix Tables 27 to 30), scenarios, where the effect modification is present in
both trials, give better results in terms of power. When only unadjusted effect estimates are
available for CB (setting 3, Appendix Tables 31 to 35), power decreases for scenarios where
effect modification is only present in CB trials.
Type I Error Rate
Type I error rates are around 5% in scenario I for MAIC and the method of Bucher, as well as
for similar and different confounder distributions and both endpoints (Table 14). In scenario
II endpoints differ, TTE endpoints stay round 5%, whereas binary endpoints lead to a type I
error rate around 10% (Table 15). In case confounder overlap differs (scenario III, Table 16),
type I error rate is still around 5%, only MAIC shows higher values for binary endpoints.
However, a clear type I error rate inflation is observed if effect modification is only present in
trial CB (scenario IV and V, Tables 17 and 18). When populations are similar, the methods
perform equally, but in case of differences MAIC leads to lower type I error rates, which are
still highly inflated. For binary endpoints, MAIC leads to inflated type I error rates in all
scenarios where effect modification is present. When the effect modification is not considered
in the estimation of effects in direct evidence (setting 2, Appendix Tables 27 to 30), type I
error rate is controlled for scenarios with effect modification in both trials (scenarios II and
III).
Coverage
Coverage is observed to be between 90% and 95% in scenario I focusing on similar cohorts
(Table 14). High treatment effects and different population distributions have a coverage
below 90%, whereas for smaller treatment effects, the coverage is above 90%. When an effect
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modifier is present (scenario II, Table 15), MAIC reaches coverage over 90% whereas Bucher
leads to values lower than 90% for binary endpoints. Considering a TTE endpoint, results
are the same between methods. When additionally confounders differ between trials in the
binary case, MAIC reaches a higher coverage, whereas for TTE endpoints both methods lead
to similar results. In scenario IV and V when population distributions differ MAIC reaches
higher power values for both endpoints, but those values are below 85% (Tables 17 and 18).
Bias and RMSE
In scenario I bias and RMSE are the same when patient cohorts are similar, but in case of
differences for MAIC higher bias and RMSE are observed for both endpoints (Table 14). For
both endpoints, the bias and the RMSE are slightly higher for MAIC when all confounders
are considered in the matching step of MAIC in scenario I. When effect modifiers are present
and regression models for effect estimation are adjusted for those effect modifiers, Bucher and
MAIC give similar results for TTE endpoints (Table 15). For the binary endpoint, MAIC
results in lower bias and RMSE. In scenario III (Table 16), confounder overlap differs, only
small differences to scenario II are recognized. Scenarios IV and V show the lowest bias
and RMSE values for TTE endpoints (Tables 17 and 18)). In those scenarios, differences
between Bucher and MAIC are negligible for both endpoints. When effect modification is
not considered in the regression models for effect estimates of AB and CB, this leads to even
slightly smaller bias and RMSE (setting 2, Appendix Tables 27 to 30). When CB is not
adjusted for any confounder, bias and RMSE increase (setting 3, Appendix Tables 31 to 35).
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Table 14: Simulation results for scenario I (setting 1). The rows include the two endpoints,
similar and different population distributions, and the considered effect sizes, the columns the
evaluation measures for these scenarios power/type I error, coverage (Cov), bias, and root
mean squared error (RMSE). Accordingly, for no effect, the column Power shows the type I
error rate (α) (adapted from Weber et al. (2020a)).
Bucher MAIC
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.385 0.919 -0.090 0.263 0.383 0.918 -0.090 0.265
TTE similar moderate 0.206 0.945 0.032 0.166 0.203 0.946 0.032 0.166
TTE similar low 0.066 0.943 0.039 0.136 0.066 0.944 0.039 0.136
TTE similar no 0.050 0.950 0.005 0.122 0.050 0.950 0.005 0.122
TTE diff high 0.430 0.913 -0.091 0.248 0.338 0.870 -0.060 0.397
TTE diff moderate 0.227 0.941 0.031 0.160 0.168 0.935 0.039 0.230
TTE diff low 0.066 0.945 0.036 0.129 0.067 0.942 0.041 0.172
TTE diff no 0.052 0.948 0.007 0.118 0.053 0.947 0.012 0.152
binary similar high 0.487 0.912 -0.228 0.438 0.485 0.913 -0.228 0.439
binary similar moderate 0.202 0.948 -0.004 0.212 0.201 0.948 -0.004 0.212
binary similar low 0.065 0.951 -0.001 0.154 0.066 0.951 -0.001 0.154
binary similar no 0.052 0.948 0.000 0.142 0.052 0.948 0.000 0.142
binary diff high 0.475 0.907 -0.241 0.457 0.346 0.881 -0.303 0.655
binary diff moderate 0.193 0.947 -0.001 0.214 0.140 0.940 -0.004 0.306
binary diff low 0.066 0.954 0.000 0.153 0.067 0.946 -0.002 0.207










Table 15: Simulation results for scenario II (setting 1). The rows include the two endpoints, similar and different population distri-
butions, and the considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov),
bias, and root mean squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper
part of the following tables contains the results for considering all confounders within MAIC and the lower part those for only effect
modifiers are included in MAIC (adapted from Weber et al. (2020a)).
Bucher MAIC - all confounders MAIC - only effect modifiers
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.061 0.814 0.519 0.834 0.062 0.813 0.520 0.837 0.061 0.814 0.519 0.834
TTE similar moderate 0.049 0.846 0.230 0.341 0.047 0.846 0.230 0.341 0.049 0.846 0.230 0.341
TTE similar low 0.053 0.932 0.076 0.191 0.054 0.932 0.076 0.191 0.053 0.932 0.076 0.191
TTE similar no 0.054 0.946 -0.007 0.155 0.053 0.947 -0.007 0.155 0.054 0.946 -0.007 0.155
TTE diff high 0.069 0.841 0.584 1.037 0.123 0.816 0.750 1.478 0.081 0.830 0.596 1.071
TTE diff moderate 0.052 0.867 0.248 0.387 0.065 0.878 0.284 0.508 0.055 0.865 0.248 0.388
TTE diff low 0.056 0.934 0.077 0.211 0.060 0.931 0.088 0.271 0.056 0.934 0.077 0.211
TTE diff no 0.052 0.948 -0.008 0.169 0.061 0.939 -0.002 0.213 0.053 0.947 -0.008 0.169
binary similar high 0.048 0.876 0.463 0.757 0.288 0.944 -0.081 0.413 0.287 0.944 -0.080 0.412
binary similar moderate 0.052 0.897 0.214 0.402 0.210 0.941 -0.054 0.255 0.210 0.942 -0.054 0.255
binary similar low 0.054 0.946 0.038 0.252 0.160 0.902 -0.127 0.237 0.160 0.902 -0.127 0.237
binary similar no 0.049 0.951 -0.018 0.226 0.123 0.877 -0.150 0.241 0.123 0.877 -0.150 0.241
binary diff high 0.049 0.901 0.448 1.002 0.222 0.918 -0.119 0.602 0.228 0.944 -0.048 0.443
binary diff moderate 0.053 0.918 0.209 0.455 0.154 0.932 -0.059 0.336 0.176 0.945 -0.039 0.265
binary diff low 0.048 0.952 0.038 0.281 0.122 0.917 -0.127 0.271 0.138 0.914 -0.115 0.234







Table 16: Simulation results for scenario III (setting 1). The rows include the two endpoints, similar and different population distri-
butions, and the considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov),
bias, and root mean squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper
part of the following tables contains the results for considering all confounders within MAIC and the lower part those for only effect
modifiers are included in MAIC (adapted from Weber et al. (2020a)).
Bucher MAIC - all confounders MAIC - only effect modifiers
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.059 0.811 0.496 0.760 0.060 0.810 0.497 0.765 0.059 0.811 0.496 0.760
TTE similar moderate 0.053 0.837 0.228 0.337 0.052 0.837 0.228 0.337 0.053 0.837 0.228 0.337
TTE similar low 0.049 0.934 0.074 0.185 0.050 0.934 0.074 0.185 0.049 0.934 0.074 0.185
TTE similar no 0.053 0.947 -0.009 0.152 0.053 0.947 -0.009 0.152 0.053 0.947 -0.009 0.152
TTE diff high 0.069 0.841 0.555 0.961 0.112 0.821 0.697 1.347 0.073 0.836 0.559 0.969
TTE diff moderate 0.055 0.863 0.237 0.376 0.072 0.878 0.262 0.476 0.056 0.864 0.237 0.376
TTE diff low 0.051 0.935 0.08 0.207 0.053 0.933 0.090 0.260 0.051 0.935 0.080 0.208
TTE diff no 0.054 0.946 -0.005 0.167 0.058 0.942 0.003 0.208 0.054 0.946 -0.005 0.167
binary similar high 0.048 0.875 0.470 0.833 0.296 0.944 -0.091 0.416 0.295 0.943 -0.091 0.416
binary similar moderate 0.049 0.905 0.208 0.401 0.220 0.941 -0.065 0.258 0.220 0.940 -0.065 0.258
binary similar low 0.047 0.947 0.046 0.252 0.147 0.906 -0.125 0.234 0.148 0.906 -0.125 0.233
binary similar no 0.047 0.953 -0.020 0.227 0.122 0.878 -0.152 0.243 0.123 0.877 -0.152 0.243
binary diff high 0.050 0.895 0.481 1.055 0.228 0.924 -0.123 0.591 0.238 0.947 -0.051 0.437
binary diff moderate 0.051 0.914 0.217 0.462 0.160 0.940 -0.062 0.329 0.178 0.946 -0.037 0.263
binary diff low 0.051 0.947 0.039 0.285 0.128 0.913 -0.128 0.270 0.141 0.910 -0.117 0.235










Table 17: Simulation results for scenario IV. The rows include the two endpoints, similar and different population distributions, and
the considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov), bias, and root
mean squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper part of the
following tables contains the results for considering all confounders within MAIC and the lower part those for only effect modifiers are
included in MAIC (adapted from Weber et al. (2020a)).
Bucher MAIC - all confounders MAIC - only effect modifiers
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.627 0.801 -0.209 0.286 0.625 0.802 -0.209 0.287 0.627 0.801 -0.209 0.286
TTE similar moderate 0.655 0.786 -0.157 0.205 0.653 0.786 -0.156 0.205 0.655 0.786 -0.157 0.205
TTE similar low 0.551 0.664 -0.182 0.214 0.549 0.665 -0.182 0.214 0.551 0.664 -0.182 0.214
TTE similar no 0.489 0.511 -0.225 0.249 0.488 0.512 -0.225 0.249 0.489 0.511 -0.225 0.249
TTE diff high 0.685 0.777 -0.214 0.278 0.505 0.770 -0.191 0.357 0.635 0.779 -0.212 0.289
TTE diff moderate 0.693 0.764 -0.157 0.202 0.481 0.825 -0.152 0.234 0.646 0.783 -0.156 0.207
TTE diff low 0.579 0.646 -0.184 0.214 0.414 0.750 -0.179 0.227 0.542 0.665 -0.183 0.215
TTE diff no 0.510 0.490 -0.227 0.250 0.380 0.620 -0.224 0.258 0.483 0.517 -0.227 0.251
binary similar high 0.712 0.766 -0.491 0.628 0.712 0.768 -0.491 0.629 0.712 0.766 -0.491 0.628
binary similar moderate 0.524 0.808 -0.262 0.361 0.524 0.809 -0.262 0.361 0.524 0.808 -0.262 0.361
binary similar low 0.362 0.740 -0.259 0.327 0.361 0.739 -0.259 0.327 0.362 0.740 -0.259 0.327
binary similar no 0.278 0.722 -0.258 0.320 0.278 0.722 -0.258 0.320 0.278 0.722 -0.258 0.320
binary diff high 0.709 0.762 -0.508 0.646 0.505 0.787 -0.563 0.816 0.657 0.776 -0.518 0.675
binary diff moderate 0.523 0.812 -0.265 0.362 0.353 0.857 -0.271 0.425 0.480 0.820 -0.266 0.372
binary diff low 0.371 0.742 -0.259 0.325 0.271 0.806 -0.259 0.353 0.347 0.756 -0.258 0.329







Table 18: Simulation results for scenario V (setting 1). The rows include the two endpoints, similar and different population distri-
butions, and the considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov),
bias, and root mean squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper
part of the following tables contains the results for considering all confounders within MAIC and the lower part those for only effect
modifiers are included in MAIC (adapted from Weber et al. (2020a)).
Bucher MAIC - all confounders MAIC - only effect modifiers
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.655 0.794 -0.207 0.277 0.650 0.791 -0.208 0.277 0.655 0.794 -0.207 0.277
TTE similar moderate 0.677 0.778 -0.156 0.202 0.674 0.777 -0.156 0.203 0.677 0.778 -0.156 0.202
TTE similar low 0.555 0.655 -0.181 0.212 0.555 0.656 -0.181 0.212 0.555 0.655 -0.181 0.212
TTE similar no 0.484 0.516 -0.224 0.248 0.483 0.517 -0.224 0.248 0.484 0.516 -0.224 0.248
TTE diff high 0.706 0.772 -0.208 0.27 0.531 0.782 -0.190 0.334 0.647 0.778 -0.206 0.280
TTE diff moderate 0.712 0.766 -0.156 0.198 0.500 0.826 -0.150 0.225 0.662 0.783 -0.155 0.202
TTE diff low 0.589 0.634 -0.183 0.212 0.433 0.734 -0.179 0.224 0.557 0.656 -0.183 0.214
TTE diff no 0.514 0.486 -0.225 0.248 0.388 0.612 -0.223 0.255 0.483 0.517 -0.225 0.249
binary similar high 0.722 0.762 -0.498 0.632 0.722 0.762 -0.498 0.632 0.712 0.766 -0.491 0.628
binary similar moderate 0.519 0.812 -0.265 0.360 0.519 0.812 -0.265 0.360 0.524 0.808 -0.262 0.361
binary similar low 0.367 0.742 -0.260 0.326 0.367 0.742 -0.260 0.326 0.362 0.740 -0.259 0.327
binary similar no 0.290 0.710 -0.263 0.325 0.290 0.710 -0.263 0.325 0.278 0.722 -0.258 0.320
binary diff high 0.707 0.768 -0.497 0.637 0.644 0.782 -0.502 0.661 0.657 0.776 -0.518 0.675
binary diff moderate 0.521 0.809 -0.263 0.361 0.485 0.821 -0.264 0.371 0.480 0.820 -0.266 0.372
binary diff low 0.370 0.734 -0.261 0.327 0.348 0.750 -0.261 0.331 0.347 0.756 -0.258 0.329
binary diff no 0.285 0.715 -0.262 0.322 0.270 0.730 -0.262 0.325 0.270 0.730 -0.261 0.325
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Effective Sample Size
When population distributions are similar, the ESS for the MAIC procedure is equal to
the actual sample size which is considered in the method of Bucher. Differences in patient
characteristics between trials and when all confounders are considered as matching variables
in MAIC cause the ESS to reach only half of the actual sample size. Whereas the ESS is
solely reduced by 15% to 20% when MAIC is adjusted for relevant effect modifiers only.
Table 19: Mean and standard deviation (sd) of Effective Sample Size (ESS) for scenario I
considering a time-to-event (TTE) as well as binary endpoint (adapted from Weber et al.
(2020a)).
Endpoint Population Effect Sample Size mean ESS sd ESS
TTE similar high 94 92.883 1.571
TTE similar moderate 396 394.731 1.783
TTE similar low 1044 1042.307 2.376
TTE similar no 1578 1575.991 2.829
TTE different high 94 38.927 6.735
TTE different moderate 396 161.756 15.513
TTE different low 1044 423.204 28.605
TTE different no 1578 639.000 37.511
binary similar high 192 190.883 1.574
binary similar moderate 648 646.692 1.848
binary similar low 1600 1598.248 2.438
binary similar no 2176 2174.037 2.799
binary different high 192 79.788 10.188
binary different moderate 648 264.013 20.993
binary different low 1600 646.443 37.148
binary different no 2176 878.080 44.440
Influence of Planned Power of Direct Comparisons
For the independent trials AB and CB, the power used for calculating the sample size is varied
to investigate the influence on the power of the indirect comparison. Trials are powered
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at 80%, 90%, 95%, and 99% including combinations of this values. In simulations it was
observed, that the power of the indirect comparison increases with increasing power of the
head-to-head comparisons. Higher treatment effects in the indirect comparison gain more
power by increasing the power in head-to-head trials (see Figure 5). However, even in case
both trials are powered at 99%, the power of the indirect comparison is less than 60% when
all method assumptions are met and the treatment effect is assumed to be high (see Appendix
A.2 Table 40). Fixing the power in the AgD trial (CB) to 80% and increasing power of the
IPD trial AB also demonstrates that there is an increase in power of the indirect comparison,
but it is still clearly below the aspired 80%. The corresponding results are plotted in Figure
6 and detailed power values are included in Table 41. The type I error rate remains at
around 5% for all power scenarios. The results for bias of the effect estimate, RMSE, and the
coverage of the 95% CI are comparable for all power scenarios; these measures are already
discussed in the paragraphs above.
Figure 5: The plot shows the power depending on the true effect of the indirect comparison
(A versus C) for balanced groups and different power scenarios for the direct trials (A versus
B and C versus B).
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Figure 6: The plot shows the power depending on the true effect of the indirect comparison
A versus C (AC) for balanced groups and different power scenarios for the direct trials (A
versus B and C versus B). Fixing the power in the AgD trial (CB) to 80% (adapted from







Table 20: Summary of the method comparison. An overview of situations where the method of Bucher outperforms the MAIC procedure
and vice versa with regard to the considered simulation scenarios and a time-to-event (TTE) endpoint is presented. 1 signifies that both
methods perform equally, 2 the method of Bucher works best, and 3 MAIC outperforms Bucher (adapted from Weber et al. (2020a)).
Theoretical situation Analysis deviations Results But, note
Scenario Endpoint Population Confounder Interaction from simulated situation Power Cov Type I error Bias/RMSE Sample Size
I TTE similar similar no 1 1 1 1 1
maximal power < 40%
TTE different similar no 2 2 1 2 2
TTE similar similar no
CB not adjusted for confounders
1 1 1 1 1
TTE different similar no 2 2 1 2 2
II TTE similar similar yes - similar 1 1 1 1 1
maximal power < 30%
TTE different similar yes - similar 3 3 2 2 2
TTE similar similar yes - similar
CB not adjusted for confounders
1 1 1 1 1
TTE different similar yes - similar 3 3 2 2 2
TTE similar similar yes - similar
Effect modification not adjusted
1 1 1 1 1
TTE different similar yes - similar 2 2 2 2 2
III TTE similar different yes - similar 1 1 1 1 1
maximal power < 15%
TTE different different yes - similar 3 1 2 1 2
TTE similar different yes - similar
CB not adjusted for confounders
1 1 1 1 1
TTE different different yes - similar 3 3 3 2 2
TTE similar different yes - similar
Effect modification not adjusted
1 1 1 1 1
TTE different different yes - similar 2 2 2 2 2
IV TTE similar similar yes - different 1 1 1 1 1
TTE different similar yes - different 2 3 3 1 2
TTE similar similar yes - different
CB not adjusted for confounders
1 1 1 1 1 maximal power < 80%
TTE different similar yes - different 2 3 3 1 2 highly inflated type I error rate
TTE similar similar yes - different
Effect modification not adjusted
1 1 1 1 1
TTE different similar yes - different 2 3 3 1 2
V TTE similar different yes - different 1 1 1 1 1
TTE different different yes - different 2 3 3 1 2
TTE similar different yes - different
CB not adjusted for confounders
1 1 1 1 1 maximal power < 80%
TTE different different yes - different 2 3 3 1 2 highly inflated type I error rate
TTE similar different yes - different
Effect modification not adjusted
1 1 1 1 1










Table 21: Summary of the method comparison. An overview of situations where the method of Bucher outperforms the MAIC procedure
and vice versa with regard to the considered simulation scenarios for a binary endpoint is presented. 1 signifies that both methods
perform equally, 2 the method of Bucher works best, and 3 MAIC outperforms Bucher (adapted from Weber et al. (2020a)).
Theoretical situation Analysis deviations Results But, note
Scenario Endpoint Population Confounder Interaction from simulated situation Power Cov Type I error Bias/RMSE Sample Size
I Binary similar similar no 1 1 1 1 1
maximal power < 50%
Binary different similar no 2 2 1 2 2
Binary similar similar no
CB not adjusted for confounders
1 1 1 1 1
Binary different similar no 2 2 1 2 2
II Binary similar similar yes - similar 3 3 2 3 1
maximal power < 35%
Binary different similar yes - similar 3 3 2 3 2
Binary similar similar yes - similar
CB not adjusted for confounders
3 3 3 3 1
Binary different similar yes - similar 3 3 3 3 2
Binary similar similar yes - similar
Effect modification not adjusted
1 1 1 1 1
Binary different similar yes - similar 2 2 2 2 2
III Binary similar different yes - similar 3 3 2 3 1
maximal power < 30%
Binary different different yes - similar 3 3 2 3 2
Binary similar different yes - similar
CB not adjusted for confounders
3 3 3 3 1
Binary different different yes - similar 3 3 3 3 2
Binary similar different yes - similar
Effect modification not adjusted
1 1 1 1 1
Binary different different yes - similar 2 1 3 1 2
IV Binary similar similar yes - different 1 1 1 1 1
Binary different similar yes - different 2 3 3 1 2
Binary similar similar yes - different
CB not adjusted for confounders
1 1 1 1 1 maximal power < 80%
Binary different similar yes - different 2 3 3 2 2 highly inflated type I error rate
Binary similar similar yes - different
Effect modification not adjusted
1 1 1 1 1
Binary different similar yes - different 2 3 3 2 2
V Binary similar different yes - different 1 1 1 1 1
Binary different different yes - different 2 3 3 2 2
Binary similar different yes - different
CB not adjusted for confounders
1 1 1 1 1 maximal power < 80%
Binary different different yes - different 2 3 3 2 2 highly inflated type I error rate
Binary similar different yes - different
Effect modification not adjusted
1 1 1 1 1
Binary different different yes - different 2 3 3 2 2
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The results of the method comparison show unsatisfactory values for power as well as bias
and RMSE. The natural progression is including more studies, and therefore increasing the
sample size, in the indirect comparison. Methods for this situation are inspected in Section
3.4.
Comment: Parts of the following Section 3.4 are already included in the submitted manuscript
Weber et al. (2020b). The manuscript has been written by myself but may contain comments
and corrections from the co-authors.
3.4 Synthesis of Evidence - Multiple Studies
A simulation study evaluates the methods described in Section 2.1 for including multiple
studies within the adjusted indirect comparison by MAIC for TTE endpoints. It aims to
investigate the methods for practically relevant scenarios in a medical context. The method
of Bucher is additionally applied in all the considered simulation settings for comparison.
Statistical performance measures of the methods are assessed and compared such as the bias
of the estimated therapy effects, RMSE, power, coverage of the 95% CI, and type I error rate.
Due to the high computation time and memory capacity required, the number of simulation
runs is limited to nsim = 2, 000 for each scenario. To evaluate the error introduced by
the simulation, the Monte Carlo standard errors of the bias are calculated. The method of
Bucher assumes that there are no differences between trials AB and CB with respect to effect
modifiers. Nevertheless, this assumption needs to be evaluated for each situation in practice.
Simulations were done using R version 3.5.1 (R Core Team, 2017) using the packages meta
(Balduzzi et al., 2019) and survival (Therneau, 2015).
3.4.1 Data Simulation
The data generating process is similar to Section 3.3.1. The key points are described below,
and details about the formulas can be found in Section 3.3.1.
The data for trials AB and CB contains one continuous and three binary variables (Table
10). A covariance matrix is specified to include a random error term (Table 10) or rather
correlations between the variables. The true treatment effects of treatment comparisons AB,
CB, and AC (defined as the difference between AB and CB) are expressed on the log HR scale.
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For generating the TTE outcomes, the event time and the censoring time are sampled from a
Weibull distribution (λevent = 0.0002, νevent = 1.8, λcensoring = 0.00012, νcensoring = 2, max.
time=100). Utilizing those times and the baseline characteristics a Cox proportional hazard
model is applied to generate the event status. The values for log HRs of the covariates in
the models are given in Table 22. Some of the simulation scenarios comprise an interaction
term between a binary baseline variable and treatment. This baseline variable is then called
effect modifier. The corresponding log HRs for the interaction term are also specified in
Table 22, where the settings of a positive and a negative interaction term is considered. The
simulation study is limited to the described data set because its purpose is not to examine
the influence of patient characteristics itself. The true effect size of indirect comparison AC
is simulated as high, moderate, low, and no effect. This classification of effect sizes follows
the recommendations in Skipka et al. (2015) and refers to the benefit assessment of new
drugs. The treatment effect in terms of log HR is assumed to follow a normal distribution to
introduce some variability in treatment effects between trials comparing the same treatments.
The mean values for the treatment effects are given in Table 23, which are combined with a
small (σ = 0.2) or a large (σ = 0.4) variance value. The desired power of 80%, 5% type I
error rate (two-sided), and the mean log HRs for the head-to-head treatment effect (see Table
23) are assumed for the sample size calculations, which are based on established formulas
(Schoenfeld, 1983). The sample sizes for trial AB and CB according to the different treatment
effects of the indirect comparison AC are given in Table 24. The underlying group allocation
ratio is 1:1 for the treatment and control group.
Table 22: Regression coefficients in terms of log hazard ratios for Cox-regression models
considered for simulation of outcomes (adapted from Weber et al. (2020b)).
Variable log HR
continuous -0.0051
binary 1 (xb1 = 1) -0.4
binary 2 (xb2 = 1) 1.122
binary 3 (xb3 = 1) -0.2
interaction:
treatment and binary 1 (=1) ±0.02
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Table 23: Mean values of a normal distribution for log hazard ratios for time-to-event end-
points for different effect classes. Where the AC column is the difference between AB and CB
(adapted from Weber et al. (2020b)).
AC AB CB
high -0.69 -0.91 -0.22
moderate -0.22 -0.44 -0.22
low -0.05 -0.27 -0.22
no 0 -0.22 -0.22
Table 24: Sample size in individual trials comparing treatment A and B (AB), comparing
treatment C and B (CB), depending on the treatment effects in the indirect comparison AC.
The sample sizes are based on sample size calculations (adapted from Weber et al. (2020b)).







The performance of the approaches for the inclusion of multiple studies are evaluated by the
bias of the effect estimate (the difference to the true treatment effect as given in Table 23, see
Formula 3.1), the RMSE (see Formula 3.2), the power, the type I error rate, and the two-sided
95% CI coverage. The calculation of CIs corresponding to the effect estimate in the regression
model relies on a normal approximation. A detailed explanation of the evaluation measures
and its calculation can be found in Section 3.3.2. Due to a lower number of simulation runs,






(δ̂AC,i − δAC)2 (3.3)
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where nsim the number of simulation runs and δ̂AC,i denotes the estimate of the true treatment
effect in simulation run i and δAC,i the mean estimate over all simulation runs (Morris et al.,
2019).
3.4.3 Simulation Scenarios
The methods for inclusion of multiple studies are applied to 2, 4, and 10 trials for the direct
comparison. If numerous studies are available for both trials AB and CB, the number of trials
is assumed to be equal. The matching variables, which are aimed to be balanced, are the
variables binary1, binary2, and the continuous one. This implies the misspecification of the
matching model since MAIC should only balance for essential effect modifiers. All baseline
variables are considered as covariates in the regression models for estimating the treatment
effects. Some of the approaches involve a synthesis of treatment effects by meta-analysis
which is implemented using fixed and random effects models. Furthermore, the influence of
the magnitude of the variance (σ = 0.2 versus σ = 0.4) in the treatment effects is evaluated.
To investigate the advantage of combining multiple studies within the MAIC procedure,
the simulation scenarios include situations where assumptions for the methods of indirect
comparisons are violated. The simulation scenarios are described in Table 25, all scenarios
are evaluated for all the described approaches.
Table 25: Simulation scenarios (adapted from Weber et al. (2020b)).
Scenario Population Interaction






This results section is split according to the classification of approaches in Section 2.2.4,
within each of the three paragraphs the different evaluation measures are discussed. Detailed
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results for the described evaluation measures of the different scenarios are documented in
Appendix Section A.3 (Tables 42 to 53). Over all scenarios, the ESS in MAIC is less than
half of the original sample size. For multiple IPD (see Table 26 at the end of this section)
the results on ESS are given for illustration; all other scenarios lead to comparable ESS.
Simulations showed similar results for positive and negative log HRs for the interaction term;
therefore, this section is limited to the results for the negative log HR.
If a meta-analysis is involved in an approach, the results described and discussed in detail
are based on the random-effects model. For selected scenarios, the fixed-effects model is
implemented additionally. In strategies where the meta-analysis is conducted to combine the
treatment effects of several indirect comparisons differences between those two models are
observed. Fixed-effects meta-analysis results in slightly higher power (Appendix Tables 54
to 59). However, the use and interpretation of a fixed-effects model for the combination of
indirect evidence should be done carefully, and its suitability needs to be checked for each
situation individually.
Results for all simulation scenarios are described and discussed for a variance of σ = 0.2 in
the treatment effect distribution. Moreover, scenarios I and II are evaluated for a variance
of σ = 0.4 in the treatment effect distribution (see Appendix Table 60 to 65). It is observed
that increasing the variance component when simulating the treatment effects for individual
trials leads to higher bias and RMSE in the effect estimate of the indirect comparison. The
power is slightly lower, and type I error rates are comparable to those of the lower variance
scenarios.
The Monte Carlo standard errors for the bias of the indirect effect estimates are all smaller
than 0.02, in most cases even lower than 0.01. Detailed results are included in the Tables in
Appendix Section A.3.
In the following the results apply for the method of Bucher and MAIC; otherwise, differences
are further described.
Figure 7, 8, 9, and 10 assume a high treatment effect and demonstrated the power, type I
error rate, bias, and RMSE of the scenarios and methods depending on the number of trials.
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One IPD trial (AC) and multiple AgD trials (CB)
Either the AgD trials are combined by a meta-analysis (approach A.1), or all indirect com-
parisons are conducted (approach A.2).
Power
In scenarios I, II, and III it is apparent that approach A.1 results in higher power values
compared to approach A.2. For high treatment effects, the desired power of at least 80% is
achieved for approach A.1 when patient characteristics are similar. Differences in baseline
characteristics between trials lead to a loss in power for MAIC under approach A.1, whereas
approach A.2 leads to the same results for both methods which are close to the results for
similar cohorts. Smaller differences between approach A.1 and A.2 are observed in scenario
IV. Applying MAIC under consideration of approach A.2 when effect modification is present
and patient characteristics differ leads to higher power values compared to approach A.1.
Increasing the number of studies leads to a power increase which is observed to be stronger
for smaller treatment effects (Appendix Table 42 and 48).
Type I error
Type I error rate is about 6% for approach A.2 and around 10% for approach A.1 under the
conditions of scenarios I and II (Appendix Table 42). In scenario III where effect modification
is present an inflated type I error rate is observed for both methods which increases by
the number of studies (Appendix Table 48). When additionally patient cohorts differ, a
substantially increased type I error rate is documented even for a small number of studies
(Appendix Table 48).
Coverage
Scenarios I and II have a coverage of around 95% for approach A.2, whereas approach A.1
results in values less than 90% (Appendix Table 42). Approach A.1 leads to lower coverage
compared to approach A.2 in scenarios III and IV, values are observed to be less than 95%
for both approaches, but some scenarios are close to 95% (Appendix Table 48).
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Bias/RMSE
Bias and RMSE increase for higher treatment effects. In scenario I bias and the RMSE
are slightly higher for approach A.2. compared to A.1. The same results are observed for
scenarios I and II for the method of Bucher. Applying MAIC the two approaches A.1 and A.2
give equal results. Bias and RMSE are higher for scenarios that include effect modification
(scenario III and IV). In scenario III RMSE is higher for approach A.2, whereas the bias is
lower or comparable to approach A.1. Scenario IV results in less biased effect estimates and
lower RMSE for approach A.2 when treatment effects are high, but the reversed results are
observed for smaller treatment effects (Appendix Table 43 and 49).
Multiple IPD trials (AC) and one AgD trial (CB)
Either the IPD trials are pooled before the indirect comparison (approach B.1), or all indirect
comparisons are conducted and effect estimates are pooled afterward (approach B.2).
Power
It is observed that the power increases by the number of trials. The higher the treatment
effect, the fewer studies are needed to reach reasonable power regions (above 80%). Appar-
ently, for the defined low treatment effect, even a high number of IPD trials cannot assure the
desired power. Scenarios I and II give the same results for the method of Bucher under both
approaches (Appendix Table 44). The approaches perform equally for MAIC when patient
cohorts are similar, but approach B.2 reaches better power values in scenario II. In case of
scenario IV approach B.2 results in high power values compared to approach B.1, whereas in
scenario III for MAIC the approach B.1 leads to higher power values, especially for a small
number of studies (Appendix Table 50).
Type I error
Type I error rate is around 5% for scenarios I and II (Appendix Table 44). Focusing on
scenarios III and IV the type I error rate is considerably increased with values between 10%
and 26% (Appendix Table 50). For MAIC, approach B.1 leads to lower type I error rates
compared to B.2 in scenario IV.
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Coverage
In scenario I and II, the coverage is around 95% and it is observed to be independent of
the number of studies. For scenarios III the coverage is above 80% and closer to 95% for
higher treatment effects. When differences between trials occur (scenario IV) the coverage
is decreasing. For MAIC, the approach B.2 performs better in scenario IV when treatment
effects are high or medium, for low and no effects approach B.1 leads to higher coverage
(Appendix Table 44 and 50).
Bias/RMSE
The bias and the RMSE values rise with increasing treatment effect. However, a higher
number of IPD trials leads to more precise estimates, meaning a lower bias and RMSE are
observed. Scenarios I and II show equal results for both approaches. The MAIC shows
better performance in terms of bias and the RMSE when applying approach B.2 in scenario
IV, whereas in scenario II, the performance is comparable (Appendix Table 45 and 51).
The presence of an effect modifier leads to higher bias, but the RMSE is not considerably
increased.
Multiple IPD trials (AC) and multiple AgD trials (CB)
When various studies cover both head-to-head comparisons, either the AgD trials are com-
bined by a meta-analysis and IPD is pooled (C.1), only IPD trials are pooled to conduct
all indirect comparisons (approach C.2), or all possible indirect comparisons are conducted
(approach C.3).
Power
Likewise the results above, the simulations show that power increases by the number of trials.
All considered approaches (approaches C.1, C.2, and C.3) give comparable results in terms of
power in scenarios I and III. In scenario II, approaches C.1, C.2, and C.3 perform similarly for
the method of Bucher. Applying MAIC lower power values are observed under approaches
C.1 and C.2 compared to C.3 as well as compared to the method of Bucher. Power is lower
in scenarios III and IV compared to scenarios I and II. In scenario II and IV MAIC reaches
the highest power when applying approach C.3 (Appendix Table 46 and 52).
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Type I error
In scenarios I and II, type I error rate is around 5% for all approaches. Scenarios III and IV
lead to clearly increased type I error rates which are increasing with the number of studies
(Appendix Table 46 and 52). But it is noticeable that under approach C.1 and C.2, MAIC
shows lower type I error rates (Appendix Table 52).
Coverage
The coverage is around 95% for scenarios I and II and smaller for scenarios III and IV
(Appendix Table 46 and 52). All methods perform equally in the situation of scenario III. In
scenario IV, applying MAIC and approach C.3 shows the best coverage for high and medium
treatment effects, whereas approaches C.1 and C.2 give better results in terms of coverage
for smaller treatment effects (Appendix Table 52).
Bias/RMSE
Bias and RMSE decrease with an increasing number of studies. For the method of Bucher,
the three approaches lead to similar results in all scenarios (Appendix Table 47 and 53). For
MAIC, scenarios I and III lead to consistent results between the strategies. Scenarios II and
IV show higher RMSE values for MAIC compared to Bucher for approaches C.1 and C.2,
























































































































































































Method ● ● ●All IC Pool IPD Pool IPD, AgD
Figure 7: The plots show the power depending on the number of trials considered for estimating the indirect treatment effect (here for
high treatment effect) for all approaches and scenarios when using the MAIC approach for indirect comparisons. The first row shows
the results for one IPD trial and multiple AgD trials, the second for one AgD trial and multiple IPD trials, and the third row for
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Figure 8: The plots show the type I error rate depending on the number of trials considered for estimating the indirect treatment effect
(here for high treatment effect) for all approaches and scenarios when using the MAIC approach for indirect comparisons. The first
row shows the results for one IPD trial and multiple AgD trials, the second for one AgD trial and multiple IPD trials, and the third


















































































































Method All IC Pool IPD Pool IPD, AgD
Figure 9: The plots show the bias depending on the number of trials considered for estimating the indirect treatment effect (here for high
treatment effect) for all approaches and scenarios when using the MAIC approach for indirect comparisons. The first row shows the
results for one IPD trial and multiple AgD trials, the second for one AgD trial and multiple IPD trials, and the third row for multiple









































































































































Method All IC Pool IPD Pool IPD, AgD
Figure 10: The plots show the Root mean squared error (RMSE) depending on the number of trials considered for estimating the
indirect treatment effect (here for high treatment effect) for all approaches and scenarios when using the MAIC approach for indirect
comparisons. The first row shows the results for one IPD trial and multiple AgD trials, the second for one AgD trial and multiple IPD
trials, and the third row for multiple IPD and AgD trials.
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Table 26: Mean and standard deviation (sd) of the Effective Sample Size (ESS) of the MAIC
procedure for the scenarios characterized by differences in patient characteristics (Scenarios
II and IV). The actual number of patients in the trial is given in the column Sample Size. As
an example, the situation including two IPD studies which are pooled for the MAIC is shown
here (adapted from Weber et al. (2020b)).
Effect Sample Size mean ESS sd ESS
high 188 81.47 11.08
medium 776 329.20 30.68
low 2156 908.63 70.65
no 3244 1368.38 100.73
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Chapter 4
Discussion
Comment: Parts of the following Chapter 4 have already been published or submitted in one of
the manuscripts Weber et al. (2019), Krisam et al. (2020), Weber et al. (2020a), and Weber
et al. (2020b). (Parts of) the manuscripts have been written by myself, but may contain
comments and corrections from the co-authors.
This chapter discusses the methods developed and applied in this thesis; a summary of its
contribution to research is given. Moreover, limitations and directions for future research
topics are presented. This is provided separately for the two main topics of this thesis 1.
Generation of Evidence (Section 4.1) and 2. Synthesis of Evidence (Section 4.2).
4.1 Generation of Evidence
4.1.1 Discussion and Contributions to Research
In situations where intervention and control group cannot be carried out at the same time;
a prospective matched case-control trial may be a good alternative to an RCT achieving
comparable study groups. This thesis presents two ways for recalculating the sample size at
an interim analysis step, the naïve and the resampling CI method (Section 2.1.1). Simula-
tions showed that the naïve method might severely overestimate the matching rate at the
interim analysis. The consequence is a low matching rate at the final analysis and, therefore,
low power what makes it hard to detect the treatment effect. The resampling CI method
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avoids this overestimation and produces a better estimate for the matching rate. So, a higher
matching rate can be achieved at the final analysis and this is related to an ascent in power.
Even a greater sample size is needed, it is still reasonable and therefore, applying the re-
sampling CI approach is an efficient alternative to the naïve approach in terms of matching
rate and power. Increasing the confidence level showed only a small influence on the sample
size in the treatment group and matching rate at the final analysis. Nevertheless, increasing
the confidence level leads to a higher sample size and increases the matching rate. A clear
advantage over a predefined higher proportion of recruited patients, is the flexibility and
adaption to the trial-specific situation. In contrast to the algorithm applied in Charpentier
et al. (2001), the resampling CI method is less time-consuming and complex since a match-
ing step is conducted twice instead matching each patient individually. The implementation
in practice is straightforward and leads to a manageable additional effort, which makes the
method relevant for applicants of prospective matched case-control trials. The application
to the KEEP SIMPLEST trial data confirmed the simulation results that the resampling CI
method leads to good results for the matching rate in contrast to the naïve approach. At the
same time, the balance of patient groups is achieved (Schönenberger et al., 2019).
The time point of interim analysis needs to be fixed beforehand. As a trade-off between
matching rate, power, and sample size, the simulations lead to the recommendation to use a
proportion of 12 to
2
3 of the number of patients in the control group at the interim analysis.
It seems that obtaining a reasonable estimate for the matching rate depends more on the
absolute number of patients at the interim analysis than on the relative number of control
patients. Giving a recommendation for an absolute number of patients needed for the interim
analysis independent of the trial size is complicated because this number would need to fit
trials with very small and also large sample sizes. Consequently, this number would be
limited by the small sample size or would not be applicable for small trials. Therefore, the
recommendation is based on the proportion of control patients.
Presumed there is a big data set of historical controls the iterative matching procedure
(Section 2.1) supplies a framework to determine an appropriate number of matching partners
per intervention patient, because the resampling CI method might fail in this situation. The
iterative matching procedure aims to potentially increase power due to a bigger sized control
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group while still the main reason of applying a matching, the differences in patient cohorts,
is addressed. By choosing the tolerance criterion τ , the procedure allows deciding whether
it is more important that all treated patients find at least one matching partner (τ = 0) or
to increase the number of patients in the control group (τ > 0). One should find a trade-
off between the matching rate and the number of matching partners because a decision to
one or the other direction may counteract the aim of finding a suitable control group and
increase power. The number M of matching partners is highly dependent on the overlap
of populations according to the considered matching variables. Nevertheless, this iterative
procedure is flexible, user-friendly, and can be implemented, for example, in a two-stage
framework which includes a scheduled interim analysis.
4.1.2 Limitations and Directions for Future Research
A limitation of the resampling CI method, as well as the iterative matching procedure are
their particular application area.
For the resampling CI method, a relatively high number of intervention patients need to be
included, which perhaps causes problems for some applications. Therefore, ethical concerns
may limit the implementation of an adaptive matched case-control trial. Another limitation
of matching approaches in general is the fact that the maximal sample size per group is
limited by the number of patients in the control group, which leads to power restrictions.
In practice, the trial could be underpowered from scratch due to a small number of control
patients.
The simulation study demonstrates that the resampling CI approach is a powerful technique
to reach a reasonable matching rate and a high power at the final analysis, but they are based
on only one single model including different types of covariates. Even though more complex
models are not evaluated in the simulations, higher model complexity is not expected to
strongly influence the performance of the approaches when model convergence is guaranteed.
A higher degree of misspecification of the propensity score model would lead to a lower
matching rate. However, this would be the case for both discussed methods, the naïve
and the resampling CI approach. More simulation scenarios are needed to give a detailed
assessment of the amount this misspecification influences the matching rate and the power.
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The developed iterative procedure for situations where a large control group exists and a
1 : M matching design is pursued, is evaluated for two different scenarios of overlap between
matching variables only. To quantify the influence of this overlap to the number of matching
partners chosen by the iterative procedure, a broader range of scenarios is needed, which
might be a topic for future research. Furthermore, the simulations do not cover an effect
estimation to quantify power and type I error, because this highly depends on the type of
endpoint and the study design. Krisam et al. (2020) includes the iterative procedure in
the Matched Threshold Crossing Design, but further research is needed to investigate the
characteristics of the procedure combined with other study designs.
4.2 Synthesis of Evidence
4.2.1 Discussion and Contributions to Research
In the field of evidence synthesis, indirect comparisons allow for estimation of therapy effects
when direct evidence is not available. To identify the possible underlying differences between
the trials constitutes an important step before conducting an indirect comparison. Based on
this investigations, a careful decision on the method for the indirect comparison should be
made to avoid bias. A checklist on how to transparently document the present situation and
to put the results into context was proposed by Kiefer et al. (2015). The simulation study
contrasting methods for indirect comparisons observes that indirect effect estimates have wide
confidence intervals in scenarios commonly met in practice. Scenarios, where the assumptions
of the methods (see Section 2.2) hold true, perform better, but the behavior is far from good
performance in terms of power. This observation is in agreement with other publications that
include simulation studies covering indirect comparisons (Mills et al., 2011; Kühnast et al.,
2017). Facing the results, the fact that indirect comparisons in early benefit assessment
mostly lead to the conclusion that there is no additional benefit is not surprising (Ruof et al.,
2014). Even though a benefit would actually exist, low power and wide confidence intervals
may cause that it will hardly be shown by the indirect comparison. The results demonstrate
that there are situations where the method of Bucher performs better than MAIC and vice
versa. Discrepancies from underlying method assumptions induce biased effect estimates,
even though in some scenarios MAIC results in less biased estimates. The presence of an effect
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modification comes to superiority of the MAIC over the method of Bucher. However, there
are also situations where MAIC leads to higher bias and less power compared to the method
of Bucher, one reason might be the one-arm weighting when models are already adjusted
for all influencing confounders. Or it is caused by adjusting matching models in MAIC for
confounders which are not effect modifiers, the weighting seems to result in more biased
effects for the indirect comparison. These results are in line with the observations of Kühnast
et al. (2017), although the underlying sample sizes are chosen differently. In practice, it may
not be given, that the models are adjusted for all relevant confounders and effect modifiers,
moreover this assumption cannot be checked and increases bias and RMSE. Differences in
the set of confounders between trials lead to similar results. Whereas, when the overlap of
effect modifiers differs, type I error rate is inflated and for binary endpoints bias and RMSE
are also higher compared to scenarios with complete overlap. Ignoring the effect modification
was observed to give better results which might be due to the fact that the evaluation focus
on the marginal effect of the treatment. The interaction term itself is not evaluated because
it cannot be assessed by the marginal effect of the interaction (Norton et al., 2004), and
the effect modification is not chosen to be extremely large. These results substantiate the
request by Leahy and Walsh (2019) that a strong justification for the assumed effect modifiers
in MAIC needs to be given. To summarize, in the case of similar patient characteristics and
adjusted effect estimates, the method of Bucher has the advantage of preserving the within-
study randomization. However, if effect modification is present in one or both trials as well as
differences with respect to effect modifiers and adjustment of regression models is observed,
MAIC provides less biased effect estimates and higher coverage.
In practice, a trial investigator may already have in mind to use a particular study for a
later indirect comparison. In case the individual IPD (or AgD) trial is planned at higher
power levels, a higher power is achieved for the indirect comparison. Situations where all
method assumptions are met gain more power than situations with differences in patient
characteristics, in the adjustment of effect estimates, or in the presence of effect modification.
So, more precise estimates in the head-to-head comparisons lead to a higher power in the
indirect comparison. Therefore, with a view to the later indirect comparison, it might worth
it to invest more sample size into the head-to-head trial because power can be influenced.
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Another attempt to achieve more precise estimates is to include more trials and therefore, a
higher sample size in the indirect comparison. Moreover, when indirect evidence is needed,
one should always consult all disposable information to avoid an additional bias due to the
choice of the study. The simulation study carried out in this thesis observes that a higher
power can be achieved by using more studies. Whereas Mills et al. (2011) report that power
is still lower than 20% when using multiple studies within the method of Bucher for the con-
sidered scenarios. Certainly, the magnitude of the gain in efficiency depends on type (AgD
or IPD) and the number of included studies as well as on the presence of effect modifica-
tion and differences in patient characteristic distributions. For situations including one IPD
study and multiple AgD studies, increasing the number of studies is not sharply enhancing
power. When assuming a higher variance in the treatment effect distribution simulations
lead to higher bias. Applying fixed or random-effects meta-analysis results are comparable
in the considered scenarios. Nevertheless, it is necessary to evaluate the underlying situation
to decide whether the strong assumptions for fixed effects meta-analysis are fulfilled. The
availability of multiple IPD studies increases power by increasing the number of available
trials, which is a direct consequence of the higher sample size. Reasonable power regions,
usually above 80%, are observed to be reached for moderate and high treatment effects. For
lower treatment effects, even ten IPD studies do not increase power noticeably. In case that
both multiple IPD and multiple AgD trials are used the power increases with the number of
trials. Bias and RMSE are rising with the treatment effect because the planned sample size
for detecting higher treatment effects is smaller which causes higher standard errors. The
use of multiple IPD studies can reduce bias and RMSE which is independent of the number
of AgD studies. Furthermore, power results can be enhanced by using more IPD trials while
increasing the number of AgD does not show an effect of the same extent. However, it is im-
portant to note that some scenarios showed an increase in type I error rates by increasing the
number of studies. Differences in patient characteristics lead to lower power (in comparison
to similar patient characteristics) in the MAIC procedure for some approaches. This may be
due to the misspecification in the matching model, meaning that not only effect modifiers are
included in the matching model. Including also confounders in MAIC is a realistic scenario
because, in practice, it is usually unknown which variables are effect modifiers and need to be
considered in MAIC. The simulations indicate that when using the MAIC due to differences
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in patient populations and the presence of effect modifications, an approach conducting all
indirect comparisons leads to better results. However, when characteristics are equal or only
one IPD trial is included, the methods which pool the treatment effects or data before con-
ducting the indirect comparison perform better. Using the Rücker et al. (2017) adjustment
for standard errors leads to higher bias, which is potentially a sign of conservatism.
In summary, the proposed methods allow enhancing quality (in terms of power, coverage,
bias, and RMSE) of indirect comparison by including all available evidence within an indirect
comparison, but underlying assumptions need to be addressed and considered in the choice
of methods and the interpretation of results.
4.2.2 Limitations and Directions for Future Research
Indirect comparisons using MAIC always suffer from the issue of defining a target population,
because IPD will be shifted towards the AgD trial, which means the AgD trial defines the
target population. The method of Bucher just assumes that the target population is the
same in both trials, which is a strong assumption and likely to be violated in practice. By
combining multiple indirect comparisons, this issue is reinforced because the treatment effect
is calculated for an average population that may not at all be relevant or observable in prac-
tice. Conducting meta-analysis to calculate an average effect estimate over different studies
before the indirect comparison is weighting the data on patient-level is the counterintuitive
direction because the treatment effect is already summarized. Further simulations are needed
to investigate the question of target populations, which should be based on different types of
simulation scenarios than considered in this thesis; this applies for the method comparison
as well as the inclusion of multiple studies.
A limitation of both simulation studies is that just the method of Bucher and the MAIC
are included because they are most often used, which is probably the case since they are
accepted in the field of HTA. Nevertheless, there are other methods available for indirect
comparisons, such as simulated treatment comparisons (Caro and Ishak, 2010; Ishak et al.,
2015a,b), cross-design synthesis (Droitcour et al., 1993), or likelihood reweighting methods
(Nie et al., 2013) for which properties are currently not sufficiently examined (Kühnast et al.,
2017). But note, that the STC by Ishak et al. (2015b) is included in the method comparison
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by Weber et al. (2020a), where similar patters for MAIC and STC are found but bias and
RMSE are observed to be higher for STC in most scenarios. Further research could compare
the less frequently used methods with the method of Bucher and MAIC to get more insights
and to give more detailed recommendations for users. Additionally, these methods are not
evaluated regarding the use of multiple studies, which also needs further investigations and
development.
One strength of the simulation study comparing the methods for adjusted indirect compar-
isons is the variety of clinically relevant scenarios, including confounders, correlations, inter-
actions (effect modification), adjustment of regression models, and overlap of effect modifiers
and confounders, which are evaluated and compared within this work. Nevertheless, the
following limitations apply to the simulation study: One clinically inspired data set is consid-
ered only, it is assumed that the interaction terms have the same sign, and treatment effect
modifiers are known; additionally, for MAIC the overlap is good enough to expect match-
ing to work well. Also, the simulations evaluating the methods for incorporating multiple
studies in indirect comparisons cover clinically relevant scenarios, including situations where
assumptions of methods for indirect comparisons are violated. Nevertheless, just one un-
derlying data example and one set of covariates in each comparison were considered, which
are the same between head-to-head trials. Moreover, the effect modification (in terms of an
interaction with treatment) was limited to one variable, and the Cox models were adjusted
for all covariates (except the interaction term). Further research is needed to explore the
performance among other regression models for estimating the treatment effect which is not
adjusted for all the effect modifiers, different overlap of effect modifiers, and various scenarios
of misspecification in the matching model. Application to other endpoints is also needed to
give complete guidance.
The sample size of all simulated trials is based on a sample size calculation for the assumed
effects making the results realistic and transferable to real trials. The treatment effects are
chosen according to official recommendations for the classification of effects in benefit assess-
ment (Skipka et al., 2015), which makes the scenarios practically relevant. When multiple
studies are used, it would be interesting if results change in case trials have substantially
different sample sizes.
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For the incorporation of multiple studies, the results concerning the evaluation measures
need to be interpreted with caution, since the mean of the effect estimate distribution is used
as a reference value to calculate the evaluation measures which may not be a good choice,
especially for a small number of studies. When the same trial is used in multiple indirect
comparisons, the approximate adjustment according to Rücker et al. (2017) was transferred,
but further research is needed to validate and extend this adjustment in the underlying
situation, as well as to examine its potential conservatism.
4.3 Conclusion
In conclusion, matching procedures are useful tools that find application in many application
areas. The power of matched case-control trials can be enhanced by using an estimate of the
trial-specific matching rate for sample size recalculation at the interim analysis. Depending on
the size of the external study arm and the aim of the current investigations, different strategies
should be followed. For small historical data, the developed resampling approach showed good
properties, whereas, for large control groups an iterative procedure to determine the number
of matching partners is the better option. In evidence synthesis, matching procedures cannot
be used straight forward because issues with the definition of the target population, low
power, and potential bias may arise. A key finding of this thesis is that matching variables
in MAIC need to be chosen carefully, because confounders, which do not modify the effect,
considerably influence the precision of the indirect comparison. Addressing the low power,
investigations for the inclusion of multiple studies in indirect comparisons are made, which
identifies promising scenarios, but a clear recommendation on how to include various studies
in MAIC cannot be given. Moreover, a careful interpretation is needed when results of
indirect comparisons are discussed and they cannot replace direct evidence by RCTs.




The gold standard for clinical studies are blinded randomized trials, but such a design is
not always feasible due to ethical or practical reasons. Using an external historical control
group out of an earlier conducted trial or registry might be an option. When using histor-
ical controls, one often faces the situation of non-comparable study populations. Matching
procedures may help to build balanced samples for comparison. In this thesis an adaptive
matched case-control trial design is established, which allows for a sample size recalculation at
a planned interim analysis with the goal to enhance the matching rate at final analysis. The
recalculation is based on the lower confidence interval limit of the matching rate observed at
interim analysis. The newly developed resampling CI method estimates the 1:1 matching rate
using a bootstrap like procedure (without replacement) and equal-sized groups for matching
at interim. A naïve approach would be to use all patients for estimating the matching rate
and directly reflect this value for recalculating the sample size. The new approach shows good
performance in terms of power and type I error rate but needs more newly recruited patients
than the naïve approach. Additionally, investigations for the time point of interim analysis
are done. Simulations result in a number of 12 to
2
3 of the control patients, however, it seems
that the time point is more depending on the actual number of patients used for matching
than on the proportion. However, if the historical control group is large and for example only
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a small phase II trial is feasible the before described method might not be a good choice.
Rather, each intervention patient may find more than one matching partner. Therefore,
an iterative procedure to determining the number of matching partners is developed. The
idea is an interim analysis, which includes an iterative increase in the number of matching
partners and a parallel calculation of the matching rate. The number will be increased as
long as the 1:M matching rate is higher than the 1:1 matching rate including a potential
tolerance. The 1:M matching rate at interim analysis can then be used for recalculating the
sample size. This procedure is easy to implement and can be combined with many study
designs, such as two-stage designs. One has to note that the number of matching partners
highly depends on the overlap of patient populations, meaning a small overlap leads to a
low number of matching partners and vice versa. To conclude, by involving the trial-specific
matching rate in the sample size recalculation one is able to enhance power in a matched
case-control trial. Not only in the generation of evidence unbalanced patient cohorts arise,
but also in evidence synthesis this poses a problem. A common situation in evidence synthesis
is an indirect comparison, where the comparison of interest, assume treatment A versus C,
is not examined in a direct comparison. But there are trials comparing A with treatment
B and another trial comparing C and B. using those trials to calculate a treatment effect
for A versus C is called indirect comparison. It is likely that the independent trials AB and
CB do not have the same underlying population. A special case, where individual patient
data is available for one of the trials is assumed. Then a matching-like procedure can help
to balance the cohorts, this method is called matching adjusted indirect comparison which
is not sufficiently examined, yet. Another widely used method for indirect comparisons is
the method of Bucher. A method comparison between those two methods is conducted for
clinically relevant scenarios where assumptions of the methods are violated. Simulations lead
to the conjecture that indirect comparisons are considerably underpowered. The method of
Bucher and the matching adjusted indirect comparison show similar performance in scenarios
without cross-trial differences. The matching approach leads to higher coverage and power
when populations differ, effect modifiers are present, and regression models are not sufficiently
adjusted. But matching confounders which do not modify the effect leads to increased bias.
Until now, indirect comparisons are applied using one study per treatment comparison be-
cause the matching adjusted indirect comparison is designed for this setting. Nevertheless,
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it is likely that there are two or even more studies comparing the same treatments. When
synthesizing evidence, one should always aim to include all appropriate evidence. Therefore,
approaches to include multiple studies in indirect comparisons are introduced and compared.
All include a step for combining treatment effects and one for calculating indirect treatment
effects. The main difference between the approaches is the order of those two steps. An
increasing number of studies can enhance power to desired regions above 80%, but it was not
possible to identify one best performing method over all considered scenarios. In conclusion,
when applying matching procedures in evidence synthesis the underlying situation needs to
be checked carefully, and matching variables need to be chosen carefully because adjusting
for confounders influences the precision of the indirect comparison.
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5.2 Zusammenfassung (Deutsch)
Der Goldstandard im Rahmen klinischer Studien ist eine doppelt-verblindete, randomisierte
Studie. Es gibt jedoch Situationen, die ein solches Design aus ethischen oder praktischen
Gründen nicht zulassen. Eine Möglichkeit dennoch einen Vergleich durchzuführen, ist die
Verwendung einer externen Kontrollgruppe, diese kann aus einer bereits durchgeführten
Studie oder auch aus einem Register stammen. Zieht man eine historische Kontrollgruppe
heran, so sind die Studienpopulationen oft nicht vergleichbar. Matchingverfahren können
dazu beitragen trotzdem einen Vergleich mit balancierten Patientengruppen durchführen zu
können. In dieser Arbeit wird ein adaptives gematchtes Fall-Kontroll-Studiendesign entwick-
elt, welches eine Zwischenauswertung mit Fallzahlrekalkulation vorsieht. Die Rekalkulation
der Fallzahl basiert auf der unteren Grenze des Konfidenzintervalls der Matchingrate bei Zwis-
chenauswertung. Der Schätzer der Matchingrate wird in diesem neuen Ansatz mittels einer
dem Bootstrap-ähnlichen Methode auf der Basis von gleich großen Gruppen bestimmt. Dieser
Ansatz zeigt gute Ergebnisse in Bezug auf Power und dem Fehler erster Art im Vergleich zu
der Herangehensweise unter Verwendung aller Kontrollpatienten bei der Zwischenauswer-
tung. Zudem wurde der Zeitpunkt der Zwischenauswertung untersucht. Simulationen kamen
zu dem Ergebnis, dass eine Zwischenauswertung nach Rekrutierung von 12 bis
2
3 der Zahl an
Kontrollpatienten eine gute Wahl ist. Jedoch scheint es, als wäre der Zeitpunkt mehr von
der absoluten Zahl an Patienten als vom Anteil abhängig. Ist die Kontrollgruppe jedoch sehr
groß ist die zuvor besprochene Methode nicht die beste Wahl. Vielmehr ist es möglich mehr
als nur einen Kontrollpatienten pro Interventionspatienten zu matchen. Um diese Anzahl an
Matchingpartnern zu bestimmen kann das entwickelte iterative Verfahren verwendet werden.
Die Idee basiert auf einer Erhöhung der Matchingpartner und gleichzeitiger Bestimmung der
Matchingrate während einer Zwischenauswertung. Die Anzahl wird solange die 1:M Match-
ingrate oberhalb der 1:1 Matchingrate abzüglich einer definierten Toleranz liegt, erhöht. Die
entsprechende 1:M Matchingrate kann dann noch für eine Fallzahlrekalkulation genutzt wer-
den. Das iterative Verfahren ist einfach zu implementieren und lässt eine Kombination mit
vielen Studiendesigns zu. Es muss beachtet werden, dass die Anzahl der Matchingpartner
maßgeblich von der Überlappung der Patientenkollektive abhängt, d.h. liegt nur wenig Über-
lappung vor können dementsprechend nur wenige Matchingpartner gefunden werden und
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umgekehrt. Daraus folgt, dass die studienspezifische Matchingrate für eine Rekalkulation der
Fallzahl von Nutzen sein kann, um die Power zu erhöhen. Nicht nur bei der Generierung
von Evidenz treten unbalancierte Populationen auf, auch in der Synthese von Evidenz spielt
dieses Problem eine Rolle. Eine häufige Situation der Evidenzsynthese ist ein indirekter
Vergleich. Dieser ist von Interesse, wenn zwei Medikamente, angenommen A und C, nicht
in einem direkten Vergleich gegenübergestellt wurden, jedoch sind Vergleiche der Medika-
mente A und B sowie C und B verfügbar. Es ist denkbar, dass die Studien AB und CB
unterschiedliche Patientenpopulationen betrachten. Liegen in der Situation eines indirekten
Vergleichs von einer Studie individuelle Patientendaten vor, kann dieses Ungleichgewicht von
Matchingverfahren adressiert werden. Neben der Methode von Bucher ist der Matching Ad-
justed Indirect Comparison eine etablierte Methode für indirekte Vergleiche, dieser ist jedoch
noch nicht hinreichend für praxisrelevante Situationen untersucht. Um diese beiden Metho-
den gegenüberzustellen und näher in praxisrelevanten Situationen (z.B. verletzte Annahmen)
zu untersuchen wird eine Simulationsstudie durchgeführt. Simulationen führen zu der Vermu-
tung, dass indirekte Vergleiche deutlich zu wenig Power haben, um einen Effekt nachweisen
zu können. Wenn sich die Studienpopulationen unterscheiden, Effektmodifikation auftritt
und Regressionsmodelle nicht ausreichend adjustiert sind, erreicht man mit dem Matching-
Ansatz eine höhere Konfidenzintervallüberdeckung sowie Power. Wird allerdings für Kovari-
aten gematcht, die den Effekt nicht beeinflussen, so führt das zu einer höheren Verzerrung, die
Matchingvariablen sollten deshalb mit Bedacht gewählt werden. Bisher wurde nur eine Studie
pro direktem Vergleich verwendet, da Matching Adjusted Indirect Comparisons für diese Sit-
uation entwickelt wurden. Es ist jedoch wahrscheinlich, dass mehrere Studien den gleichen
Vergleich durchgeführt haben. Kombiniert man Evidenz, sollten immer alle verfügbaren Stu-
dien verwendet werden. Um eine Vielzahl von Studien in indirekte Vergleiche einbinden zu
können, werden verschiedene Ansätze entwickelt und verglichen. Diese beinhalten alle einen
Schritt für die Synthese der Evidenz und einen für den indirekten Vergleich. Der Hauptunter-
schied zwischen den Ansätzen ist die Reihenfolge dieser beiden Schritte. Berücksichtigt man
eine höhere Zahl an Studien kann die gewünschte Power von 80% erreicht werden. Es war
allerdings nicht möglich eine Methode zu identifizieren, die in allen betrachteten Szenarien die
besten Ergebnisse erzielt. Folglich muss die zugrunde liegende Situation sorgfältig analysiert
werden, sowie die Methodik und die Matchingvariablen mit Bedacht gewählt werden.
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Appendix A
Appendix A: Additional Tables and
Figures
A.1 Generation of Evidence - Resampling CI Method
The results (power, type I error rate, mean matching rate, and mean sample size) for the
time point of interim analysis for a small control group (ncontrol = 50) and a large control
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Figure 11: Power, type I error rate, mean matching rate, and mean sample size in the treated group for different time points of the






























































































Figure 12: Power, type I error rate, mean matching rate, and mean sample size in the treated group for different time points of the
interim analysis (ncontrol = 500) (adapted from Weber et al. (2019)).
124 Appendix A. Appendix A: Additional Tables and Figures
Comment: Parts of the following Section A.2 are already included in the accepted manuscript
Weber et al. (2020a). The manuscript has been written by myself, but may contain comments
and corrections from the co-authors.
A.2 Synthesis of Evidence - Method Comparison
In addition to the setting where all regression models are adjusted for relevant confounders
and effect modifiers, the method comparison was done for the situation where
• the regression models for estimating the treatment effect in trial AB and CB do not
include an interaction for the effect modification (Tables 27 to 30),
• the regression models for estimating the treatment effect in trial CB are not adjusted
for confounders (Tables 31 to 35).
The corresponding detailed results are given in the following Tables 27 to 35.
The ESS for the remaining scenarios are given in Tables 36 to 39.
Detailed results on the power of the indirect comparison depending on the planned power of
head-to-head trials are shown in Table 40 (AB and CB trials are planned for the same level)











Table 27: Simulation results for scenario II. The rows include the two endpoints, similar and different population distributions, and the
considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov), bias, and root mean
squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper part of the following
tables contains the results for considering all confounders within MAIC and the lower part those for only effect modifiers are included
in MAIC. The regression models for estimating the treatment effect in trial AB and CB do not include an interaction for the effect
modification (setting 2) (adapted from Weber et al. (2020a)).
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.114 0.901 0.213 0.414 0.116 0.902 0.213 0.416 0.114 0.901 0.213 0.414
TTE similar moderate 0.085 0.885 0.134 0.219 0.086 0.886 0.134 0.219 0.085 0.885 0.134 0.219
TTE similar low 0.061 0.938 0.049 0.137 0.061 0.936 0.049 0.137 0.061 0.938 0.049 0.137
TTE similar no 0.053 0.947 -0.014 0.117 0.053 0.947 -0.014 0.117 0.053 0.947 -0.014 0.117
TTE diff high 0.247 0.942 0.057 0.278 0.151 0.880 0.258 0.630 0.130 0.896 0.205 0.424
TTE diff moderate 0.192 0.939 0.054 0.163 0.078 0.900 0.155 0.292 0.084 0.882 0.138 0.227
TTE diff low 0.124 0.946 -0.006 0.119 0.062 0.932 0.056 0.179 0.064 0.936 0.048 0.141
TTE diff no 0.093 0.907 -0.058 0.123 0.058 0.942 -0.009 0.148 0.055 0.945 -0.013 0.120
binary similar high 0.200 0.943 0.050 0.388 0.200 0.942 0.050 0.390 0.200 0.943 0.050 0.388
binary similar moderate 0.107 0.931 0.078 0.229 0.107 0.931 0.078 0.229 0.107 0.931 0.078 0.229
binary similar low 0.072 0.944 0.003 0.158 0.071 0.944 0.003 0.158 0.072 0.944 0.003 0.158
binary similar no 0.049 0.951 -0.019 0.144 0.049 0.951 -0.019 0.144 0.049 0.951 -0.019 0.144
binary diff high 0.315 0.945 -0.085 0.399 0.175 0.922 0.012 0.576 0.156 0.935 0.084 0.432
binary diff moderate 0.180 0.947 0.006 0.216 0.095 0.933 0.071 0.314 0.096 0.925 0.092 0.249
binary diff low 0.098 0.941 -0.036 0.160 0.065 0.946 0.005 0.207 0.059 0.949 0.017 0.165













Table 28: Simulation results for scenario III. The rows include the two endpoints, similar and different population distributions, and
the considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov), bias, and root
mean squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper part of the
following tables contains the results for considering all confounders within MAIC and the lower part those for only effect modifiers are
included in MAIC. The regression models for estimating the treatment effect in trial AB and CB do not include an interaction for the
effect modification (setting 2) (adapted from Weber et al. (2020a)).
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.121 0.900 0.202 0.381 0.121 0.899 0.202 0.383 0.121 0.900 0.202 0.381
TTE similar moderate 0.090 0.874 0.133 0.216 0.091 0.875 0.133 0.216 0.090 0.874 0.133 0.216
TTE similar low 0.060 0.940 0.046 0.133 0.060 0.939 0.046 0.133 0.060 0.940 0.046 0.133
TTE similar no 0.056 0.944 -0.014 0.114 0.056 0.944 -0.014 0.114 0.056 0.944 -0.014 0.114
TTE diff high 0.270 0.946 0.047 0.257 0.148 0.886 0.246 0.576 0.132 0.901 0.195 0.393
TTE diff moderate 0.208 0.942 0.050 0.157 0.089 0.896 0.145 0.276 0.091 0.884 0.132 0.22
TTE diff low 0.124 0.948 -0.006 0.116 0.060 0.935 0.056 0.172 0.063 0.933 0.049 0.139
TTE diff no 0.092 0.908 -0.057 0.120 0.056 0.944 -0.007 0.142 0.056 0.944 -0.012 0.117
binary similar high 0.209 0.945 0.038 0.389 0.209 0.945 0.038 0.390 0.209 0.945 0.038 0.389
binary similar moderate 0.122 0.938 0.067 0.227 0.121 0.938 0.067 0.227 0.122 0.938 0.067 0.227
binary similar low 0.066 0.952 0.004 0.156 0.067 0.951 0.004 0.156 0.066 0.952 0.004 0.156
binary similar no 0.052 0.948 -0.022 0.147 0.052 0.948 -0.022 0.147 0.052 0.948 -0.022 0.147
binary diff high 0.321 0.946 -0.090 0.393 0.173 0.926 0.009 0.566 0.163 0.937 0.081 0.424
binary diff moderate 0.184 0.950 0.008 0.216 0.094 0.938 0.069 0.309 0.095 0.927 0.094 0.250
binary diff low 0.098 0.941 -0.037 0.160 0.060 0.948 0.004 0.203 0.060 0.947 0.015 0.164











Table 29: Simulation results for scenario IV. The rows include the two endpoints, similar and different population distributions, and
the considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov), bias, and root
mean squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper part of the
following tables contains the results for considering all confounders within MAIC and the lower part those for only effect modifiers are
included in MAIC. The regression models for estimating the treatment effect in trial AB and CB do not include an interaction for the
effect modification (setting 2) (adapted from Weber et al. (2020a)).
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.550 0.852 -0.171 0.271 0.550 0.852 -0.171 0.273 0.550 0.852 -0.171 0.271
TTE similar moderate 0.526 0.881 -0.096 0.168 0.524 0.880 -0.096 0.168 0.526 0.881 -0.096 0.168
TTE similar low 0.377 0.822 -0.111 0.155 0.378 0.824 -0.111 0.155 0.377 0.822 -0.111 0.155
TTE similar no 0.301 0.699 -0.151 0.181 0.301 0.699 -0.151 0.181 0.301 0.699 -0.151 0.181
TTE diff high 0.615 0.837 -0.176 0.260 0.451 0.808 -0.151 0.362 0.565 0.832 -0.174 0.275
TTE diff moderate 0.567 0.871 -0.097 0.163 0.370 0.891 -0.092 0.210 0.523 0.875 -0.096 0.171
TTE diff low 0.412 0.808 -0.112 0.154 0.266 0.863 -0.107 0.178 0.376 0.822 -0.112 0.158
TTE diff no 0.323 0.677 -0.152 0.181 0.224 0.776 -0.149 0.194 0.298 0.702 -0.152 0.182
binary similar high 0.637 0.845 -0.363 0.519 0.634 0.845 -0.363 0.520 0.637 0.845 -0.363 0.519
binary similar moderate 0.398 0.903 -0.132 0.250 0.398 0.903 -0.132 0.250 0.398 0.903 -0.132 0.250
binary similar low 0.225 0.867 -0.129 0.202 0.225 0.867 -0.129 0.202 0.225 0.867 -0.129 0.202
binary similar no 0.148 0.852 -0.126 0.192 0.148 0.852 -0.126 0.192 0.148 0.852 -0.126 0.192
binary diff high 0.629 0.846 -0.376 0.535 0.435 0.845 -0.432 0.720 0.566 0.849 -0.387 0.567
binary diff moderate 0.400 0.902 -0.134 0.252 0.251 0.911 -0.140 0.335 0.362 0.905 -0.135 0.266
binary diff low 0.229 0.871 -0.129 0.201 0.153 0.901 -0.129 0.243 0.208 0.878 -0.128 0.207













Table 30: Simulation results for scenario V. The rows include the two endpoints, similar and different population distributions, and the
considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov), bias, and root mean
squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper part of the following
tables contains the results for considering all confounders within MAIC and the lower part those for only effect modifiers are included
in MAIC. The regression models for estimating the treatment effect in trial AB and CB do not include an interaction for the effect
modification (setting 2) (adapted from Weber et al. (2020a)).
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.580 0.846 -0.168 0.260 0.579 0.848 -0.168 0.260 0.580 0.846 -0.168 0.260
TTE similar moderate 0.552 0.879 -0.095 0.164 0.552 0.880 -0.095 0.164 0.552 0.879 -0.095 0.164
TTE similar low 0.391 0.822 -0.110 0.153 0.391 0.822 -0.110 0.153 0.391 0.822 -0.110 0.153
TTE similar no 0.311 0.689 -0.150 0.180 0.310 0.690 -0.150 0.180 0.311 0.689 -0.150 0.180
TTE diff high 0.631 0.836 -0.169 0.251 0.470 0.818 -0.150 0.333 0.576 0.833 -0.167 0.264
TTE diff moderate 0.586 0.878 -0.095 0.157 0.385 0.896 -0.089 0.199 0.533 0.885 -0.094 0.164
TTE diff low 0.420 0.803 -0.112 0.152 0.281 0.859 -0.108 0.173 0.388 0.816 -0.112 0.156
TTE diff no 0.331 0.669 -0.151 0.180 0.229 0.771 -0.149 0.192 0.305 0.695 -0.150 0.182
binary similar high 0.644 0.848 -0.367 0.520 0.641 0.849 -0.367 0.521 0.644 0.848 -0.367 0.520
binary similar moderate 0.405 0.908 -0.135 0.250 0.405 0.908 -0.135 0.251 0.405 0.908 -0.135 0.250
binary similar low 0.227 0.869 -0.131 0.204 0.226 0.869 -0.131 0.204 0.227 0.869 -0.131 0.204
binary similar no 0.143 0.857 -0.129 0.193 0.143 0.857 -0.129 0.193 0.143 0.857 -0.129 0.193
binary diff high 0.624 0.847 -0.368 0.527 0.422 0.848 -0.413 0.697 0.560 0.856 -0.372 0.554
binary diff moderate 0.408 0.906 -0.134 0.252 0.258 0.910 -0.139 0.333 0.364 0.906 -0.135 0.265
binary diff low 0.224 0.867 -0.129 0.200 0.159 0.899 -0.128 0.240 0.207 0.875 -0.129 0.207











Table 31: Simulation results for scenario I. The rows include the two endpoints, similar and different population distributions, and
the considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov), bias, and root
mean squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The regression models for
estimating the treatment effect in trial CB are not adjusted for confounders (setting 3) (adapted from Weber et al. (2020a)).
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.385 0.919 -0.090 0.263 0.383 0.918 -0.090 0.265
TTE similar moderate 0.206 0.945 0.032 0.166 0.203 0.946 0.032 0.166
TTE similar low 0.066 0.943 0.039 0.136 0.066 0.944 0.039 0.136
TTE similar no 0.050 0.950 0.005 0.122 0.050 0.950 0.005 0.122
TTE diff high 0.430 0.913 -0.091 0.248 0.338 0.870 -0.060 0.397
TTE diff moderate 0.227 0.941 0.031 0.160 0.168 0.935 0.039 0.230
TTE diff low 0.066 0.945 0.036 0.129 0.067 0.942 0.041 0.172
TTE diff no 0.052 0.948 0.007 0.118 0.053 0.947 0.012 0.152
binary similar high 0.487 0.912 -0.228 0.438 0.485 0.913 -0.228 0.439
binary similar moderate 0.202 0.948 -0.004 0.212 0.201 0.948 -0.004 0.212
binary similar low 0.065 0.951 -0.001 0.154 0.066 0.951 -0.001 0.154
binary similar no 0.052 0.948 0.000 0.142 0.052 0.948 0.000 0.142
binary diff high 0.475 0.907 -0.241 0.457 0.346 0.881 -0.303 0.655
binary diff moderate 0.193 0.947 -0.001 0.214 0.140 0.940 -0.004 0.306
binary diff low 0.066 0.954 0.000 0.153 0.067 0.946 -0.002 0.207













Table 32: Simulation results for scenario II. The rows include the two endpoints, similar and different population distributions, and the
considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov), bias, and root mean
squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper part of the following
tables contains the results for considering all confounders within MAIC and the lower part those for only effect modifiers are included
in MAIC. The regression models for estimating the treatment effect in trial CB are not adjusted for confounders and effect modifiers
(setting 3) (adapted from Weber et al. (2020a)).
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.064 0.758 0.628 0.943 0.067 0.760 0.628 0.946 0.064 0.758 0.628 0.943
TTE similar moderate 0.061 0.719 0.326 0.419 0.061 0.720 0.326 0.419 0.061 0.719 0.326 0.419
TTE similar low 0.077 0.823 0.172 0.245 0.078 0.825 0.172 0.245 0.077 0.823 0.172 0.245
TTE similar no 0.086 0.914 0.087 0.173 0.086 0.914 0.087 0.173 0.086 0.914 0.087 0.173
TTE diff high 0.073 0.801 0.697 1.157 0.125 0.790 0.873 1.624 0.083 0.790 0.707 1.181
TTE diff moderate 0.062 0.770 0.346 0.467 0.074 0.820 0.385 0.593 0.064 0.769 0.347 0.469
TTE diff low 0.074 0.854 0.173 0.264 0.072 0.886 0.185 0.327 0.074 0.853 0.173 0.264
TTE diff no 0.079 0.921 0.088 0.191 0.072 0.928 0.095 0.240 0.080 0.920 0.088 0.191
binary similar high 0.049 0.816 0.593 0.833 0.200 0.943 0.050 0.388 0.200 0.943 0.050 0.388
binary similar moderate 0.065 0.799 0.345 0.468 0.107 0.931 0.078 0.229 0.107 0.931 0.078 0.229
binary similar low 0.082 0.872 0.168 0.273 0.072 0.944 0.003 0.158 0.072 0.944 0.003 0.158
binary similar no 0.092 0.908 0.112 0.219 0.049 0.951 -0.019 0.144 0.049 0.951 -0.019 0.144
binary diff high 0.052 0.861 0.579 1.060 0.156 0.935 0.084 0.432 0.156 0.935 0.084 0.432
binary diff moderate 0.063 0.852 0.340 0.514 0.096 0.925 0.092 0.249 0.096 0.925 0.092 0.249
binary diff low 0.069 0.897 0.170 0.303 0.059 0.949 0.017 0.165 0.059 0.949 0.017 0.165











Table 33: Simulation results for scenario III. The rows include the two endpoints, similar and different population distributions, and
the considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov), bias, and root
mean squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper part of the
following tables contains the results for considering all confounders within MAIC and the lower part those for only effect modifiers are
included in MAIC. The regression models for estimating the treatment effect in trial CB are not adjusted for confounders and effect
modifiers (setting 3) (adapted from Weber et al. (2020a)).
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.063 0.746 0.601 0.868 0.063 0.746 0.601 0.868 0.064 0.758 0.628 0.943
TTE similar moderate 0.064 0.709 0.325 0.416 0.064 0.709 0.325 0.416 0.061 0.719 0.326 0.419
TTE similar low 0.076 0.826 0.170 0.240 0.076 0.826 0.170 0.240 0.077 0.823 0.172 0.245
TTE similar no 0.088 0.912 0.088 0.171 0.088 0.912 0.088 0.171 0.086 0.914 0.087 0.173
TTE diff high 0.071 0.793 0.667 1.076 0.076 0.788 0.672 1.087 0.083 0.790 0.707 1.181
TTE diff moderate 0.066 0.763 0.336 0.456 0.067 0.761 0.336 0.457 0.064 0.769 0.347 0.469
TTE diff low 0.077 0.847 0.176 0.263 0.076 0.845 0.176 0.263 0.074 0.853 0.173 0.264
TTE diff no 0.083 0.917 0.091 0.189 0.083 0.917 0.091 0.189 0.080 0.920 0.088 0.191
binary similar high 0.055 0.817 0.600 0.905 0.209 0.945 0.038 0.390 0.209 0.945 0.038 0.389
binary similar moderate 0.065 0.809 0.340 0.467 0.121 0.938 0.067 0.227 0.122 0.938 0.067 0.227
binary similar low 0.083 0.876 0.174 0.277 0.067 0.951 0.004 0.156 0.066 0.952 0.004 0.156
binary similar no 0.091 0.909 0.111 0.222 0.052 0.948 -0.022 0.147 0.052 0.948 -0.022 0.147
binary diff high 0.052 0.857 0.614 1.115 0.173 0.926 0.009 0.566 0.163 0.937 0.081 0.424
binary diff moderate 0.063 0.843 0.348 0.523 0.094 0.938 0.069 0.309 0.095 0.927 0.094 0.250
binary diff low 0.070 0.899 0.171 0.306 0.060 0.948 0.004 0.203 0.060 0.947 0.015 0.164













Table 34: Simulation results for scenario IV. The rows include the two endpoints, similar and different population distributions, and
the considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov), bias, and root
mean squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper part of the
following tables contains the results for considering all confounders within MAIC and the lower part those for only effect modifiers are
included in MAIC. The regression models for estimating the treatment effect in trial CB are not adjusted for confounders and effect
modifiers (setting 3) (adapted from Weber et al. (2020a)).
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.550 0.852 -0.171 0.271 0.550 0.852 -0.171 0.273 0.550 0.852 -0.171 0.271
TTE similar moderate 0.526 0.881 -0.096 0.168 0.524 0.880 -0.096 0.168 0.526 0.881 -0.096 0.168
TTE similar low 0.377 0.822 -0.111 0.155 0.378 0.824 -0.111 0.155 0.377 0.822 -0.111 0.155
TTE similar no 0.301 0.699 -0.151 0.181 0.301 0.699 -0.151 0.181 0.301 0.699 -0.151 0.181
TTE diff high 0.615 0.837 -0.176 0.260 0.451 0.808 -0.151 0.362 0.565 0.832 -0.174 0.275
TTE diff moderate 0.567 0.871 -0.097 0.163 0.370 0.891 -0.092 0.210 0.523 0.875 -0.096 0.171
TTE diff low 0.412 0.808 -0.112 0.154 0.266 0.863 -0.107 0.178 0.376 0.822 -0.112 0.158
TTE diff no 0.323 0.677 -0.152 0.181 0.224 0.776 -0.149 0.194 0.298 0.702 -0.152 0.182
binary similar high 0.637 0.845 -0.363 0.519 0.634 0.845 -0.363 0.520 0.637 0.845 -0.363 0.519
binary similar moderate 0.398 0.903 -0.132 0.250 0.398 0.903 -0.132 0.250 0.398 0.903 -0.132 0.250
binary similar low 0.225 0.867 -0.129 0.202 0.225 0.867 -0.129 0.202 0.225 0.867 -0.129 0.202
binary similar no 0.148 0.852 -0.126 0.192 0.148 0.852 -0.126 0.192 0.148 0.852 -0.126 0.192
binary diff high 0.629 0.846 -0.376 0.535 0.435 0.845 -0.432 0.720 0.566 0.849 -0.387 0.567
binary diff moderate 0.400 0.902 -0.134 0.252 0.251 0.911 -0.140 0.335 0.362 0.905 -0.135 0.266
binary diff low 0.229 0.871 -0.129 0.201 0.153 0.901 -0.129 0.243 0.208 0.878 -0.128 0.207











Table 35: Simulation results for scenario V. The rows include the two endpoints, similar and different population distributions, and the
considered effect sizes, the columns the evaluation measures for these scenarios power/type I error, coverage (Cov), bias, and root mean
squared error (RMSE). Accordingly, for no effect, the column Power shows the type I error rate (α). The upper part of the following
tables contains the results for considering all confounders within MAIC and the lower part those for only effect modifiers are included
in MAIC. The regression models for estimating the treatment effect in trial CB are not adjusted for confounders and effect modifiers
(setting 3) (adapted from Weber et al. (2020a)).
EP Pat Char Effect Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE Power (α) Cov Bias RMSE
TTE similar high 0.655 0.794 -0.207 0.277 0.650 0.791 -0.208 0.277 0.655 0.794 -0.207 0.277
TTE similar moderate 0.677 0.778 -0.156 0.202 0.674 0.777 -0.156 0.203 0.677 0.778 -0.156 0.202
TTE similar low 0.555 0.655 -0.181 0.212 0.555 0.656 -0.181 0.212 0.555 0.655 -0.181 0.212
TTE similar no 0.484 0.516 -0.224 0.248 0.483 0.517 -0.224 0.248 0.484 0.516 -0.224 0.248
TTE diff high 0.706 0.772 -0.208 0.270 0.531 0.782 -0.190 0.334 0.647 0.778 -0.206 0.280
TTE diff moderate 0.712 0.766 -0.156 0.198 0.500 0.826 -0.150 0.225 0.662 0.783 -0.155 0.202
TTE diff low 0.589 0.634 -0.183 0.212 0.433 0.734 -0.179 0.224 0.557 0.656 -0.183 0.214
TTE diff no 0.514 0.486 -0.225 0.248 0.388 0.612 -0.223 0.255 0.483 0.517 -0.225 0.249
binary similar high 0.644 0.848 -0.367 0.520 0.644 0.848 -0.367 0.520 0.637 0.845 -0.363 0.519
binary similar moderate 0.405 0.908 -0.135 0.250 0.405 0.908 -0.135 0.250 0.398 0.903 -0.132 0.250
binary similar low 0.227 0.869 -0.131 0.204 0.227 0.869 -0.131 0.204 0.225 0.867 -0.129 0.202
binary similar no 0.143 0.857 -0.129 0.193 0.143 0.857 -0.129 0.193 0.148 0.852 -0.126 0.192
binary diff high 0.624 0.847 -0.368 0.527 0.560 0.856 -0.372 0.554 0.566 0.849 -0.387 0.567
binary diff moderate 0.408 0.906 -0.134 0.252 0.364 0.906 -0.135 0.265 0.362 0.905 -0.135 0.266
binary diff low 0.224 0.867 -0.129 0.200 0.207 0.875 -0.129 0.207 0.208 0.878 -0.128 0.207
binary diff no 0.147 0.853 -0.131 0.192 0.140 0.860 -0.130 0.197 0.140 0.860 -0.128 0.197
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Table 36: Mean Effective Sample Size (ESS) for scenario II considering a time-to-event
(TTE) as well as binary endpoints. The ESS is given for MAIC is adjusted for all confounders
(Conf.) and for the case where it is only adjusted for effect modifiers (EM) (adapted from
Weber et al. (2020a)).
Endpoint Population Effect Sample Size ESS ESS
all Conf. only EM
TTE similar high 94 92.903 94.000
TTE similar moderate 396 394.759 396.000
TTE similar low 1044 1042.348 1044.000
TTE similar no 1578 1575.976 1578.000
TTE different high 94 38.927 78.638
TTE different moderate 396 161.868 332.960
TTE different low 1044 423.169 876.646
TTE different no 1578 639.260 1326.495
binary similar high 192 190.860 192.000
binary similar moderate 648 646.708 648.000
binary similar low 1600 1598.201 1600.000
binary similar no 2176 2173.999 2176.000
binary different high 192 80.000 161.920
binary different moderate 648 264.195 545.278
binary different low 1600 646.039 1344.015
binary different no 2176 877.268 1828.161
A.2. Synthesis of Evidence - Method Comparison 135
Table 37: Mean Effective Sample Size (ESS) for scenario III considering a time-to-event
(TTE) as well as binary endpoint. The ESS is given for MAIC is adjusted for all confounders
and for the case where it is only adjusted for effect modifiers (EM) (adapted from Weber et
al. (2020a)).
Endpoint Population Effect Sample Size ESS ESS
all Conf. only EM
TTE similar high 94 92.873 94.000
TTE similar moderate 396 394.721 396.000
TTE similar low 1044 1042.343 1044.000
TTE similar no 1578 1576.018 1578.000
TTE different high 94 40.584 78.638
TTE different moderate 396 169.355 332.960
TTE different low 1044 443.025 876.646
TTE different no 1578 669.056 1326.495
binary similar high 192 190.923 192.000
binary similar moderate 648 646.681 648.000
binary similar low 1600 1598.250 1600.000
binary similar no 2176 2174.023 2176.000
binary different high 192 83.314 161.920
binary different moderate 648 276.291 545.278
binary different low 1600 676.922 1344.015
binary different no 2176 919.657 1828.161
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Table 38: Mean Effective Sample Size (ESS) for scenario IV considering a time-to-event
(TTE) as well as binary endpoint. The ESS is given for MAIC is adjusted for all confounders
and for the case where it is only adjusted for effect modifiers (EM) (adapted from Weber et
al. (2020a)).
Endpoint Population Effect Sample Size ESS ESS
all Conf. only EM
TTE similar high 94 92.898 94.000
TTE similar moderate 396 394.726 396.000
TTE similar low 1044 1042.335 1044.000
TTE similar no 1578 1575.942 1578.000
TTE different high 94 38.847 78.638
TTE different moderate 396 161.790 332.960
TTE different low 1044 423.595 876.646
TTE different no 1578 638.925 1326.495
binary similar high 192 190.867 192.000
binary similar moderate 648 646.692 648.000
binary similar low 1600 1598.270 1600.000
binary similar no 2176 2174.004 2176.000
binary different high 192 79.816 161.920
binary different moderate 648 264.143 545.278
binary different low 1600 646.770 1344.015
binary different no 2176 877.447 1828.161
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Table 39: Mean Effective Sample Size (ESS) for scenario V considering a time-to-event
(TTE) as well as binary endpoint. The ESS is given for MAIC is adjusted for all confounders
and for the case where it is only adjusted for effect modifiers (EM) (adapted from Weber et
al. (2020a)).
Endpoint Population Effect Sample Size ESS ESS
all Conf. only EM
TTE similar high 94 92.884 94.000
TTE similar moderate 396 394.747 396.000
TTE similar low 1044 1042.346 1044.000
TTE similar no 1578 1576.017 1578.000
TTE different high 94 40.588 78.638
TTE different moderate 396 169.266 332.960
TTE different low 1044 443.368 876.646
TTE different no 1578 668.927 1326.495
binary similar high 192 190.911 192.000
binary similar moderate 648 646.720 648.000
binary similar low 1600 1598.301 1600.000
binary similar no 2176 2173.999 2176.000
binary different high 192 83.332 161.920
binary different moderate 648 276.422 545.278
binary different low 1600 676.120 1344.015
binary different no 2176 919.719 1828.161
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Table 40: Power for indirect comparison for individual planned power is the same in aggre-
gated data trial and individual patient data trial set to 90%, 95%, or 99%. The results are
given for scenario I having similar patient populations without interaction. They demonstrate
the influence of the power of the individual trials on the power of the indirect comparison.
The power is given for both endpoints, in case of no effect the column shows the type I error
rate (α) (adapted from Weber et al. (2020a)).
Binary Time-to-event
Effect Planned Power Bucher MAIC Bucher MAIC
high 90% 0.317 0.316 0.338 0.337
moderate 90% 0.200 0.201 0.170 0.167
low 90% 0.081 0.080 0.075 0.075
no 90% 0.054 0.054 0.054 0.055
high 95% 0.371 0.371 0.436 0.432
moderate 95% 0.229 0.229 0.242 0.241
low 95% 0.087 0.088 0.073 0.072
no 95% 0.049 0.050 0.051 0.052
high 99% 0.497 0.498 0.549 0.549
moderate 99% 0.308 0.308 0.310 0.309
low 99% 0.101 0.100 0.077 0.077
no 99% 0.055 0.055 0.055 0.055
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Table 41: Power for indirect comparison under consideration of trials with individual planned
power of 80% in the aggregated data trial. The results are given for scenario I having similar
patient populations without interaction. They demonstrate the influence of the power of the
individual trials on the power of the indirect comparison. The power is given for both end-
points, in case of no effect the column shows the type I error rate (α) (adapted from Weber
et al. (2020a)).
Planned Power Binary Time-to-event
Effect IPD trial (AB) Bucher MAIC Bucher MAIC
high 80% 0.253 0.253 0.243 0.249
moderate 80% 0.160 0.162 0.173 0.173
low 80% 0.071 0.071 0.065 0.064
no 80% 0.046 0.046 0.060 0.058
high 90% 0.306 0.305 0.346 0.348
moderate 90% 0.188 0.187 0.179 0.183
low 90% 0.076 0.077 0.069 0.070
no 90% 0.048 0.048 0.047 0.048
high 95% 0.363 0.363 0.414 0.411
moderate 95% 0.215 0.216 0.225 0.226
low 95% 0.081 0.081 0.074 0.074
no 95% 0.053 0.053 0.041 0.041
high 99% 0.453 0.453 0.531 0.526
moderate 99% 0.267 0.266 0.234 0.233
low 99% 0.089 0.089 0.060 0.060
no 99% 0.049 0.050 0.067 0.066
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Comment: Parts of the following Section A.3 are already included in the submitted manuscript
Weber et al. (2020b). The manuscript has been written by myself, but may contain comments
and corrections from the co-authors.
A.3 Synthesis of Evidence - Inclusion of multiple studies in
indirect comparisons
This section contains the detailed results of the simulation study investigating the inclusion
of multiple studies in indirect comparisons.
Three different settings are evaluated:
• all regression models are adjusted for confounders, meta-analysis is performed by a
random effects model, and a variance value of σ = 0.2 is assumed in the generation of
the true treatment effect (Tables 42 to 53),
• all regression models are adjusted for confounders, meta-analysis is performed by a
fixed effects model, and a variance value of σ = 0.2 is assumed in the generation of the
true treatment effect (Tables 54 to 59),
• all regression models are adjusted for confounders, meta-analysis is performed by a
random effects model, and a variance value of σ = 0.4 is assumed in the generation of














Table 42: One IPD trial (individual patient data) and multiple AgD trials (aggregated data) - scenario I and II. Power and coverage
are presented for approach A.1 (pooled AgD) and A.2 (all indirect comparisons) and both methods for indirect comparisons, Bucher
and MAIC. All meta-analyses are based on a random effects model.
Popu- Effect Trials True Mean Effect Power Coverage
lation Size Effect Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.713 -0.713 -0.742 -0.742 0.808 0.804 0.444 0.444 0.881 0.885 0.951 0.951
similar high 4 -0.69 -0.743 -0.743 -0.777 -0.777 0.846 0.843 0.459 0.459 0.878 0.878 0.953 0.953
similar high 10 -0.69 -0.726 -0.726 -0.756 -0.756 0.842 0.845 0.445 0.445 0.869 0.873 0.949 0.949
similar moderate 2 -0.22 -0.234 -0.234 -0.231 -0.231 0.547 0.551 0.250 0.250 0.902 0.902 0.952 0.952
similar moderate 4 -0.22 -0.232 -0.232 -0.234 -0.234 0.571 0.567 0.267 0.267 0.883 0.879 0.948 0.948
similar moderate 10 -0.22 -0.232 -0.232 -0.234 -0.234 0.512 0.610 0.278 0.278 0.879 0.879 0.958 0.958
similar low 2 -0.05 -0.053 -0.053 -0.052 -0.052 0.150 0.152 0.091 0.089 0.905 0.903 0.940 0.942
similar low 4 -0.05 -0.051 -0.051 -0.052 -0.052 0.184 0.186 0.090 0.090 0.879 0.878 0.943 0.943
similar low 10 -0.05 -0.052 -0.052 -0.051 -0.051 0.209 0.207 0.087 0.087 0.875 0.878 0.946 0.946
similar no 2 0 -0.003 -0.003 -0.002 -0.002 0.094 0.094 0.069 0.065 0.907 0.906 0.932 0.936
similar no 4 0 0.002 0.002 0.002 0.002 0.109 0.110 0.060 0.060 0.892 0.890 0.940 0.940
similar no 10 0 -0.001 -0.001 -0.001 -0.001 0.130 0.130 0.065 0.065 0.871 0.871 0.936 0.936
different high 2 -0.69 -0.734 -0.756 -0.766 -0.766 0.822 0.635 0.456 0.456 0.866 0.821 0.947 0.947
different high 4 -0.69 -0.725 -0.759 -0.746 -0.746 0.833 0.639 0.446 0.446 0.870 0.844 0.956 0.956
different high 10 -0.69 -0.729 -0.755 -0.766 -0.766 0.850 0.6265 0.458 0.458 0.866 0.850 0.940 0.940
different moderate 2 -0.22 -0.234 -0.239 -0.237 -0.237 0.538 0.3915 0.257 0.256 0.881 0.868 0.945 0.945
different moderate 4 -0.22 -0.231 -0.232 -0.233 -0.233 0.562 0.388 0.273 0.273 0.883 0.876 0.950 0.950
different moderate 10 -0.22 -0.231 -0.230 -0.236 -0.236 0.593 0.4015 0.282 0.282 0.864 0.851 0.933 0.933
different low 2 -0.05 -0.050 -0.054 -0.051 -0.051 0.146 0.146 0.081 0.077 0.905 0.895 0.944 0.948
different low 4 -0.05 -0.051 -0.056 -0.050 -0.050 0.159 0.174 0.079 0.079 0.885 0.881 0.947 0.947
different low 10 -0.05 -0.045 -0.047 -0.046 -0.046 0.173 0.159 0.076 0.076 0.881 0.885 0.945 0.945
different no 2 0 0.000 -0.002 -0.001 -0.001 0.099 0.106 0.059 0.054 0.901 0.895 0.941 0.947
different no 4 0 0.002 0.003 0.002 0.002 0.099 0.1205 0.049 0.049 0.902 0.879 0.951 0.951













Table 43: One IPD trial (individual patient data) and multiple AgD trials (aggregated data) - scenario I and II. The mean effect, bias,
and the root mean squared error (RMSE) are presented for approach A.1 (pooled AgD) and A.2 (all indirect comparisons) and both
methods for indirect comparisons, Bucher and MAIC. All meta-analyses are based on a random effects model.
Popu- Effect Trials Bias MC Error for Bias RMSE
lation Size Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.023 -0.023 -0.052 -0.052 0.007 0.007 0.010 0.010 0.300 0.302 0.433 0.433
similar high 4 -0.053 -0.053 -0.087 -0.087 0.007 0.007 0.010 0.010 0.303 0.305 0.433 0.433
similar high 10 -0.036 -0.036 -0.066 -0.066 0.007 0.007 0.010 0.010 0.301 0.302 0.436 0.436
similar moderate 2 -0.014 -0.014 -0.011 -0.011 0.003 0.003 0.004 0.004 0.136 0.136 0.178 0.178
similar moderate 4 -0.012 -0.012 -0.014 -0.014 0.003 0.003 0.004 0.004 0.135 0.135 0.178 0.178
similar moderate 10 -0.012 -0.012 -0.014 -0.014 0.003 0.003 0.004 0.004 0.129 0.129 0.171 0.171
similar low 2 -0.003 -0.003 -0.002 -0.002 0.002 0.002 0.003 0.003 0.094 0.094 0.117 0.117
similar low 4 -0.001 -0.001 -0.002 -0.002 0.002 0.002 0.002 0.002 0.085 0.086 0.109 0.109
similar low 10 -0.002 -0.002 -0.001 -0.001 0.002 0.002 0.002 0.002 0.078 0.078 0.103 0.103
similar no 2 -0.003 -0.003 -0.002 -0.002 0.002 0.002 0.002 0.002 0.085 0.085 0.101 0.101
similar no 4 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.073 0.073 0.091 0.091
similar no 10 -0.001 -0.001 -0.001 -0.001 0.002 0.002 0.002 0.002 0.066 0.066 0.086 0.086
different high 2 -0.044 -0.066 -0.076 -0.076 0.007 0.010 0.010 0.010 0.316 0.46 0.452 0.452
different high 4 -0.035 -0.069 -0.056 -0.056 0.007 0.010 0.010 0.010 0.303 0.437 0.428 0.428
different high 10 -0.039 -0.065 -0.076 -0.076 0.007 0.0098 0.010 0.010 0.302 0.442 0.438 0.438
different moderate 2 -0.014 -0.019 -0.017 -0.017 0.003 0.005 0.004 0.004 0.143 0.200 0.184 0.184
different moderate 4 -0.011 -0.012 -0.013 -0.013 0.003 0.004 0.004 0.004 0.135 0.191 0.178 0.178
different moderate 10 -0.011 -0.010 -0.016 -0.016 0.003 0.004 0.004 0.004 0.133 0.195 0.182 0.182
different low 2 0.000 -0.004 -0.001 -0.001 0.002 0.003 0.003 0.003 0.097 0.125 0.118 0.118
different low 4 -0.001 -0.006 0.000 0.000 0.002 0.003 0.002 0.002 0.085 0.117 0.108 0.108
different low 10 0.005 0.003 0.004 0.004 0.002 0.003 0.002 0.002 0.077 0.111 0.102 0.102
different no 2 0.000 -0.002 -0.001 -0.001 0.002 0.002 0.002 0.002 0.087 0.108 0.103 0.103
different no 4 0.002 0.003 0.002 0.002 0.002 0.002 0.002 0.002 0.073 0.098 0.090 0.090














Table 44: One AgD trial (aggregated data) and multiple IPD trials (individual patient data) - scenario I and II. Power and coverage
are presented for approach B.1 (pooled IPD) and B.2 (all indirect comparisons) and both methods for indirect comparisons, Bucher
and MAIC. Results for scenario I and II are presented. All meta-analyses are based on a random effects model.
Popu- Effect Trials True Mean Effect Power Coverage
lation Size Effect Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.711 -0.712 -0.719 -0.732 0.702 0.701 0.691 0.587 0.952 0.951 0.952 0.968
similar high 4 -0.69 -0.720 -0.720 -0.734 -0.743 0.932 0.930 0.927 0.887 0.948 0.944 0.946 0.957
similar high 10 -0.69 -0.698 -0.698 -0.720 -0.722 0.998 0.998 0.998 0.997 0.949 0.946 0.941 0.944
similar moderate 2 -0.22 -0.237 -0.238 -0.238 -0.239 0.382 0.384 0.388 0.338 0.951 0.952 0.948 0.958
similar moderate 4 -0.22 -0.232 -0.231 -0.234 -0.235 0.520 0.5175 0.526 0.510 0.949 0.948 0.948 0.953
similar moderate 10 -0.22 -0.230 -0.230 -0.234 -0.234 0.678 0.678 0.692 0.691 0.941 0.941 0.939 0.940
similar low 2 -0.05 -0.056 -0.056 -0.056 -0.056 0.092 0.093 0.091 0.082 0.946 0.946 0.947 0.952
similar low 4 -0.05 -0.051 -0.051 -0.052 -0.052 0.099 0.098 0.100 0.100 0.935 0.934 0.936 0.937
similar low 10 -0.05 -0.047 -0.047 -0.048 -0.048 0.098 0.096 0.100 0.100 0.940 0.941 0.942 0.942
similar no 2 0 -0.002 -0.002 -0.002 -0.002 0.059 0.060 0.062 0.057 0.941 0.940 0.939 0.943
similar no 4 0 0.003 0.003 0.002 0.002 0.055 0.055 0.055 0.055 0.945 0.945 0.945 0.945
similar no 10 0 0.002 0.002 0.001 0.001 0.052 0.053 0.053 0.053 0.948 0.948 0.947 0.947
different high 2 -0.69 -0.729 -0.749 -0.739 -0.750 0.716 0.495 0.700 0.608 0.948 0.918 0.947 0.958
different high 4 -0.69 -0.714 -0.727 -0.726 -0.734 0.924 0.722 0.919 0.873 0.939 0.937 0.943 0.952
different high 10 -0.69 -0.704 -0.707 -0.729 -0.731 1.000 0.946 0.999 0.996 0.952 0.943 0.940 0.945
different moderate 2 -0.22 -0.232 -0.237 -0.234 -0.234 0.367 0.243 0.366 0.319 0.944 0.936 0.943 0.950
different moderate 4 -0.22 -0.225 -0.226 -0.228 -0.228 0.476 0.327 0.488 0.479 0.951 0.946 0.947 0.950
different moderate 10 -0.22 -0.231 -0.231 -0.236 -0.236 0.645 0.521 0.658 0.658 0.938 0.939 0.933 0.933
different low 2 -0.05 -0.049 -0.051 -0.049 -0.049 0.081 0.073 0.081 0.073 0.941 0.941 0.938 0.945
different low 4 -0.05 -0.051 -0.055 -0.052 -0.052 0.090 0.078 0.091 0.091 0.944 0.951 0.946 0.946
different low 10 -0.05 -0.048 -0.049 -0.049 -0.049 0.097 0.094 0.098 0.098 0.942 0.943 0.941 0.941
different no 2 0 -0.002 -0.004 -0.003 -0.003 0.064 0.062 0.063 0.058 0.936 0.939 0.938 0.942
different no 4 0 -0.001 -0.002 -0.001 -0.001 0.052 0.055 0.052 0.052 0.949 0.946 0.949 0.949













Table 45: One AgD trial (aggregated data) and multiple IPD trials (individual patient data) - scenario I and II. The mean effect, bias,
and the root mean squared error (RMSE) are presented for approach B.1 (pooled IPD) and B.2 (all indirect comparisons) and both
methods for indirect comparisons, Bucher and MAIC. All meta-analyses are based on a random effects model.
Popu- Effect Trials Bias MC Error for Bias RMSE
lation Size Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.021 -0.022 -0.029 -0.042 0.007 0.007 0.007 0.007 0.291 0.293 0.299 0.305
similar high 4 -0.030 -0.030 -0.044 -0.053 0.005 0.005 0.005 0.005 0.215 0.216 0.224 0.228
similar high 10 -0.008 -0.008 -0.030 -0.032 0.003 0.003 0.004 0.004 0.145 0.146 0.163 0.160
similar moderate 2 -0.017 -0.018 -0.018 -0.019 0.003 0.003 0.003 0.003 0.142 0.143 0.144 0.144
similar moderate 4 -0.012 -0.011 -0.014 -0.015 0.003 0.003 0.003 0.003 0.117 0.117 0.118 0.118
similar moderate 10 -0.010 -0.010 -0.014 -0.014 0.002 0.002 0.002 0.002 0.097 0.098 0.098 0.098
similar low 2 -0.006 -0.006 -0.006 -0.006 0.002 0.002 0.002 0.002 0.107 0.107 0.107 0.107
similar low 4 -0.001 -0.001 -0.002 -0.002 0.002 0.002 0.002 0.002 0.096 0.096 0.097 0.097
similar low 10 0.003 0.003 0.002 0.002 0.002 0.002 0.002 0.002 0.087 0.087 0.087 0.087
similar no 2 -0.002 -0.002 -0.002 -0.002 0.002 0.002 0.002 0.002 0.102 0.101 0.102 0.102
similar no 4 0.003 0.003 0.002 0.002 0.002 0.002 0.002 0.002 0.090 0.090 0.090 0.090
similar no 10 0.002 0.002 0.001 0.001 0.002 0.002 0.002 0.002 0.083 0.083 0.083 0.083
different high 2 -0.039 -0.059 -0.049 -0.060 0.007 0.0098 0.007 0.007 0.305 0.444 0.316 0.321
different high 4 -0.024 -0.037 -0.036 -0.044 0.005 0.007 0.005 0.005 0.217 0.296 0.228 0.230
different high 10 -0.014 -0.017 -0.039 -0.041 0.003 0.005 0.004 0.004 0.148 0.200 0.178 0.174
different moderate 2 -0.012 -0.017 -0.014 -0.014 0.003 0.005 0.003 0.003 0.151 0.202 0.153 0.153
different moderate 4 -0.005 -0.006 -0.008 -0.008 0.003 0.003 0.003 0.003 0.120 0.152 0.121 0.121
different moderate 10 -0.011 -0.011 -0.016 -0.016 0.002 0.003 0.002 0.002 0.103 0.119 0.104 0.104
different low 2 0.001 -0.001 0.001 0.001 0.003 0.003 0.003 0.003 0.114 0.135 0.114 0.114
different low 4 -0.001 -0.005 -0.002 -0.002 0.002 0.003 0.002 0.002 0.100 0.112 0.100 0.100
different low 10 0.002 0.001 0.001 0.001 0.002 0.002 0.002 0.002 0.093 0.099 0.093 0.093
different no 2 -0.002 -0.004 -0.003 -0.003 0.002 0.003 0.002 0.002 0.107 0.123 0.107 0.107
different no 4 -0.001 -0.002 -0.001 -0.001 0.002 0.002 0.002 0.002 0.093 0.103 0.093 0.093














Table 46: Multiple AgD trials (aggregated data) and multiple IPD trials (individual patient data) - scenario I and II. Power and
coverage are presented for approach C.1 (pooled IPD, pooled AgD), C.2 (pooled IPD, all indirect comparisons), and C.3 (all indirect
comparisons) and both methods for indirect comparisons, Bucher and MAIC. All meta-analyses are based on a random effects model.
Popu- Effect Trials True Mean Effect Power Coverage
lation Size Effect All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.711 -0.712 -0.710 -0.711 -0.718 -0.722 0.720 0.717 0.720 0.715 0.700 0.687 0.952 0.956 0.952 0.955 0.951 0.955
similar high 4 -0.69 -0.717 -0.717 -0.717 -0.717 -0.728 -0.728 0.961 0.961 0.961 0.960 0.952 0.952 0.954 0.953 0.954 0.954 0.948 0.948
similar high 10 -0.69 -0.701 -0.701 -0.700 -0.700 -0.712 -0.711 1.000 1.000 1.000 1.000 1.000 1.000 0.951 0.952 0.952 0.952 0.944 0.944
similar moderate 2 -0.22 -0.236 -0.236 -0.236 -0.236 -0.237 -0.237 0.442 0.442 0.442 0.439 0.441 0.432 0.953 0.953 0.953 0.954 0.954 0.957
similar moderate 4 -0.22 -0.230 -0.230 -0.230 -0.230 -0.231 -0.231 0.699 0.700 0.698 0.695 0.695 0.695 0.946 0.943 0.946 0.944 0.945 0.945
similar moderate 10 -0.22 -0.229 -0.229 -0.229 -0.229 -0.231 -0.231 0.976 0.976 0.976 0.976 0.976 0.976 0.955 0.954 0.955 0.954 0.952 0.952
similar low 2 -0.05 -0.054 -0.054 -0.054 -0.053 -0.054 -0.054 0.099 0.099 0.099 0.093 0.099 0.099 0.943 0.943 0.942 0.946 0.943 0.944
similar low 4 -0.05 -0.050 -0.050 -0.049 -0.049 -0.050 -0.050 0.137 0.133 0.139 0.129 0.144 0.144 0.948 0.946 0.948 0.949 0.947 0.947
similar low 10 -0.05 -0.050 -0.050 -0.050 -0.050 -0.050 -0.050 0.249 0.251 0.249 0.247 0.256 0.256 0.949 0.948 0.949 0.949 0.950 0.950
similar no 2 0 -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 0.057 0.058 0.057 0.055 0.057 0.057 0.944 0.942 0.944 0.946 0.943 0.944
similar no 4 0 0.002 0.002 0.002 0.002 0.002 0.002 0.063 0.062 0.063 0.058 0.062 0.062 0.938 0.939 0.937 0.943 0.939 0.939
similar no 10 0 -0.001 -0.001 -0.001 -0.001 -0.001 -0.001 0.053 0.054 0.054 0.053 0.054 0.054 0.948 0.947 0.947 0.948 0.946 0.946
different high 2 -0.69 -0.730 -0.750 -0.730 -0.750 -0.739 -0.742 0.738 0.503 0.737 0.503 0.711 0.698 0.946 0.919 0.946 0.919 0.945 0.947
different high 4 -0.69 -0.713 -0.726 -0.712 -0.726 -0.720 -0.720 0.956 0.749 0.956 0.750 0.946 0.946 0.958 0.942 0.957 0.942 0.949 0.949
different high 10 -0.69 -0.705 -0.708 -0.704 -0.707 -0.718 -0.718 1.000 0.973 1.000 0.972 1.000 1.000 0.952 0.946 0.952 0.946 0.938 0.938
different moderate 2 -0.22 -0.234 -0.239 -0.233 -0.238 -0.234 -0.235 0.419 0.271 0.418 0.268 0.423 0.415 0.945 0.940 0.945 0.942 0.942 0.945
different moderate 4 -0.22 -0.229 -0.230 -0.228 -0.230 -0.230 -0.230 0.672 0.428 0.671 0.425 0.676 0.676 0.938 0.946 0.938 0.945 0.939 0.939
different moderate 10 -0.22 -0.231 -0.230 -0.230 -0.230 -0.233 -0.233 0.971 0.791 0.970 0.789 0.968 0.968 0.943 0.936 0.943 0.936 0.936 0.936
different low 2 -0.05 -0.050 -0.052 -0.049 -0.051 -0.050 -0.050 0.097 0.077 0.098 0.074 0.099 0.096 0.947 0.944 0.947 0.947 0.947 0.950
different low 4 -0.05 -0.051 -0.054 -0.050 -0.054 -0.051 -0.051 0.131 0.102 0.132 0.100 0.133 0.133 0.950 0.950 0.950 0.952 0.949 0.949
different low 10 -0.05 -0.048 -0.049 -0.048 -0.048 -0.048 -0.048 0.218 0.152 0.216 0.147 0.221 0.221 0.948 0.950 0.950 0.952 0.949 0.949
different no 2 0 0.000 -0.002 0.000 -0.002 0.000 0.000 0.066 0.055 0.067 0.054 0.068 0.068 0.934 0.946 0.934 0.947 0.932 0.933
different no 4 0 0.002 0.000 0.002 0.000 0.002 0.002 0.057 0.047 0.058 0.044 0.056 0.056 0.943 0.954 0.943 0.956 0.945 0.945













Table 47: Multiple AgD trials (aggregated data) and multiple IPD trials (individual patient data) - scenario I and II. The mean effect,
bias, and the root mean squared error (RMSE) are presented for approach C.1 (pooled IPD, pooled AgD), C.2 (pooled IPD, all indirect
comparisons), and C.3 (all indirect comparisons) and both methods for indirect comparisons, Bucher and MAIC. All meta-analyses
are based on a random effects model.
Popu- Effect Trials Bias MC Error for Bias RMSE
lation Size Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.021 -0.022 -0.020 -0.021 -0.028 -0.032 0.006 0.006 0.006 0.006 0.007 0.007 0.285 0.287 0.285 0.287 0.293 0.294
similar high 4 -0.027 -0.027 -0.027 -0.027 -0.038 -0.038 0.005 0.005 0.005 0.005 0.005 0.005 0.202 0.203 0.202 0.203 0.210 0.210
similar high 10 -0.011 -0.011 -0.010 -0.010 -0.022 -0.021 0.003 0.003 0.003 0.003 0.003 0.003 0.123 0.123 0.123 0.123 0.144 0.137
similar moderate 2 -0.016 -0.016 -0.016 -0.016 -0.017 -0.017 0.003 0.003 0.003 0.003 0.003 0.003 0.130 0.130 0.130 0.130 0.132 0.132
similar moderate 4 -0.010 -0.010 -0.010 -0.010 -0.011 -0.011 0.002 0.002 0.002 0.002 0.002 0.002 0.095 0.095 0.095 0.095 0.096 0.096
similar moderate 10 -0.009 -0.009 -0.009 -0.009 -0.011 -0.011 0.001 0.001 0.001 0.001 0.001 0.001 0.058 0.058 0.058 0.058 0.059 0.059
similar low 2 -0.004 -0.004 -0.004 -0.003 -0.004 -0.004 0.002 0.002 0.002 0.002 0.002 0.002 0.090 0.091 0.090 0.091 0.091 0.091
similar low 4 0.000 0.000 0.001 0.001 0.000 0.000 0.001 0.001 0.001 0.001 0.001 0.001 0.064 0.064 0.064 0.064 0.064 0.064
similar low 10 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.001 0.001 0.001 0.001 0.001 0.040 0.040 0.040 0.040 0.040 0.040
similar no 2 -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 0.002 0.002 0.002 0.002 0.002 0.002 0.082 0.082 0.082 0.082 0.082 0.082
similar no 4 0.002 0.002 0.002 0.002 0.002 0.002 0.001 0.001 0.001 0.001 0.001 0.001 0.058 0.058 0.058 0.058 0.058 0.058
similar no 10 -0.001 -0.001 -0.001 -0.001 -0.001 -0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.035 0.035 0.035 0.035 0.036 0.036
different high 2 -0.040 -0.060 -0.040 -0.060 -0.049 -0.052 0.007 0.010 0.007 0.010 0.007 0.007 0.298 0.439 0.298 0.439 0.309 0.311
different high 4 -0.023 -0.036 -0.022 -0.036 -0.030 -0.030 0.005 0.006 0.005 0.006 0.005 0.005 0.201 0.285 0.201 0.284 0.211 0.211
different high 10 -0.015 -0.018 -0.014 -0.017 -0.028 -0.028 0.003 0.004 0.003 0.004 0.004 0.003 0.123 0.181 0.123 0.181 0.158 0.150
different moderate 2 -0.014 -0.019 -0.013 -0.018 -0.014 -0.015 0.003 0.004 0.003 0.004 0.003 0.003 0.138 0.193 0.138 0.193 0.140 0.140
different moderate 4 -0.009 -0.010 -0.008 -0.010 -0.010 -0.010 0.002 0.003 0.002 0.003 0.002 0.002 0.096 0.134 0.096 0.134 0.097 0.097
different moderate 10 -0.011 -0.010 -0.010 -0.010 -0.013 -0.013 0.001 0.002 0.001 0.002 0.001 0.001 0.061 0.085 0.061 0.085 0.063 0.063
different low 2 0.000 -0.002 0.001 -0.001 0.000 0.000 0.002 0.003 0.002 0.003 0.002 0.002 0.095 0.120 0.095 0.120 0.095 0.095
different low 4 -0.001 -0.004 0.000 -0.004 -0.001 -0.001 0.002 0.002 0.002 0.002 0.002 0.002 0.065 0.085 0.065 0.085 0.065 0.065
different low 10 0.002 0.001 0.002 0.002 0.002 0.002 0.001 0.001 0.001 0.001 0.001 0.001 0.040 0.053 0.040 0.053 0.040 0.040
different no 2 0.000 -0.002 0.000 -0.002 0.000 0.000 0.002 0.002 0.002 0.002 0.002 0.002 0.085 0.105 0.085 0.105 0.085 0.085
different no 4 0.002 0.000 0.002 0.000 0.002 0.002 0.001 0.002 0.001 0.002 0.001 0.001 0.058 0.073 0.058 0.072 0.058 0.058














Table 48: One IPD trial (individual patient data) and multiple AgD trials (aggregated data) - scenario III and IV. Power and coverage
are presented for approach A.1 (pooled AgD) and A.2 (all indirect comparisons) and both methods for indirect comparisons, Bucher
and MAIC. An interaction is considered in the outcome generation process. All meta-analyses are based on a random effects model.
Popu- Effect Trials True Mean Effect Power Coverage
lation Size Effect Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.468 -0.471 -0.528 -0.528 0.518 0.521 0.262 0.262 0.750 0.756 0.916 0.916
similar high 4 -0.69 -0.495 -0.498 -0.551 -0.551 0.576 0.580 0.274 0.274 0.794 0.797 0.938 0.938
similar high 10 -0.69 -0.514 -0.516 -0.550 -0.550 0.622 0.623 0.295 0.295 0.796 0.798 0.921 0.921
similar moderate 2 -0.22 -0.152 -0.153 -0.179 -0.179 0.306 0.304 0.159 0.151 0.845 0.845 0.939 0.940
similar moderate 4 -0.22 -0.184 -0.185 -0.214 -0.214 0.430 0.427 0.238 0.238 0.862 0.866 0.943 0.943
similar moderate 10 -0.22 -0.222 -0.223 -0.239 -0.239 0.576 0.580 0.300 0.300 0.884 0.884 0.947 0.947
similar low 2 -0.05 -0.067 -0.067 -0.087 -0.089 0.155 0.154 0.106 0.087 0.913 0.911 0.934 0.950
similar low 4 -0.05 -0.102 -0.102 -0.127 -0.127 0.312 0.307 0.206 0.204 0.856 0.856 0.898 0.900
similar low 10 -0.05 -0.136 -0.136 -0.153 -0.153 0.520 0.519 0.319 0.319 0.711 0.7085 0.827 0.827
similar no 2 0 -0.038 -0.038 -0.055 -0.060 0.096 0.097 0.078 0.055 0.904 0.904 0.922 0.946
similar no 4 0 -0.075 -0.075 -0.097 -0.098 0.215 0.218 0.177 0.168 0.786 0.782 0.824 0.833
similar no 10 0 -0.105 -0.105 -0.119 -0.119 0.453 0.444 0.288 0.288 0.548 0.556 0.713 0.713
different high 2 -0.69 -0.504 -0.324 -0.550 -0.550 0.587 0.276 0.283 0.283 0.800 0.683 0.916 0.916
different high 4 -0.69 -0.531 -0.352 -0.570 -0.570 0.646 0.314 0.297 0.297 0.816 0.700 0.926 0.926
different high 10 -0.69 -0.540 -0.352 -0.571 -0.571 0.652 0.300 0.306 0.306 0.819 0.686 0.929 0.929
different moderate 2 -0.22 -0.218 -0.123 -0.234 -0.234 0.474 0.214 0.267 0.265 0.888 0.821 0.942 0.942
different moderate 4 -0.22 -0.244 -0.149 -0.261 -0.261 0.601 0.235 0.325 0.325 0.884 0.847 0.938 0.938
different moderate 10 -0.22 -0.260 -0.168 -0.266 -0.266 0.690 0.295 0.334 0.334 0.867 0.838 0.937 0.937
different low 2 -0.05 -0.108 -0.047 -0.116 -0.117 0.275 0.118 0.1735 0.152 0.861 0.911 0.908 0.920
different low 4 -0.05 -0.133 -0.075 -0.143 -0.143 0.453 0.191 0.266 0.266 0.751 0.883 0.860 0.861
different low 10 -0.05 -0.152 -0.094 -0.156 -0.156 0.644 0.240 0.333 0.333 0.624 0.864 0.818 0.818
different no 2 0 -0.079 -0.031 -0.086 -0.087 0.199 0.119 0.139 0.118 0.802 0.882 0.861 0.882
different no 4 0 -0.103 -0.058 -0.112 -0.112 0.358 0.178 0.237 0.233 0.643 0.823 0.764 0.767













Table 49: One IPD trial (individual patient data) and multiple AgD trials (aggregated data) - scenario III and IV. The mean effect,
bias, and the root mean squared error (RMSE) are presented for approach A.1 (pooled AgD) and A.2 (all indirect comparisons) and both
methods for indirect comparisons, Bucher and MAIC. An interaction is considered in the outcome generation process. All meta-analyses
are based on a random effects model.
Popu- Effect Trials Bias MC Error for Bias RMSE
lation Size Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 0.222 0.219 0.162 0.162 0.007 0.007 0.009 0.009 0.372 0.371 0.446 0.446
similar high 4 0.195 0.192 0.139 0.139 0.006 0.006 0.009 0.009 0.339 0.339 0.419 0.419
similar high 10 0.176 0.174 0.140 0.140 0.006 0.006 0.009 0.009 0.336 0.336 0.432 0.432
similar moderate 2 0.068 0.067 0.041 0.041 0.003 0.003 0.004 0.004 0.155 0.155 0.184 0.184
similar moderate 4 0.036 0.035 0.006 0.006 0.003 0.003 0.004 0.004 0.141 0.141 0.178 0.178
similar moderate 10 -0.002 -0.003 -0.019 -0.019 0.003 0.003 0.004 0.004 0.127 0.127 0.171 0.171
similar low 2 -0.017 -0.017 -0.037 -0.039 0.002 0.002 0.003 0.003 0.099 0.099 0.126 0.128
similar low 4 -0.052 -0.052 -0.077 -0.077 0.002 0.002 0.003 0.003 0.102 0.103 0.134 0.134
similar low 10 -0.086 -0.086 -0.103 -0.103 0.002 0.002 0.002 0.002 0.119 0.119 0.148 0.148
similar no 2 -0.038 -0.038 -0.055 -0.060 0.002 0.002 0.002 0.002 0.096 0.096 0.117 0.121
similar no 4 -0.075 -0.075 -0.097 -0.098 0.002 0.002 0.002 0.002 0.109 0.109 0.138 0.138
similar no 10 -0.105 -0.105 -0.119 -0.119 0.002 0.002 0.002 0.002 0.127 0.127 0.150 0.150
different high 2 0.186 0.366 0.140 0.140 0.007 0.009 0.009 0.009 0.343 0.551 0.439 0.439
different high 4 0.159 0.338 0.120 0.120 0.006 0.009 0.009 0.009 0.329 0.540 0.428 0.428
different high 10 0.150 0.338 0.119 0.119 0.006 0.010 0.009 0.009 0.322 0.541 0.421 0.421
different moderate 2 0.002 0.097 -0.014 -0.014 0.003 0.004 0.004 0.004 0.142 0.220 0.184 0.184
different moderate 4 -0.024 0.071 -0.041 -0.041 0.003 0.004 0.004 0.004 0.134 0.199 0.178 0.178
different moderate 10 -0.040 0.052 -0.046 -0.046 0.003 0.004 0.004 0.004 0.133 0.196 0.178 0.178
different low 2 -0.058 0.003 -0.066 -0.067 0.002 0.003 0.003 0.003 0.113 0.123 0.135 0.135
different low 4 -0.083 -0.025 -0.093 -0.093 0.002 0.003 0.003 0.003 0.121 0.122 0.144 0.144
different low 10 -0.102 -0.044 -0.106 -0.106 0.002 0.002 0.002 0.002 0.128 0.117 0.147 0.147
different no 2 -0.079 -0.031 -0.086 -0.087 0.002 0.003 0.002 0.002 0.117 0.115 0.133 0.134
different no 4 -0.103 -0.058 -0.112 -0.112 0.002 0.002 0.002 0.002 0.129 0.117 0.147 0.147














Table 50: One AgD trial (aggregated data) and multiple IPD trials (individual patient data) - scenario III and IV. Power and coverage
are presented for approach B.1 (pooled IPD) and B.2 (all indirect comparisons) and both methods for indirect comparisons, Bucher
and MAIC. An interaction is considered in the outcome generation process. All meta-analyses are based on a random effects model.
Popu- Effect Trials True Mean Effect Power Coverage
lation Size Effect Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.565 -0.567 -0.579 -0.584 0.482 0.479 0.482 0.399 0.914 0.921 0.923 0.939
similar high 4 -0.69 -0.536 -0.539 -0.561 -0.564 0.670 0.669 0.690 0.648 0.894 0.891 0.914 0.925
similar high 10 -0.69 -0.535 -0.537 -0.569 -0.570 0.8735 0.874 0.885 0.885 0.852 0.853 0.879 0.881
similar moderate 2 -0.22 -0.254 -0.255 -0.256 -0.256 0.311 0.317 0.314 0.296 0.944 0.944 0.941 0.949
similar moderate 4 -0.22 -0.253 -0.253 -0.255 -0.255 0.378 0.380 0.381 0.379 0.939 0.938 0.939 0.939
similar moderate 10 -0.22 -0.253 -0.253 -0.257 -0.257 0.454 0.451 0.461 0.461 0.943 0.942 0.941 0.941
similar low 2 -0.05 -0.167 -0.167 -0.168 -0.168 0.213 0.210 0.214 0.212 0.859 0.865 0.857 0.861
similar low 4 -0.05 -0.166 -0.166 -0.167 -0.167 0.241 0.237 0.243 0.243 0.862 0.862 0.863 0.863
similar low 10 -0.05 -0.167 -0.167 -0.168 -0.168 0.246 0.248 0.247 0.247 0.860 0.856 0.858 0.858
similar no 2 0 -0.136 -0.136 -0.136 -0.136 0.165 0.162 0.163 0.162 0.836 0.838 0.838 0.838
similar no 4 0 -0.140 -0.139 -0.140 -0.140 0.188 0.189 0.187 0.187 0.813 0.811 0.813 0.813
similar no 10 0 -0.140 -0.140 -0.140 -0.140 0.188 0.188 0.189 0.189 0.812 0.812 0.812 0.812
different high 2 -0.69 -0.557 -0.375 -0.575 -0.581 0.489 0.201 0.501 0.426 0.927 0.831 0.926 0.946
different high 4 -0.69 -0.545 -0.356 -0.568 -0.571 0.720 0.270 0.734 0.678 0.903 0.762 0.921 0.932
different high 10 -0.69 -0.534 -0.334 -0.567 -0.567 0.926 0.393 0.936 0.933 0.831 0.557 0.873 0.879
different moderate 2 -0.22 -0.275 -0.178 -0.277 -0.277 0.423 0.160 0.423 0.388 0.934 0.933 0.934 0.941
different moderate 4 -0.22 -0.273 -0.176 -0.276 -0.276 0.524 0.194 0.538 0.533 0.927 0.933 0.926 0.927
different moderate 10 -0.22 -0.274 -0.178 -0.278 -0.278 0.624 0.290 0.632 0.632 0.917 0.927 0.913 0.913
different low 2 -0.05 -0.172 -0.111 -0.173 -0.173 0.278 0.111 0.278 0.274 0.844 0.932 0.840 0.845
different low 4 -0.05 -0.168 -0.110 -0.169 -0.169 0.296 0.142 0.300 0.300 0.828 0.922 0.827 0.827
different low 10 -0.05 -0.162 -0.104 -0.163 -0.163 0.298 0.136 0.302 0.302 0.835 0.937 0.834 0.834
different no 2 0 -0.137 -0.089 -0.138 -0.138 0.199 0.100 0.199 0.196 0.801 0.900 0.802 0.804
different no 4 0 -0.134 -0.086 -0.134 -0.134 0.220 0.112 0.222 0.222 0.78 0.889 0.778 0.778













Table 51: One AgD trial (aggregated data) and multiple IPD trials (individual patient data) - scenario III and IV. The mean effect,
bias, and the root mean squared error (RMSE) are presented for approach B.1 (pooled IPD) and B.2 (all indirect comparisons) and both
methods for indirect comparisons, Bucher and MAIC. An interaction is considered in the outcome generation process. All meta-analyses
are based on a random effects model.
Popu- Effect Trials Bias MC Error for Bias RMSE
lation Size Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 0.125 0.123 0.111 0.106 0.007 0.007 0.007 0.007 0.328 0.328 0.333 0.334
similar high 4 0.154 0.151 0.129 0.126 0.005 0.005 0.005 0.005 0.270 0.270 0.266 0.266
similar high 10 0.155 0.153 0.121 0.120 0.004 0.004 0.004 0.004 0.232 0.231 0.216 0.216
similar moderate 2 -0.034 -0.035 -0.036 -0.036 0.004 0.004 0.004 0.004 0.175 0.175 0.176 0.177
similar moderate 4 -0.033 -0.033 -0.035 -0.035 0.003 0.003 0.003 0.003 0.157 0.158 0.158 0.158
similar moderate 10 -0.033 -0.033 -0.037 -0.037 0.003 0.003 0.003 0.003 0.143 0.144 0.145 0.145
similar low 2 -0.117 -0.117 -0.118 -0.118 0.003 0.003 0.003 0.003 0.186 0.186 0.186 0.186
similar low 4 -0.116 -0.116 -0.117 -0.117 0.003 0.003 0.003 0.003 0.179 0.179 0.180 0.180
similar low 10 -0.117 -0.117 -0.118 -0.118 0.003 0.003 0.003 0.003 0.174 0.174 0.174 0.174
similar no 2 -0.136 -0.136 -0.136 -0.136 0.003 0.003 0.003 0.003 0.193 0.193 0.193 0.193
similar no 4 -0.140 -0.139 -0.140 -0.140 0.003 0.003 0.003 0.003 0.195 0.195 0.195 0.195
similar no 10 -0.140 -0.140 -0.140 -0.140 0.003 0.003 0.003 0.003 0.190 0.190 0.191 0.191
different high 2 0.133 0.315 0.115 0.109 0.006 0.009 0.007 0.007 0.315 0.517 0.319 0.319
different high 4 0.145 0.334 0.122 0.119 0.005 0.007 0.005 0.005 0.258 0.445 0.254 0.253
different high 10 0.156 0.356 0.123 0.123 0.004 0.005 0.004 0.004 0.220 0.411 0.205 0.205
different moderate 2 -0.055 0.042 -0.057 -0.057 0.004 0.005 0.004 0.004 0.169 0.213 0.171 0.171
different moderate 4 -0.053 0.044 -0.056 -0.056 0.003 0.004 0.003 0.003 0.147 0.171 0.149 0.149
different moderate 10 -0.054 0.042 -0.058 -0.058 0.003 0.003 0.003 0.003 0.135 0.143 0.138 0.138
different low 2 -0.122 -0.061 -0.123 -0.123 0.003 0.003 0.003 0.003 0.176 0.157 0.177 0.177
different low 4 -0.118 -0.060 -0.119 -0.119 0.003 0.003 0.003 0.003 0.167 0.144 0.168 0.168
different low 10 -0.112 -0.054 -0.113 -0.113 0.003 0.003 0.003 0.003 0.157 0.125 0.157 0.157
different no 2 -0.137 -0.089 -0.138 -0.138 0.003 0.003 0.003 0.003 0.182 0.161 0.182 0.182
different no 4 -0.134 -0.086 -0.134 -0.134 0.003 0.003 0.003 0.003 0.177 0.152 0.177 0.177














Table 52: Multiple AgD trials (aggregated data) and multiple IPD trials (individual patient data) - scenario III and IV. Power and
coverage are presented for approach C.1 (pooled IPD, pooled AgD), C.2 (pooled IPD, all indirect comparisons), and C.3 (all indirect
comparisons) and both methods for indirect comparisons, Bucher and MAIC. An interaction is considered in the outcome generation
process. All meta-analyses are based on a random effects model.
Popu- Effect Trials True Mean Effect Power Coverage
lation Size Effect All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.463 -0.466 -0.492 -0.495 -0.505 -0.507 0.396 0.400 0.432 0.430 0.426 0.412 0.845 0.848 0.864 0.869 0.874 0.879
similar high 4 -0.69 -0.471 -0.475 -0.500 -0.504 -0.522 -0.522 0.697 0.700 0.749 0.752 0.743 0.743 0.795 0.799 0.842 0.839 0.860 0.860
similar high 10 -0.69 -0.501 -0.504 -0.518 -0.521 -0.544 -0.544 0.985 0.988 0.992 0.992 0.992 0.992 0.655 0.665 0.712 0.713 0.780 0.780
similar moderate 2 -0.22 -0.153 -0.153 -0.175 -0.177 -0.176 -0.177 0.220 0.215 0.250 0.224 0.254 0.245 0.916 0.914 0.939 0.943 0.941 0.944
similar moderate 4 -0.22 -0.186 -0.186 -0.210 -0.210 -0.212 -0.212 0.484 0.488 0.566 0.558 0.570 0.570 0.933 0.937 0.943 0.946 0.946 0.946
similar moderate 10 -0.22 -0.221 -0.221 -0.235 -0.235 -0.238 -0.238 0.933 0.935 0.954 0.954 0.952 0.952 0.945 0.946 0.943 0.943 0.942 0.942
similar low 2 -0.05 -0.067 -0.067 -0.081 -0.087 -0.081 -0.083 0.111 0.111 0.130 0.094 0.133 0.123 0.945 0.944 0.944 0.961 0.941 0.946
similar low 4 -0.05 -0.102 -0.102 -0.118 -0.121 -0.119 -0.119 0.303 0.304 0.363 0.314 0.367 0.367 0.893 0.893 0.854 0.876 0.850 0.850
similar low 10 -0.05 -0.137 -0.137 -0.147 -0.147 -0.147 -0.147 0.807 0.808 0.845 0.838 0.848 0.848 0.559 0.552 0.481 0.493 0.476 0.476
similar no 2 0 -0.038 -0.038 -0.048 -0.057 -0.049 -0.051 0.065 0.066 0.074 0.048 0.075 0.073 0.936 0.935 0.927 0.953 0.925 0.928
similar no 4 0 -0.073 -0.073 -0.086 -0.091 -0.086 -0.086 0.199 0.200 0.237 0.187 0.240 0.240 0.802 0.801 0.763 0.814 0.760 0.760
similar no 10 0 -0.106 -0.106 -0.114 -0.115 -0.114 -0.114 0.656 0.658 0.709 0.691 0.710 0.710 0.345 0.342 0.291 0.309 0.291 0.291
different high 2 -0.69 -0.499 -0.318 -0.510 -0.330 -0.528 -0.529 0.445 0.167 0.464 0.176 0.472 0.463 0.885 0.789 0.894 0.798 0.904 0.907
different high 4 -0.69 -0.512 -0.323 -0.522 -0.334 -0.542 -0.542 0.766 0.258 0.788 0.271 0.787 0.787 0.847 0.683 0.859 0.703 0.879 0.879
different high 10 -0.69 -0.519 -0.320 -0.525 -0.326 -0.550 -0.550 0.993 0.474 0.994 0.487 0.993 0.993 0.708 0.409 0.727 0.423 0.795 0.795
different moderate 2 -0.22 -0.216 -0.119 -0.225 -0.129 -0.226 -0.227 0.367 0.121 0.398 0.128 0.396 0.385 0.947 0.905 0.948 0.911 0.948 0.950
different moderate 4 -0.22 -0.239 -0.143 -0.247 -0.152 -0.250 -0.250 0.714 0.199 0.740 0.219 0.738 0.738 0.953 0.909 0.944 0.918 0.943 0.943
different moderate 10 -0.22 -0.259 -0.164 -0.263 -0.168 -0.266 -0.266 0.990 0.505 0.993 0.525 0.993 0.993 0.904 0.900 0.892 0.906 0.887 0.887
different low 2 -0.05 -0.108 -0.047 -0.115 -0.057 -0.116 -0.116 0.207 0.069 0.226 0.062 0.226 0.220 0.906 0.955 0.900 0.961 0.898 0.902
different low 4 -0.05 -0.134 -0.076 -0.140 -0.084 -0.141 -0.141 0.475 0.146 0.503 0.165 0.505 0.505 0.762 0.928 0.739 0.930 0.733 0.733
different low 10 -0.05 -0.152 -0.094 -0.155 -0.098 -0.156 -0.156 0.928 0.383 0.935 0.405 0.936 0.936 0.373 0.882 0.352 0.866 0.344 0.344
different no 2 0 -0.079 -0.032 -0.084 -0.040 -0.084 -0.085 0.155 0.067 0.168 0.058 0.167 0.161 0.846 0.933 0.833 0.943 0.833 0.840
different no 4 0 -0.102 -0.055 -0.106 -0.062 -0.107 -0.107 0.361 0.118 0.386 0.126 0.387 0.387 0.640 0.882 0.615 0.875 0.614 0.614













Table 53: Multiple AgD trials (aggregated data) and multiple IPD trials (individual patient data) - scenario III and IV. The mean effect,
bias, and the root mean squared error (RMSE) are presented for approach C.1 (pooled IPD, pooled AgD), C.2 (pooled IPD, all indirect
comparisons), and C.3 (all indirect comparisons) and both methods for indirect comparisons, Bucher and MAIC. An interaction is
considered in the outcome generation process. All meta-analyses are based on a random effects model.
Popu- Effect Trials Bias MC Error for Bias RMSE
lation Size Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 0.227 0.224 0.198 0.195 0.185 0.183 0.006 0.006 0.006 0.006 0.007 0.007 0.365 0.364 0.348 0.347 0.351 0.351
similar high 4 0.219 0.215 0.190 0.186 0.168 0.168 0.004 0.004 0.004 0.004 0.005 0.005 0.290 0.287 0.269 0.267 0.263 0.263
similar high 10 0.189 0.186 0.172 0.169 0.146 0.146 0.003 0.003 0.003 0.003 0.003 0.003 0.224 0.222 0.210 0.208 0.195 0.195
similar moderate 2 0.067 0.067 0.045 0.043 0.044 0.043 0.003 0.003 0.003 0.003 0.003 0.003 0.150 0.151 0.143 0.144 0.144 0.144
similar moderate 4 0.034 0.034 0.010 0.010 0.008 0.008 0.002 0.002 0.002 0.002 0.002 0.002 0.104 0.104 0.101 0.101 0.101 0.101
similar moderate 10 -0.001 -0.001 -0.015 -0.015 -0.018 -0.018 0.001 0.001 0.001 0.001 0.002 0.002 0.064 0.064 0.066 0.066 0.068 0.068
similar low 2 -0.017 -0.017 -0.031 -0.037 -0.031 -0.033 0.002 0.002 0.002 0.002 0.002 0.002 0.095 0.095 0.100 0.105 0.101 0.102
similar low 4 -0.052 -0.052 -0.068 -0.071 -0.069 -0.069 0.002 0.002 0.002 0.002 0.002 0.002 0.088 0.088 0.099 0.102 0.100 0.100
similar low 10 -0.087 -0.087 -0.097 -0.097 -0.097 -0.097 0.001 0.001 0.001 0.001 0.001 0.001 0.099 0.099 0.108 0.109 0.109 0.109
similar no 2 -0.038 -0.038 -0.048 -0.057 -0.049 -0.051 0.002 0.002 0.002 0.002 0.002 0.002 0.095 0.095 0.100 0.107 0.100 0.102
similar no 4 -0.073 -0.073 -0.086 -0.091 -0.086 -0.086 0.002 0.002 0.002 0.002 0.002 0.002 0.099 0.099 0.109 0.113 0.109 0.109
similar no 10 -0.106 -0.106 -0.114 -0.115 -0.114 -0.114 0.001 0.001 0.001 0.001 0.001 0.001 0.115 0.115 0.123 0.124 0.123 0.123
different high 2 0.191 0.372 0.180 0.36 0.162 0.161 0.0061 0.0089 0.0061 0.0089 0.006 0.006 0.332 0.546 0.326 0.538 0.328 0.328
different high 4 0.178 0.367 0.168 0.356 0.148 0.148 0.004 0.006 0.004 0.006 0.005 0.005 0.261 0.460 0.255 0.452 0.249 0.249
different high 10 0.171 0.370 0.165 0.364 0.140 0.140 0.003 0.004 0.003 0.004 0.003 0.003 0.207 0.410 0.203 0.405 0.189 0.189
different moderate 2 0.004 0.101 -0.005 0.091 -0.006 -0.007 0.003 0.004 0.003 0.004 0.003 0.003 0.136 0.216 0.137 0.211 0.138 0.138
different moderate 4 -0.019 0.077 -0.027 0.068 -0.030 -0.030 0.002 0.003 0.002 0.003 0.002 0.002 0.097 0.152 0.099 0.148 0.101 0.101
different moderate 10 -0.039 0.056 -0.043 0.052 -0.046 -0.046 0.001 0.002 0.001 0.002 0.001 0.001 0.072 0.100 0.075 0.098 0.077 0.077
different low 2 -0.058 0.003 -0.065 -0.007 -0.066 -0.066 0.002 0.003 0.002 0.003 0.002 0.002 0.110 0.118 0.114 0.118 0.115 0.115
different low 4 -0.084 -0.026 -0.090 -0.034 -0.091 -0.091 0.002 0.002 0.002 0.002 0.002 0.002 0.109 0.093 0.114 0.096 0.115 0.115
different low 10 -0.102 -0.044 -0.105 -0.048 -0.106 -0.106 0.001 0.001 0.001 0.001 0.001 0.001 0.111 0.070 0.114 0.072 0.115 0.115
different no 2 -0.079 -0.032 -0.084 -0.040 -0.084 -0.085 0.002 0.002 0.002 0.002 0.002 0.002 0.116 0.110 0.119 0.113 0.119 0.120
different no 4 -0.102 -0.055 -0.106 -0.062 -0.107 -0.107 0.001 0.002 0.001 0.002 0.001 0.001 0.120 0.095 0.124 0.099 0.125 0.125














Table 54: One IPD trial (individual patient data) and multiple AgD trials (aggregated data) - scenario I and II. Mean Effect, power, and
coverage are presented for approach A.1 (pooled AgD) and A.2 (all indirect comparisons) and both methods for indirect comparisons,
Bucher and MAIC. All meta-analyses are based on a fixed effects model.
Popu- Effect Trials True Mean Effect Power Coverage
lation Size Effect Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.713 -0.713 -0.742 -0.742 0.808 0.804 0.444 0.444 0.881 0.885 0.951 0.951
similar high 4 -0.69 -0.743 -0.743 -0.777 -0.777 0.846 0.843 0.459 0.459 0.878 0.878 0.953 0.953
similar high 10 -0.69 -0.726 -0.726 -0.756 -0.756 0.842 0.845 0.445 0.445 0.869 0.873 0.949 0.949
similar moderate 2 -0.22 -0.234 -0.234 -0.231 -0.231 0.547 0.551 0.250 0.250 0.902 0.902 0.952 0.952
similar moderate 4 -0.22 -0.232 -0.232 -0.234 -0.234 0.571 0.567 0.267 0.267 0.883 0.879 0.948 0.948
similar moderate 10 -0.22 -0.232 -0.232 -0.234 -0.234 0.512 0.610 0.278 0.278 0.879 0.879 0.958 0.958
similar low 2 -0.05 -0.053 -0.053 -0.052 -0.052 0.150 0.152 0.091 0.091 0.905 0.903 0.940 0.940
similar low 4 -0.05 -0.051 -0.051 -0.052 -0.052 0.184 0.186 0.090 0.090 0.879 0.878 0.943 0.943
similar low 10 -0.05 -0.052 -0.052 -0.051 -0.051 0.209 0.207 0.087 0.087 0.875 0.878 0.946 0.946
similar no 2 0 -0.003 -0.003 -0.002 -0.002 0.094 0.094 0.069 0.069 0.907 0.906 0.932 0.932
similar no 4 0 0.002 0.002 0.002 0.002 0.109 0.110 0.060 0.060 0.892 0.890 0.940 0.940
similar no 10 0 -0.001 -0.001 -0.001 -0.001 0.130 0.130 0.065 0.065 0.871 0.871 0.936 0.936
different high 2 -0.69 -0.734 -0.756 -0.766 -0.766 0.822 0.6345 0.456 0.456 0.866 0.821 0.947 0.947
different high 4 -0.69 -0.725 -0.759 -0.746 -0.746 0.833 0.639 0.446 0.446 0.870 0.844 0.956 0.956
different high 10 -0.69 -0.729 -0.755 -0.766 -0.766 0.850 0.6265 0.458 0.458 0.866 0.850 0.940 0.940
different moderate 2 -0.22 -0.234 -0.239 -0.237 -0.237 0.538 0.3915 0.257 0.257 0.881 0.868 0.945 0.945
different moderate 4 -0.22 -0.231 -0.232 -0.233 -0.233 0.562 0.388 0.273 0.273 0.883 0.876 0.950 0.950
different moderate 10 -0.22 -0.231 -0.230 -0.236 -0.236 0.593 0.4015 0.282 0.282 0.864 0.851 0.933 0.933
different low 2 -0.05 -0.050 -0.054 -0.051 -0.051 0.146 0.146 0.081 0.081 0.905 0.895 0.944 0.944
different low 4 -0.05 -0.051 -0.056 -0.050 -0.050 0.159 0.174 0.079 0.079 0.885 0.881 0.947 0.947
different low 10 -0.05 -0.045 -0.047 -0.046 -0.046 0.173 0.159 0.076 0.076 0.881 0.885 0.945 0.945
different no 2 0 0.000 -0.002 -0.001 -0.001 0.099 0.106 0.059 0.059 0.901 0.895 0.941 0.941
different no 4 0 0.002 0.003 0.002 0.002 0.099 0.121 0.049 0.049 0.902 0.879 0.951 0.951













Table 55: One IPD trial (individual patient data) and multiple AgD trials (aggregated data) - scenario I and II. The bias, its Monte
Carlo (MC) standard error, and the root mean squared error (RMSE) are presented for approach A.1 (pooled AgD) and A.2 (all indirect
comparisons) and both methods for indirect comparisons, Bucher and MAIC. All meta-analyses are based on a fixed effects model.
Popu- Effect Trials Bias MC Error for Bias RMSE
lation Size Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.023 -0.023 -0.052 -0.052 0.007 0.007 0.010 0.010 0.300 0.302 0.433 0.433
similar high 4 -0.053 -0.053 -0.087 -0.087 0.007 0.007 0.010 0.010 0.303 0.305 0.433 0.433
similar high 10 -0.036 -0.036 -0.066 -0.066 0.007 0.007 0.010 0.010 0.301 0.302 0.436 0.436
similar moderate 2 -0.014 -0.014 -0.011 -0.011 0.003 0.003 0.004 0.004 0.136 0.136 0.178 0.178
similar moderate 4 -0.012 -0.012 -0.014 -0.014 0.003 0.003 0.004 0.004 0.135 0.135 0.178 0.178
similar moderate 10 -0.012 -0.012 -0.014 -0.014 0.003 0.003 0.004 0.004 0.129 0.129 0.171 0.171
similar low 2 -0.003 -0.003 -0.002 -0.002 0.002 0.002 0.003 0.003 0.094 0.094 0.117 0.117
similar low 4 -0.001 -0.001 -0.002 -0.002 0.002 0.002 0.002 0.002 0.085 0.086 0.109 0.109
similar low 10 -0.002 -0.002 -0.001 -0.001 0.002 0.002 0.002 0.002 0.078 0.078 0.103 0.103
similar no 2 -0.003 -0.003 -0.002 -0.002 0.002 0.002 0.002 0.002 0.085 0.085 0.101 0.101
similar no 4 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.073 0.073 0.091 0.091
similar no 10 -0.001 -0.001 -0.001 -0.001 0.002 0.002 0.002 0.002 0.066 0.066 0.086 0.086
different high 2 -0.044 -0.066 -0.076 -0.076 0.007 0.010 0.010 0.010 0.316 0.46 0.452 0.452
different high 4 -0.035 -0.069 -0.056 -0.056 0.007 0.010 0.010 0.010 0.303 0.437 0.428 0.428
different high 10 -0.039 -0.065 -0.076 -0.076 0.007 0.0098 0.010 0.010 0.302 0.442 0.438 0.438
different moderate 2 -0.014 -0.019 -0.017 -0.017 0.003 0.005 0.004 0.004 0.143 0.200 0.184 0.184
different moderate 4 -0.011 -0.012 -0.013 -0.013 0.003 0.004 0.004 0.004 0.135 0.191 0.178 0.178
different moderate 10 -0.011 -0.010 -0.016 -0.016 0.003 0.004 0.004 0.004 0.133 0.195 0.182 0.182
different low 2 0.000 -0.004 -0.001 -0.001 0.002 0.003 0.003 0.003 0.097 0.125 0.118 0.118
different low 4 -0.001 -0.006 0.000 0.000 0.002 0.003 0.002 0.002 0.085 0.117 0.108 0.108
different low 10 0.005 0.003 0.004 0.004 0.002 0.003 0.002 0.002 0.077 0.111 0.102 0.102
different no 2 0.000 -0.002 -0.001 -0.001 0.002 0.002 0.002 0.002 0.087 0.108 0.103 0.103
different no 4 0.002 0.003 0.002 0.002 0.002 0.002 0.002 0.002 0.073 0.098 0.090 0.090
different no 10 -0.005 -0.008 -0.006 -0.006 0.002 0.002 0.002 0.002 0.067 0.096 0.086 0.086
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Table 56: One AgD trial (individual patient data) and multiple IPD trials (aggregated data)
- scenario I and II. Mean effect, power, and coverage are presented for approach B.2 (all
indirect comparisons) and both methods for indirect comparisons, Bucher and MAIC. All
meta-analyses are based on a fixed effects model. Note, approach B.1 does not include a
meta-analysis.
Population Effect Size Trials True Effect Mean Effect Power Coverage
Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.719 -0.719 0.691 0.691 0.952 0.952
similar high 4 -0.69 -0.734 -0.734 0.927 0.927 0.946 0.946
similar high 10 -0.69 -0.720 -0.720 0.998 0.998 0.941 0.941
similar moderate 2 -0.22 -0.238 -0.238 0.388 0.388 0.948 0.948
similar moderate 4 -0.22 -0.234 -0.234 0.526 0.526 0.948 0.948
similar moderate 10 -0.22 -0.234 -0.234 0.692 0.692 0.939 0.939
similar low 2 -0.05 -0.056 -0.056 0.091 0.091 0.947 0.947
similar low 4 -0.05 -0.052 -0.052 0.100 0.100 0.936 0.936
similar low 10 -0.05 -0.048 -0.048 0.100 0.100 0.942 0.942
similar no 2 0 -0.002 -0.002 0.062 0.062 0.939 0.939
similar no 4 0 0.002 0.002 0.055 0.055 0.945 0.945
similar no 10 0 0.001 0.001 0.053 0.053 0.947 0.947
different high 2 -0.69 -0.739 -0.739 0.700 0.700 0.947 0.947
different high 4 -0.69 -0.726 -0.726 0.919 0.919 0.943 0.943
different high 10 -0.69 -0.729 -0.729 0.999 0.999 0.940 0.940
different moderate 2 -0.22 -0.234 -0.234 0.366 0.366 0.943 0.943
different moderate 4 -0.22 -0.228 -0.228 0.488 0.488 0.947 0.947
different moderate 10 -0.22 -0.236 -0.236 0.658 0.658 0.933 0.933
different low 2 -0.05 -0.049 -0.049 0.081 0.081 0.938 0.938
different low 4 -0.05 -0.052 -0.052 0.091 0.091 0.946 0.946
different low 10 -0.05 -0.049 -0.049 0.098 0.098 0.941 0.941
different no 2 0 -0.003 -0.003 0.063 0.063 0.938 0.938
different no 4 0 -0.001 -0.001 0.052 0.052 0.949 0.949
different no 10 0 -0.001 -0.001 0.058 0.058 0.943 0.943
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Table 57: One AgD trial (individual patient data) and multiple IPD trials (aggregated data) -
scenario I and II. The bias, its Monte Carlo (MC) standard error, and the root mean squared
error (RMSE) are presented for approach B.2 (all indirect comparisons) and both methods
for indirect comparisons, Bucher and MAIC. All meta-analyses are based on a fixed effects
model. Note, approach B.1 does not include a meta-analysis.
Population Effect Size Trials Bias MC Error for Bias RMSE
Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.029 -0.029 0.007 0.007 0.299 0.299
similar high 4 -0.044 -0.044 0.005 0.005 0.224 0.224
similar high 10 -0.030 -0.030 0.004 0.004 0.163 0.163
similar moderate 2 -0.018 -0.018 0.003 0.003 0.144 0.144
similar moderate 4 -0.014 -0.014 0.003 0.003 0.118 0.118
similar moderate 10 -0.014 -0.014 0.002 0.002 0.098 0.098
similar low 2 -0.006 -0.006 0.002 0.002 0.107 0.107
similar low 4 -0.002 -0.002 0.002 0.002 0.097 0.097
similar low 10 0.002 0.002 0.002 0.002 0.087 0.087
similar no 2 -0.002 -0.002 0.002 0.002 0.102 0.102
similar no 4 0.002 0.002 0.002 0.002 0.090 0.090
similar no 10 0.001 0.001 0.002 0.002 0.083 0.083
different high 2 -0.049 -0.049 0.007 0.007 0.316 0.316
different high 4 -0.036 -0.036 0.005 0.005 0.228 0.228
different high 10 -0.039 -0.039 0.004 0.004 0.178 0.178
different moderate 2 -0.014 -0.014 0.003 0.003 0.153 0.153
different moderate 4 -0.008 -0.008 0.003 0.003 0.121 0.121
different moderate 10 -0.016 -0.016 0.002 0.002 0.104 0.104
different low 2 0.001 0.001 0.003 0.003 0.114 0.114
different low 4 -0.002 -0.002 0.002 0.002 0.100 0.100
different low 10 0.001 0.001 0.002 0.002 0.093 0.093
different no 2 -0.003 -0.003 0.002 0.002 0.107 0.107
different no 4 -0.001 -0.001 0.002 0.002 0.093 0.093














Table 58: Multiple AgD trials (aggregated data) and multiple IPD trials (individual patient data) - scenario I and II . Mean Effect,
power, and coverage are presented for approach C.1 (pooled IPD, pooled AgD), C.2 (pooled IPD, all indirect comparisons), and C.3
(all indirect comparisons) and both methods for indirect comparisons, Bucher and MAIC. All meta-analyses are based on a fixed effects
model.
Popu- Effect Trials True Mean Effect Power Coverage
lation Size Effect All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.711 -0.712 -0.710 -0.711 -0.718 -0.718 0.720 0.717 0.720 0.715 0.700 0.700 0.952 0.956 0.952 0.955 0.951 0.951
similar high 4 -0.69 -0.717 -0.717 -0.717 -0.717 -0.728 -0.728 0.961 0.961 0.961 0.960 0.952 0.952 0.954 0.953 0.954 0.954 0.948 0.948
similar high 10 -0.69 -0.701 -0.701 -0.700 -0.700 -0.712 -0.712 1.000 1.000 1.000 1.000 1.000 1.000 0.951 0.952 0.952 0.952 0.944 0.944
similar moderate 2 -0.22 -0.236 -0.236 -0.236 -0.236 -0.237 -0.237 0.442 0.442 0.442 0.441 0.441 0.441 0.953 0.953 0.953 0.954 0.954 0.954
similar moderate 4 -0.22 -0.230 -0.230 -0.230 -0.230 -0.231 -0.231 0.699 0.700 0.698 0.695 0.695 0.695 0.946 0.943 0.946 0.944 0.945 0.945
similar moderate 10 -0.22 -0.229 -0.229 -0.229 -0.229 -0.231 -0.231 0.976 0.976 0.976 0.976 0.976 0.976 0.955 0.954 0.955 0.954 0.952 0.952
similar low 2 -0.05 -0.054 -0.054 -0.054 -0.053 -0.054 -0.054 0.099 0.099 0.099 0.100 0.099 0.099 0.943 0.943 0.942 0.943 0.943 0.943
similar low 4 -0.05 -0.050 -0.050 -0.049 -0.049 -0.050 -0.050 0.137 0.133 0.139 0.133 0.144 0.144 0.948 0.946 0.948 0.948 0.947 0.947
similar low 10 -0.05 -0.050 -0.050 -0.050 -0.050 -0.050 -0.050 0.249 0.251 0.249 0.247 0.256 0.256 0.949 0.948 0.949 0.949 0.950 0.950
similar no 2 0 -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 0.057 0.058 0.057 0.058 0.057 0.057 0.944 0.942 0.944 0.943 0.943 0.943
similar no 4 0 0.002 0.002 0.002 0.002 0.002 0.002 0.063 0.062 0.063 0.062 0.062 0.062 0.938 0.939 0.937 0.938 0.939 0.939
similar no 10 0 -0.001 -0.001 -0.001 -0.001 -0.001 -0.001 0.053 0.054 0.054 0.054 0.054 0.054 0.948 0.947 0.947 0.947 0.946 0.946
different high 2 -0.69 -0.730 -0.750 -0.730 -0.750 -0.739 -0.739 0.738 0.503 0.737 0.503 0.711 0.711 0.946 0.919 0.946 0.919 0.945 0.945
different high 4 -0.69 -0.713 -0.726 -0.712 -0.726 -0.720 -0.720 0.956 0.749 0.956 0.750 0.946 0.946 0.958 0.942 0.957 0.942 0.949 0.949
different high 10 -0.69 -0.705 -0.708 -0.704 -0.707 -0.718 -0.718 1.000 0.973 1.000 0.972 1.000 1.000 0.952 0.946 0.952 0.946 0.938 0.938
different moderate 2 -0.22 -0.234 -0.239 -0.233 -0.238 -0.234 -0.234 0.419 0.271 0.418 0.268 0.423 0.423 0.945 0.940 0.945 0.942 0.942 0.942
different moderate 4 -0.22 -0.229 -0.230 -0.228 -0.230 -0.230 -0.230 0.672 0.428 0.671 0.425 0.676 0.676 0.938 0.946 0.938 0.945 0.939 0.939
different moderate 10 -0.22 -0.231 -0.230 -0.230 -0.230 -0.233 -0.233 0.971 0.791 0.970 0.789 0.968 0.968 0.943 0.936 0.943 0.936 0.936 0.936
different low 2 -0.05 -0.050 -0.052 -0.049 -0.051 -0.050 -0.050 0.097 0.077 0.098 0.075 0.099 0.099 0.947 0.944 0.947 0.944 0.947 0.947
different low 4 -0.05 -0.051 -0.054 -0.050 -0.054 -0.051 -0.051 0.131 0.102 0.132 0.100 0.133 0.133 0.950 0.950 0.950 0.951 0.949 0.949
different low 10 -0.05 -0.048 -0.049 -0.048 -0.048 -0.048 -0.048 0.218 0.152 0.216 0.147 0.221 0.221 0.948 0.950 0.950 0.952 0.949 0.949
different no 2 0 0.000 -0.002 0.000 -0.002 0.000 0.000 0.066 0.055 0.067 0.055 0.068 0.068 0.934 0.946 0.934 0.946 0.932 0.932
different no 4 0 0.002 0.000 0.002 0.000 0.002 0.002 0.057 0.047 0.058 0.046 0.056 0.056 0.943 0.954 0.943 0.955 0.945 0.945













Table 59: Multiple AgD trials (aggregated data) and multiple IPD trials (individual patient data) - scenario I and II. The bias, its
Monte Carlo (MC) standard error, and the root mean squared error (RMSE) are presented for approach C.1 (pooled IPD, pooled AgD),
C.2 (pooled IPD, all indirect comparisons), and C.3 (all indirect comparisons) and both methods for indirect comparisons, Bucher and
MAIC. All meta-analyses are based on a fixed effects model.
Popu- Effect Trials Bias MC Error for Bias RMSE
lation Size Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.021 -0.022 -0.020 -0.021 -0.028 -0.028 0.006 0.006 0.006 0.006 0.007 0.007 0.285 0.287 0.285 0.287 0.293 0.293
similar high 4 -0.027 -0.027 -0.027 -0.027 -0.038 -0.038 0.005 0.005 0.005 0.005 0.005 0.005 0.202 0.203 0.202 0.203 0.210 0.210
similar high 10 -0.011 -0.011 -0.010 -0.010 -0.022 -0.022 0.003 0.003 0.003 0.003 0.003 0.003 0.123 0.123 0.123 0.123 0.144 0.144
similar moderate 2 -0.016 -0.016 -0.016 -0.016 -0.017 -0.017 0.003 0.003 0.003 0.003 0.003 0.003 0.130 0.130 0.130 0.130 0.132 0.132
similar moderate 4 -0.010 -0.010 -0.010 -0.010 -0.011 -0.011 0.002 0.002 0.002 0.002 0.002 0.002 0.095 0.095 0.095 0.095 0.096 0.096
similar moderate 10 -0.009 -0.009 -0.009 -0.009 -0.011 -0.011 0.001 0.001 0.001 0.001 0.001 0.001 0.058 0.058 0.058 0.058 0.059 0.059
similar low 2 -0.004 -0.004 -0.004 -0.003 -0.004 -0.004 0.002 0.002 0.002 0.002 0.002 0.002 0.090 0.091 0.090 0.091 0.091 0.091
similar low 4 0.000 0.000 0.001 0.001 0.000 0.000 0.001 0.001 0.001 0.001 0.001 0.001 0.064 0.064 0.064 0.064 0.064 0.064
similar low 10 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.001 0.001 0.001 0.001 0.001 0.040 0.040 0.040 0.040 0.040 0.040
similar no 2 -0.003 -0.003 -0.003 -0.003 -0.003 -0.003 0.002 0.002 0.002 0.002 0.002 0.002 0.082 0.082 0.082 0.082 0.082 0.082
similar no 4 0.002 0.002 0.002 0.002 0.002 0.002 0.001 0.001 0.001 0.001 0.001 0.001 0.058 0.058 0.058 0.058 0.058 0.058
similar no 10 -0.001 -0.001 -0.001 -0.001 -0.001 -0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.035 0.035 0.035 0.035 0.036 0.036
different high 2 -0.040 -0.060 -0.040 -0.060 -0.049 -0.049 0.007 0.010 0.007 0.010 0.007 0.007 0.298 0.439 0.298 0.439 0.309 0.309
different high 4 -0.023 -0.036 -0.022 -0.036 -0.030 -0.030 0.005 0.006 0.005 0.006 0.005 0.005 0.201 0.285 0.201 0.284 0.211 0.211
different high 10 -0.015 -0.018 -0.014 -0.017 -0.028 -0.028 0.003 0.004 0.003 0.004 0.004 0.004 0.123 0.181 0.123 0.181 0.158 0.158
different moderate 2 -0.014 -0.019 -0.013 -0.018 -0.014 -0.014 0.003 0.004 0.003 0.004 0.003 0.003 0.138 0.193 0.138 0.193 0.140 0.140
different moderate 4 -0.009 -0.010 -0.008 -0.010 -0.010 -0.010 0.002 0.003 0.002 0.003 0.002 0.002 0.096 0.134 0.096 0.134 0.097 0.097
different moderate 10 -0.011 -0.010 -0.010 -0.010 -0.013 -0.013 0.001 0.002 0.001 0.002 0.001 0.001 0.061 0.085 0.061 0.085 0.063 0.063
different low 2 0.000 -0.002 0.001 -0.001 0.000 0.000 0.002 0.003 0.002 0.003 0.002 0.002 0.095 0.120 0.095 0.120 0.095 0.095
different low 4 -0.001 -0.004 0.000 -0.004 -0.001 -0.001 0.002 0.002 0.002 0.002 0.002 0.002 0.065 0.085 0.065 0.085 0.065 0.065
different low 10 0.002 0.001 0.002 0.002 0.002 0.002 0.001 0.001 0.001 0.001 0.001 0.001 0.040 0.053 0.040 0.053 0.040 0.040
different no 2 0.000 -0.002 0.000 -0.002 0.000 0.000 0.002 0.002 0.002 0.002 0.002 0.002 0.085 0.105 0.085 0.104 0.085 0.085
different no 4 0.002 0.000 0.002 0.000 0.002 0.002 0.001 0.002 0.001 0.002 0.001 0.001 0.058 0.073 0.058 0.072 0.058 0.058














Table 60: One IPD trial (individual patient data) and multiple AgD trials (aggregated data) - scenario I and II. Mean Effect, power, and
coverage are presented for approach A.1 (pooled AgD) and A.2 (all indirect comparisons) and both methods for indirect comparisons,
Bucher and MAIC. All meta-analyses are based on a random effects model. A variance value of σ = 0.4 is assumed in the generation
of the true treatment effect.
Popu- Effect Trials True Mean Effect Power Coverage
lation Size Effect Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.747 -0.748 -0.781 -0.781 0.807 0.805 0.431 0.431 0.866 0.862 0.946 0.946
similar high 4 -0.69 -0.764 -0.764 -0.805 -0.805 0.833 0.834 0.453 0.453 0.856 0.856 0.939 0.939
similar high 10 -0.69 -0.766 -0.766 -0.797 -0.797 0.853 0.853 0.448 0.448 0.859 0.861 0.943 0.943
similar moderate 2 -0.22 -0.227 -0.227 -0.230 -0.230 0.514 0.513 0.249 0.249 0.863 0.862 0.933 0.933
similar moderate 4 -0.22 -0.237 -0.237 -0.241 -0.241 0.591 0.593 0.295 0.295 0.860 0.863 0.941 0.941
similar moderate 10 -0.22 -0.231 -0.231 -0.233 -0.233 0.603 0.602 0.285 0.285 0.854 0.851 0.939 0.939
similar low 2 -0.05 -0.051 -0.051 -0.051 -0.051 0.181 0.181 0.111 0.108 0.859 0.861 0.913 0.915
similar low 4 -0.05 -0.051 -0.051 -0.051 -0.051 0.220 0.222 0.111 0.111 0.845 0.847 0.922 0.922
similar low 10 -0.05 -0.050 -0.050 -0.049 -0.049 0.241 0.241 0.118 0.118 0.824 0.822 0.908 0.908
similar no 2 0 -0.001 -0.001 0.001 0.001 0.140 0.140 0.103 0.096 0.860 0.861 0.8975 0.904
similar no 4 0 0.003 0.003 0.003 0.003 0.165 0.162 0.097 0.097 0.836 0.839 0.903 0.904
similar no 10 0 0.000 0.000 0.001 0.001 0.175 0.176 0.086 0.086 0.825 0.824 0.914 0.914
different high 2 -0.69 -0.763 -0.798 -0.797 -0.797 0.817 0.626 0.448 0.448 0.863 0.825 0.938 0.938
different high 4 -0.69 -0.769 -0.808 -0.806 -0.806 0.840 0.652 0.460 0.460 0.865 0.816 0.943 0.943
different high 10 -0.69 -0.769 -0.81 -0.815 -0.815 0.848 0.657 0.479 0.479 0.871 0.826 0.941 0.941
different moderate 2 -0.22 -0.232 -0.232 -0.235 -0.235 0.5215 0.371 0.270 0.269 0.859 0.856 0.940 0.940
different moderate 4 -0.22 -0.237 -0.236 -0.240 -0.240 0.582 0.4025 0.289 0.289 0.846 0.851 0.928 0.928
different moderate 10 -0.22 -0.233 -0.238 -0.233 -0.233 0.595 0.423 0.274 0.274 0.855 0.8645 0.935 0.935
different low 2 -0.05 -0.048 -0.049 -0.050 -0.050 0.167 0.166 0.105 0.101 0.872 0.8645 0.914 0.920
different low 4 -0.05 -0.048 -0.050 -0.048 -0.048 0.209 0.191 0.119 0.119 0.839 0.844 0.913 0.913
different low 10 -0.05 -0.057 -0.059 -0.057 -0.057 0.2435 0.190 0.125 0.125 0.847 0.857 0.916 0.916
different no 2 0 0.003 0.003 0.002 0.002 0.133 0.137 0.090 0.078 0.868 0.864 0.910 0.922
different no 4 0 -0.001 0.001 -0.001 -0.001 0.170 0.150 0.105 0.105 0.831 0.850 0.896 0.896













Table 61: One IPD trial (individual patient data) and multiple AgD trials (aggregated data) - scenario I and II. The bias, its Monte
Carlo (MC) standard error, and the root mean squared error (RMSE) are presented for approach A.1 (pooled AgD) and A.2 (all indirect
comparisons) and both methods for indirect comparisons, Bucher and MAIC. All meta-analyses are based on a random effects model.
A variance value of σ = 0.4 is assumed in the generation of the true treatment effect.
Popu- Effect Trials Bias MC Error for Bias RMSE
lation Size Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.057 -0.058 -0.091 -0.091 0.007 0.007 0.010 0.010 0.324 0.327 0.468 0.468
similar high 4 -0.074 -0.074 -0.115 -0.115 0.007 0.007 0.011 0.011 0.334 0.335 0.487 0.487
similar high 10 -0.076 -0.076 -0.107 -0.107 0.007 0.007 0.010 0.010 0.325 0.327 0.472 0.472
similar moderate 2 -0.007 -0.007 -0.010 -0.010 0.003 0.003 0.004 0.004 0.145 0.146 0.190 0.190
similar moderate 4 -0.017 -0.017 -0.021 -0.021 0.003 0.003 0.004 0.004 0.141 0.141 0.184 0.184
similar moderate 10 -0.011 -0.011 -0.013 -0.013 0.003 0.003 0.004 0.004 0.137 0.137 0.179 0.179
similar low 2 -0.001 -0.001 -0.001 -0.001 0.002 0.002 0.003 0.003 0.105 0.105 0.129 0.129
similar low 4 -0.001 -0.001 -0.001 -0.001 0.002 0.002 0.003 0.003 0.095 0.095 0.120 0.120
similar low 10 0.000 0.000 0.001 0.001 0.002 0.002 0.003 0.003 0.088 0.088 0.116 0.116
similar no 2 -0.001 -0.001 0.001 0.001 0.002 0.002 0.003 0.003 0.095 0.095 0.113 0.113
similar no 4 0.003 0.003 0.003 0.003 0.002 0.002 0.002 0.002 0.083 0.083 0.104 0.104
similar no 10 0.000 0.000 0.001 0.001 0.002 0.002 0.002 0.002 0.074 0.074 0.095 0.095
different high 2 -0.073 -0.108 -0.107 -0.107 0.007 0.011 0.011 0.011 0.334 0.481 0.480 0.480
different high 4 -0.079 -0.118 -0.116 -0.116 0.007 0.011 0.011 0.011 0.331 0.489 0.493 0.493
different high 10 -0.079 -0.120 -0.125 -0.125 0.007 0.010 0.010 0.010 0.320 0.473 0.481 0.481
different moderate 2 -0.012 -0.012 -0.015 -0.015 0.003 0.005 0.004 0.004 0.153 0.206 0.191 0.191
different moderate 4 -0.017 -0.016 -0.020 -0.020 0.003 0.005 0.004 0.004 0.143 0.201 0.189 0.189
different moderate 10 -0.013 -0.018 -0.013 -0.013 0.003 0.004 0.004 0.004 0.135 0.190 0.181 0.181
different low 2 0.002 0.001 0.000 0.000 0.002 0.003 0.003 0.003 0.106 0.134 0.130 0.130
different low 4 0.002 0.000 0.002 0.002 0.002 0.003 0.003 0.003 0.099 0.128 0.123 0.123
different low 10 -0.007 -0.009 -0.007 -0.007 0.002 0.003 0.003 0.003 0.087 0.116 0.114 0.114
different no 2 0.003 0.003 0.002 0.002 0.002 0.003 0.003 0.003 0.096 0.118 0.114 0.114
different no 4 -0.001 0.001 -0.001 -0.001 0.002 0.002 0.002 0.002 0.087 0.108 0.108 0.108














Table 62: One AgD trial (aggregated data) and multiple IPD trials (individual patient data) - scenario I and II. Mean effect, power, and
coverage are presented for approach B.1 (pooled IPD) and B.2 (all indirect comparisons) and both methods for indirect comparisons,
Bucher and MAIC. Results for scenario I and II are presented. All meta-analyses are based on a random effects model. A variance
value of σ = 0.4 is assumed in the generation of the true treatment effect.
Popu- Effect Trials True Mean Effect Power Coverage
lation Size Effect Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.742 -0.743 -0.751 -0.765 0.701 0.697 0.686 0.589 0.949 0.946 0.946 0.959
similar high 4 -0.69 -0.748 -0.748 -0.761 -0.772 0.934 0.927 0.919 0.870 0.937 0.937 0.930 0.942
similar high 10 -0.69 -0.734 -0.734 -0.758 -0.761 0.999 0.999 0.998 0.997 0.924 0.923 0.912 0.918
similar moderate 2 -0.22 -0.226 -0.226 -0.227 -0.228 0.363 0.357 0.365 0.317 0.935 0.932 0.933 0.943
similar moderate 4 -0.22 -0.235 -0.235 -0.237 -0.238 0.536 0.537 0.536 0.515 0.910 0.911 0.907 0.913
similar moderate 10 -0.22 -0.227 -0.227 -0.231 -0.231 0.655 0.656 0.668 0.668 0.912 0.916 0.913 0.913
similar low 2 -0.05 -0.051 -0.051 -0.052 -0.052 0.123 0.123 0.123 0.115 0.912 0.911 0.912 0.919
similar low 4 -0.05 -0.051 -0.051 -0.052 -0.052 0.136 0.136 0.137 0.136 0.903 0.900 0.902 0.905
similar low 10 -0.05 -0.050 -0.050 -0.051 -0.051 0.152 0.152 0.155 0.155 0.910 0.908 0.909 0.909
similar no 2 0 -0.002 -0.002 -0.003 -0.003 0.097 0.096 0.097 0.090 0.904 0.905 0.904 0.910
similar no 4 0 0.002 0.002 0.001 0.001 0.103 0.100 0.102 0.101 0.898 0.900 0.899 0.900
similar no 10 0 -0.001 -0.001 -0.002 -0.002 0.087 0.086 0.085 0.085 0.913 0.914 0.915 0.915
different high 2 -0.69 -0.759 -0.795 -0.766 -0.782 0.715 0.507 0.699 0.588 0.945 0.914 0.944 0.956
different high 4 -0.69 -0.744 -0.763 -0.759 -0.772 0.931 0.721 0.931 0.881 0.937 0.932 0.932 0.941
different high 10 -0.69 -0.741 -0.749 -0.765 -0.768 0.998 0.954 0.998 0.997 0.936 0.931 0.926 0.932
different moderate 2 -0.22 -0.233 -0.234 -0.235 -0.235 0.384 0.246 0.387 0.340 0.919 0.924 0.918 0.930
different moderate 4 -0.22 -0.232 -0.231 -0.235 -0.235 0.497 0.357 0.504 0.492 0.914 0.924 0.915 0.918
different moderate 10 -0.22 -0.231 -0.233 -0.235 -0.235 0.632 0.530 0.640 0.640 0.931 0.933 0.931 0.931
different low 2 -0.05 -0.050 -0.050 -0.050 -0.050 0.105 0.089 0.104 0.096 0.916 0.921 0.919 0.927
different low 4 -0.05 -0.051 -0.052 -0.052 -0.052 0.130 0.104 0.130 0.128 0.906 0.922 0.906 0.907
different low 10 -0.05 -0.052 -0.051 -0.053 -0.053 0.139 0.133 0.143 0.143 0.902 0.907 0.903 0.903
different no 2 0 0.002 0.003 0.002 0.002 0.089 0.078 0.089 0.081 0.911 0.922 0.911 0.919
different no 4 0 0.002 0.003 0.001 0.001 0.090 0.084 0.091 0.091 0.911 0.916 0.909 0.909













Table 63: One AgD trial (aggregated data) and multiple IPD trials (individual patient data) - scenario I and II. The bias, its Monte
Carlo (MC) standard error, and the root mean squared error (RMSE) are presented for approach B.1 (pooled IPD) and B.2 (all indirect
comparisons) and both methods for indirect comparisons, Bucher and MAIC. All meta-analyses are based on a random effects model.
A variance value of σ = 0.4 is assumed in the generation of the true treatment effect. Results for are presented.
Popu- Effect Trials Bias MC Error for Bias RMSE
lation Size Pool AgD All Ind. Comp Pool AgD All Ind. Comp Pool AgD All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.052 -0.053 -0.061 -0.075 0.007 0.007 0.007 0.007 0.314 0.317 0.330 0.336
similar high 4 -0.058 -0.058 -0.071 -0.082 0.005 0.005 0.005 0.005 0.236 0.237 0.250 0.256
similar high 10 -0.044 -0.044 -0.068 -0.071 0.004 0.004 0.004 0.004 0.164 0.165 0.189 0.187
similar moderate 2 -0.006 -0.006 -0.007 -0.008 0.003 0.004 0.004 0.004 0.154 0.155 0.155 0.156
similar moderate 4 -0.015 -0.015 -0.017 -0.018 0.003 0.003 0.003 0.003 0.133 0.133 0.134 0.134
similar moderate 10 -0.007 -0.007 -0.011 -0.011 0.002 0.002 0.002 0.002 0.107 0.107 0.108 0.108
similar low 2 -0.001 -0.001 -0.002 -0.002 0.003 0.003 0.003 0.003 0.120 0.120 0.120 0.120
similar low 4 -0.001 -0.001 -0.002 -0.002 0.002 0.002 0.002 0.002 0.108 0.108 0.108 0.108
similar low 10 0.000 0.000 -0.001 -0.001 0.002 0.002 0.002 0.002 0.100 0.100 0.100 0.100
similar no 2 -0.002 -0.002 -0.003 -0.003 0.003 0.003 0.003 0.003 0.111 0.111 0.111 0.111
similar no 4 0.002 0.002 0.001 0.001 0.002 0.002 0.002 0.002 0.106 0.106 0.106 0.106
similar no 10 -0.001 -0.001 -0.002 -0.002 0.002 0.002 0.002 0.002 0.096 0.096 0.096 0.096
different high 2 -0.069 -0.105 -0.076 -0.092 0.007 0.010 0.007 0.007 0.323 0.465 0.334 0.342
different high 4 -0.054 -0.073 -0.069 -0.082 0.005 0.007 0.005 0.006 0.230 0.323 0.252 0.279
different high 10 -0.051 -0.059 -0.075 -0.078 0.004 0.005 0.004 0.004 0.163 0.216 0.179 0.181
different moderate 2 -0.013 -0.014 -0.015 -0.015 0.004 0.005 0.004 0.004 0.164 0.213 0.164 0.165
different moderate 4 -0.012 -0.011 -0.015 -0.015 0.003 0.004 0.003 0.003 0.134 0.165 0.135 0.136
different moderate 10 -0.011 -0.013 -0.015 -0.015 0.002 0.003 0.002 0.002 0.108 0.122 0.109 0.109
different low 2 0.000 0.000 0.000 0.000 0.003 0.003 0.003 0.003 0.122 0.144 0.122 0.122
different low 4 -0.001 -0.002 -0.002 -0.002 0.003 0.003 0.003 0.003 0.112 0.122 0.112 0.112
different low 10 -0.002 -0.001 -0.003 -0.003 0.002 0.003 0.002 0.002 0.104 0.111 0.105 0.105
different no 2 0.002 0.003 0.002 0.002 0.003 0.003 0.003 0.003 0.115 0.133 0.115 0.115
different no 4 0.002 0.003 0.001 0.001 0.002 0.003 0.002 0.002 0.106 0.115 0.106 0.106














Table 64: Multiple AgD trials (aggregated data) and multiple IPD trials (individual patient data) - scenario I and II. Mean effect,
power, and coverage are presented for approach C.1 (pooled IPD, pooled AgD), C.2 (pooled IPD, all indirect comparisons), and C.3 (all
indirect comparisons) and both methods for indirect comparisons, Bucher and MAIC. All meta-analyses are based on a random effects
model. A variance value of σ = 0.4 is assumed in the generation of the true treatment effect.
Popu- Effect Trials True Mean Effect Power Coverage
lation Size Effect All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.69 -0.743 -0.744 -0.743 -0.743 -0.751 -0.755 0.715 0.710 0.714 0.708 0.694 0.684 0.953 0.949 0.953 0.950 0.942 0.944
similar high 4 -0.69 -0.748 -0.748 -0.747 -0.747 -0.757 -0.757 0.958 0.956 0.958 0.955 0.947 0.946 0.935 0.936 0.935 0.936 0.934 0.934
similar high 10 -0.69 -0.734 -0.734 -0.733 -0.733 -0.746 -0.746 0.100 0.100 0.100 0.100 0.100 0.100 0.940 0.941 0.941 0.942 0.929 0.929
similar moderate 2 -0.22 -0.226 -0.227 -0.226 -0.226 -0.227 -0.227 0.410 0.411 0.407 0.404 0.406 0.399 0.936 0.938 0.937 0.939 0.931 0.932
similar moderate 4 -0.22 -0.235 -0.235 -0.234 -0.234 -0.236 -0.236 0.698 0.698 0.697 0.694 0.692 0.692 0.919 0.918 0.919 0.921 0.913 0.913
similar moderate 10 -0.22 -0.228 -0.228 -0.227 -0.227 -0.229 -0.229 0.966 0.967 0.966 0.966 0.966 0.966 0.934 0.934 0.934 0.935 0.933 0.933
similar low 2 -0.05 -0.051 -0.051 -0.050 -0.050 -0.051 -0.051 0.132 0.132 0.131 0.118 0.130 0.128 0.913 0.910 0.913 0.919 0.913 0.916
similar low 4 -0.05 -0.049 -0.049 -0.049 -0.049 -0.049 -0.049 0.179 0.177 0.179 0.166 0.179 0.179 0.908 0.909 0.907 0.915 0.909 0.909
similar low 10 -0.05 -0.050 -0.050 -0.049 -0.049 -0.050 -0.050 0.274 0.272 0.268 0.265 0.271 0.271 0.917 0.916 0.914 0.917 0.917 0.917
similar no 2 0 -0.001 -0.001 -0.001 -0.001 -0.001 -0.001 0.096 0.096 0.095 0.079 0.097 0.095 0.905 0.905 0.905 0.921 0.904 0.906
similar no 4 0 0.003 0.003 0.003 0.003 0.003 0.003 0.094 0.095 0.093 0.082 0.092 0.092 0.906 0.906 0.907 0.918 0.909 0.909
similar no 10 0 -0.001 -0.001 -0.001 -0.001 -0.001 -0.001 0.109 0.109 0.107 0.099 0.110 0.110 0.892 0.891 0.893 0.901 0.890 0.890
different high 2 -0.69 -0.761 -0.797 -0.760 -0.796 -0.766 -0.771 0.737 0.514 0.736 0.514 0.715 0.705 0.944 0.915 0.945 0.914 0.943 0.944
different high 4 -0.69 -0.747 -0.766 -0.746 -0.765 -0.757 -0.759 0.962 0.752 0.962 0.751 0.949 0.949 0.940 0.926 0.941 0.926 0.932 0.932
different high 10 -0.69 -0.741 -0.749 -0.740 -0.748 -0.752 -0.752 1.000 0.978 1.000 0.978 1.000 1.000 0.932 0.927 0.932 0.928 0.924 0.924
different moderate 2 -0.22 -0.231 -0.232 -0.230 -0.231 -0.232 -0.232 0.420 0.262 0.419 0.261 0.422 0.411 0.917 0.927 0.918 0.928 0.918 0.919
different moderate 4 -0.22 -0.232 -0.231 -0.231 -0.230 -0.233 -0.233 0.676 0.442 0.671 0.439 0.671 0.671 0.931 0.939 0.932 0.938 0.931 0.931
different moderate 10 -0.22 -0.229 -0.231 -0.228 -0.230 -0.230 -0.230 0.972 0.789 0.971 0.785 0.968 0.968 0.941 0.953 0.940 0.953 0.939 0.939
different low 2 -0.05 -0.048 -0.048 -0.048 -0.047 -0.048 -0.048 0.121 0.097 0.120 0.089 0.122 0.118 0.917 0.928 0.917 0.934 0.918 0.920
different low 4 -0.05 -0.049 -0.050 -0.049 -0.049 -0.049 -0.049 0.169 0.123 0.167 0.120 0.168 0.168 0.912 0.929 0.910 0.931 0.911 0.911
different low 10 -0.05 -0.053 -0.053 -0.053 -0.052 -0.053 -0.053 0.293 0.196 0.289 0.194 0.294 0.294 0.911 0.926 0.909 0.926 0.909 0.909
different no 2 0 0.003 0.003 0.003 0.004 0.003 0.003 0.098 0.080 0.098 0.075 0.098 0.093 0.903 0.920 0.903 0.926 0.902 0.907
different no 4 0 -0.001 0.000 -0.001 0.001 -0.001 -0.001 0.104 0.078 0.103 0.077 0.101 0.101 0.896 0.923 0.897 0.923 0.899 0.899













Table 65: Multiple AgD trials (aggregated data) and multiple IPD trials (individual patient data) - scenario I and II. The bias, its
Monte Carlo (MC) standard error, and the root mean squared error (RMSE) are presented for approach C.1 (pooled IPD, pooled AgD),
C.2 (pooled IPD, all indirect comparisons), and C.3 (all indirect comparisons) and both methods for indirect comparisons, Bucher and
MAIC. All meta-analyses are based on a random effects model. A variance value of σ = 0.4 is assumed in the generation of the true
treatment effect.
Popu- Effect Trials Bias MC Error for Bias RMSE
lation Size Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp Pooled IPD, AgD Pooled IPD, All All Ind. Comp
Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC Bucher MAIC
similar high 2 -0.053 -0.054 -0.053 -0.053 -0.061 -0.065 0.007 0.007 0.007 0.007 0.007 0.007 0.306 0.309 0.306 0.309 0.321 0.322
similar high 4 -0.058 -0.058 -0.057 -0.057 -0.067 -0.067 0.005 0.005 0.005 0.005 0.005 0.005 0.221 0.221 0.221 0.221 0.235 0.235
similar high 10 -0.044 -0.044 -0.043 -0.043 -0.056 -0.056 0.003 0.003 0.003 0.003 0.003 0.003 0.136 0.136 0.135 0.136 0.163 0.157
similar moderate 2 -0.006 -0.007 -0.006 -0.006 -0.007 -0.007 0.003 0.003 0.003 0.003 0.003 0.003 0.139 0.140 0.139 0.140 0.141 0.141
similar moderate 4 -0.015 -0.015 -0.014 -0.014 -0.016 -0.016 0.002 0.002 0.002 0.002 0.002 0.002 0.103 0.103 0.103 0.103 0.104 0.104
similar moderate 10 -0.008 -0.008 -0.007 -0.007 -0.009 -0.009 0.001 0.001 0.001 0.001 0.001 0.001 0.063 0.063 0.063 0.063 0.064 0.064
similar low 2 -0.001 -0.001 0.000 0.000 -0.001 -0.001 0.002 0.002 0.002 0.002 0.002 0.002 0.101 0.102 0.101 0.102 0.102 0.102
similar low 4 0.001 0.001 0.001 0.001 0.001 0.001 0.002 0.002 0.002 0.002 0.002 0.002 0.073 0.073 0.073 0.073 0.073 0.074
similar low 10 0.000 0.000 0.001 0.001 0.000 0.000 0.001 0.001 0.001 0.001 0.001 0.001 0.044 0.044 0.044 0.044 0.045 0.045
similar no 2 -0.001 -0.001 -0.001 -0.001 -0.001 -0.001 0.002 0.002 0.002 0.002 0.002 0.002 0.092 0.092 0.092 0.092 0.092 0.092
similar no 4 0.003 0.003 0.003 0.003 0.003 0.003 0.002 0.002 0.002 0.002 0.002 0.002 0.065 0.065 0.065 0.065 0.065 0.065
similar no 10 -0.001 -0.001 -0.001 -0.001 -0.001 -0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.042 0.042 0.042 0.042 0.042 0.042
different high 2 -0.071 -0.107 -0.070 -0.106 -0.076 -0.081 0.007 0.010 0.007 0.010 0.007 0.007 0.317 0.461 0.317 0.461 0.328 0.330
different high 4 -0.057 -0.076 -0.056 -0.075 -0.067 -0.069 0.005 0.007 0.005 0.007 0.005 0.0057 0.217 0.313 0.217 0.313 0.239 0.263
different high 10 -0.051 -0.059 -0.050 -0.058 -0.062 -0.062 0.003 0.004 0.003 0.004 0.003 0.003 0.141 0.201 0.141 0.200 0.153 0.153
different moderate 2 -0.011 -0.012 -0.010 -0.011 -0.012 -0.012 0.003 0.005 0.003 0.005 0.003 0.003 0.149 0.200 0.149 0.200 0.150 0.150
different moderate 4 -0.012 -0.011 -0.011 -0.010 -0.013 -0.013 0.002 0.003 0.002 0.003 0.002 0.002 0.103 0.141 0.103 0.141 0.104 0.104
different moderate 10 -0.009 -0.011 -0.008 -0.010 -0.010 -0.010 0.001 0.002 0.001 0.002 0.001 0.001 0.061 0.083 0.061 0.083 0.062 0.062
different low 2 0.002 0.002 0.002 0.003 0.002 0.002 0.002 0.003 0.002 0.003 0.002 0.002 0.102 0.129 0.102 0.129 0.102 0.102
different low 4 0.001 0.000 0.001 0.001 0.001 0.001 0.002 0.002 0.002 0.002 0.002 0.002 0.074 0.091 0.074 0.091 0.075 0.075
different low 10 -0.003 -0.003 -0.003 -0.002 -0.003 -0.003 0.001 0.001 0.001 0.001 0.001 0.001 0.047 0.059 0.047 0.059 0.048 0.048
different no 2 0.003 0.003 0.003 0.004 0.003 0.003 0.002 0.003 0.002 0.003 0.002 0.002 0.094 0.115 0.094 0.115 0.094 0.094
different no 4 -0.001 0.000 -0.001 0.001 -0.001 -0.001 0.002 0.002 0.002 0.002 0.002 0.002 0.068 0.081 0.068 0.081 0.068 0.068




MAIC - Method of Moments
The method of moments is applied to estimate β in the following equation
ωi = exp(β0 + x′iβ)
such that the mean baseline characteristics of the IPD matches the AgD data. Therefore,
the estimate β̂ of β solves the following equation
0 =
∑





where ti is the ith patient in trial AB for i = 1, . . . , nAB. By definition the correct weights
for balancing the populations are provided by this formula because a logistic model (xi
contains all confounders and a correctly specified model) provides a consistent estimate of
the treatment effect.
The finite solutions to formula B.1 are unique and will converge to the true β if the logistic
regression model is correctly specified. To see this first note that
0 =
∑







(xi − xCB) exp(x′iβ)
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It can be assumed, that xCB = 0 (normalize all baseline characteristics by xCB). This results


















This function Q′′(β) is positive definite for all β , hence Q(β) is convex and any finite solution
of Equation B.1 is unique and coincide with the global minimum of Q(β) (Signorovitch et al.,
2010).
Appendix C
Appendix C: Implementations in R
In this chapter, selected R codes used for the simulations are given.
C.1 Generation of Evidence - Resampling CI Method
The following R function includes the data generating process, the naïve approach, and the
resampling CI method.
#########################################################################
# Function f o r s imu la t i on o f resampl ing CI method and naive approach
# The data gene ra t i on proce s s i s inc luded in the func t i on
#########################################################################
matching_resamplingCI_fct = func t i on (
# number o f s imu la t i on runs
n_sim=10000 ,
## data genera t i on proce s s
# r e g r e s s i o n c o e f f i c i e n t s f o r group model ( l o g i s t i c model )
alpha0 = −.15 ,
a_age = .002 ,
a_sex = 0.02 ,
a_diab = 0.026 ,
# r e g r e s s i o n c o e f f i c i e n t s f o r outcome model ( l o g i s t i c model )
beta0 = −0.5 ,
b_age = −0.07 ,
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b_ASPECTS = 0 .2 ,
b_NIHSS = 0 .1 ,
b_group = 1 ,
# number o f pa t i e n t s in group 0
n = 100 ,
# d i s t r i b u t i o n parameters equal in both groups
age_mean = 70 ,
age_sd = 15 ,
sex_p = 0 .5 ,
diab_p = 0 .2 ,
# d i s t r i b u t i o n parameters f o r ( " new " ) treatment group
group1_ASPECTS_p = .75 ,
group1_NIHSS_mean = 16 ,
group1_NIHSS_sd = 4 ,
# d i s t r i b u t i o n parameters f o r ( a l r eady e x i s t i n g ) c on t r o l group
group0_ASPECTS_p = .8 ,
group0_NIHSS_mean = 17 ,
group0_NIHSS_sd = 5 ,
# f r a c t i o n o f pa t i e n t s f o r i n t e r ims ana l y s i s ( a vec to r i f mu l t ip l e time
po in t s f o r the in te r im ana l y s i s )
interim = 0 .5 ,
# number o f matching par tne r s : 1 : k matching
k = 1 ,
# c a l i p e r f o r propens i ty s co r e matching
ca = 0 .2 ,
# number o f resampl ing s t ep s
boot = 200 ,
# quan t i l e f o r resampl ing CI method
q_CI = .99
) {
r e qu i r e ( Matching )
r e qu i r e ( boot )
# c a l c u l a t i n g the number o f pa t i e n t s r e c r u i t e d f o r the in te r im ana l y s i s
n_interim = interim ∗ n ∗ k
C.1. Generation of Evidence - Resampling CI Method 169
n_interim_group0 = interim ∗ n
# i n i t i a l i z i n g r e l e van t outcome va lue s
# inte r im ana l y i s
p_value_interim_H0_naiv = rep (NA , n_sim )
p_value_interim_H1_naiv = rep (NA , n_sim )
p_value_interim_H0 = rep (NA , n_sim )
p_value_interim_H1 = rep (NA , n_sim )
matching_rate = rep (NA , n_sim )
matching_rate_sd = rep (NA , n_sim )
matching_rate_interim_naiv = rep (NA , n_sim )
# number o f pa t i e n t s added to the number used at in te r im ana l y s i s
n_add_naiv = rep (NA , n_sim )
# naive approach
n_naiv = rep (NA , n_sim )
p_value_naiv_H0 = rep (NA , n_sim )
p_value_naiv_H1 = rep (NA , n_sim )
matching_rate_naiv = rep (NA , n_sim )
# resampl ing CI method
n_CI = rep (NA , n_sim )
p_value_CI_H0 = rep (NA , n_sim )
p_value_CI_H1 = rep (NA , n_sim )
matching_rate_CI = rep (NA , n_sim )
results = l i s t ( )
f o r (i in 1 : l ength (n_interim ) ) {
f o r (s in 1 : n_sim ) {
# se t seed
s e t . seed (123456+s )
# i n i t i a l i z i n g data s e t
# genera t ing a big data s e t ( f o r having enough pa t i en t s f o r the f i n a l
a n a l y s i s )
data = matrix (NA , nco l =8, nrow=n∗40∗k∗ 2)
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colnames ( data ) = c ( " sex " , " diab " , " age " , " group " , "ASPECTS" ,
"NIHSS_Aufnahme " , "NIHSS_d i f_H0" , "NIHSS_d i f_H1" )
# ba s e l i n e v a r i a b l e s used in group model : e . g . sex , d iabetes , and age
data [ , 1 ] = sample ( c (0 , 1 ) , n∗40∗k∗ 2 , prob=c ( sex_p , 1−sex_p ) , r ep l a c e=T )
data [ , 2 ] = sample ( c (0 , 1 ) , n∗40∗k∗ 2 , prob=c(1−diab_p , diab_p ) , r ep l a c e=T )
data [ , 3 ] = rnorm (n∗ 40 , mean=age_mean , sd=age_sd )
# group model
data [ , 4 ] = rbinom (n∗40∗k∗ 2 ,1 , inv . logit ( alpha0 + a_sex∗ data [ , 1 ] +
a_diab ∗ data [ , 2 ] +
a_age ∗ data [ , 3 ] ) )
# order data by group
data = data [ order ( data [ , 4 ] ) , ]
n_group0 = length ( which ( data [ ,4]==0) )
n_group1 = length ( which ( data [ ,4]==1) )
# ba s e l i n e v a r i a b l e s used in outcome model : e . g . ASPECTS, NIHSS
data [ , 5 ] = c ( rbinom (n_group0 , 10 , group0_ASPECTS_p ) ,
rbinom (n_group1 , 10 , group1_ASPECTS_p ) )
data [ , 6 ] = c ( round ( rnorm (n_group0 , mean=group0_NIHSS_mean ,
sd=group0_NIHSS_sd ) ) ,
round ( rnorm (n_group1 , mean=group1_NIHSS_mean ,
sd=group1_NIHSS_sd ) ) )
# outcome model under H0
data [ , 7 ] = c ( sample ( c (0 , 1 ) , n_group0 , prob=c ( 0 . 5 , 0 . 5 ) , r ep l a c e=T ) ,
sample ( c (0 , 1 ) , n_group1 , prob=c ( 0 . 5 , 0 . 5 ) , r ep l a c e=T ) )
# outcome model under H1
data [ , 8 ] = rbinom (n∗40∗k∗ 2 ,1 , inv . logit ( beta0 +
b_group ∗ data [ , 4 ] +
b_age ∗ data [ , 3 ] +
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##################################################################
# inte r im ana l y s i s
data_matching = as . data . frame ( data [ c ( 1 : n , (n_group0+1) : ( n_group0+c e i l i n g (
n_interim [ i ] ) ) ) , ] )
# model f o r propens i ty s co r e
fit1 <− glm ( group ~ diab + NIHSS_Aufnahme + age , data = data_matching ,
f ami ly = " binomial " )
glm . f i t t e d <− l og ( fit1$ f i t t e d / (1 − fit1$ f i t t e d ) )
# propens i ty s co r e matching
rr <− Match ( Tr = data_matching$group , X = glm . f i t t e d ,
r ep l a c e = F , M = k , ties = F , caliper = ca )
# McNemar Test f o r H1 ( d i f f e r e n c e e x i s t s )
test_interim_H1_naiv = mcnemar . test ( matrix ( c (
sum( i f e l s e ( data_matching$NIHSS_dif_H1 [ rr$ index . c on t r o l ]<1 &
data_matching$NIHSS_dif_H1 [ rr$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H1 [ rr$ index . c on t r o l ]>0 &
data_matching$NIHSS_dif_H1 [ rr$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H1 [ rr$ index . c on t r o l ]<1 &
data_matching$NIHSS_dif_H1 [ rr$ index . treated ] >0 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H1 [ rr$ index . c on t r o l ]>0 &
data_matching$NIHSS_dif_H1 [ rr$ index . treated ] >0 ,1 ,0) ) ) ,
nrow=2) ,
correct=F )
# McNemar Test f o r H0 (no d i f f e r e n c e e x i s t s )
test_interim_H0_naiv = mcnemar . test ( matrix ( c (
sum( i f e l s e ( data_matching$NIHSS_dif_H0 [ rr$ index . c on t r o l ]<1 &
data_matching$NIHSS_dif_H0 [ rr$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H0 [ rr$ index . c on t r o l ]>0 &
data_matching$NIHSS_dif_H0 [ rr$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H0 [ rr$ index . c on t r o l ]<1 &
data_matching$NIHSS_dif_H0 [ rr$ index . treated ] >0 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H0 [ rr$ index . c on t r o l ]>0 &
data_matching$NIHSS_dif_H0 [ rr$ index . treated ] >0 ,1 ,0) ) ) ,
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nrow=2) ,
correct=F )
# save p−va lue s o f in te r im ana l y s i s
p_value_interim_H0_naiv [ s ] = test_interim_H0_naiv$p . value
p_value_interim_H1_naiv [ s ] = test_interim_H1_naiv$p . value
# ca l c u l a t e matching ra t e at in te r im ana l y s i s
matching_rate_interim_naiv [ s ] = (n_interim [ i]−rr$ndrops ) /n_interim [ i ]
# number o f pa t i e n t s a dd i t i o n a l l y needed f o r f i n a l a n a l y s i s
n_add_naiv [ s ] = c e i l i n g (n/matching_rate_interim_naiv [ s ] − n_interim [ i ] )
rm(rr , glm . f i t t e d , fit )
# r e c r u i t add i t i ona l data f o r naiv method
data_a l l_naiv = as . data . frame (
data [ c ( 1 : n , (n_group0+1) : ( n_group0+n_interim [ i ] +c e i l i n g (n_add_naiv [ s ] )
) ) , ]
)
############################################
# f i n a l a n a l y s i s
# propens i ty s co r e matching with complete data
fit2 <− glm ( group ~ diab +NIHSS_Aufnahme +age , data = data_a l l_naiv ,
f ami ly = " binomial " )
glm . fitted2 <− l og ( fit2$ f i t t e d / (1 − fit2$ f i t t e d ) )
rr2 <− Match ( Tr = data_a l l_naiv$group , X = glm . fitted2 ,
r e p l a c e = F , M = k , ties = F , caliper = ca )
# McNemar Test f o r H1 ( d i f f e r e n c e e x i s t s )
test_naiv_H1 = mcnemar . test ( matrix ( c (
sum( i f e l s e ( data_a l l_naiv$NIHSS_dif_H1 [ rr2$ index . c on t r o l ]<1 &
data_a l l_naiv$NIHSS_dif_H1 [ rr2$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_naiv$NIHSS_dif_H1 [ rr2$ index . c on t r o l ]>0 &
data_a l l_naiv$NIHSS_dif_H1 [ rr2$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_naiv$NIHSS_dif_H1 [ rr2$ index . c on t r o l ]<1 &
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data_a l l_naiv$NIHSS_dif_H1 [ rr2$ index . treated ] >0 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_naiv$NIHSS_dif_H1 [ rr2$ index . c on t r o l ]>0 &
data_a l l_naiv$NIHSS_dif_H1 [ rr2$ index . treated ] >0 ,1 ,0) ) ) ,
nrow=2) ,
correct=F )
# McNemar Test f o r H0 (no d i f f e r e n c e e x i s t s )
test_naiv_H0 = mcnemar . test ( matrix ( c (
sum( i f e l s e ( data_a l l_naiv$NIHSS_dif_H0 [ rr2$ index . c on t r o l ]<1 &
data_a l l_naiv$NIHSS_dif_H0 [ rr2$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_naiv$NIHSS_dif_H0 [ rr2$ index . c on t r o l ]>0 &
data_a l l_naiv$NIHSS_dif_H0 [ rr2$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_naiv$NIHSS_dif_H0 [ rr2$ index . c on t r o l ]<1 &
data_a l l_naiv$NIHSS_dif_H0 [ rr2$ index . treated ] >0 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_naiv$NIHSS_dif_H0 [ rr2$ index . c on t r o l ]>0 &
data_a l l_naiv$NIHSS_dif_H0 [ rr2$ index . treated ] >0 ,1 ,0) ) ) ,
nrow=2) ,
correct=F )
# save p−va lue s o f f i n a l a n a l y s i s
p_value_naiv_H1 [ s ] = test_naiv_H1$p . value
p_value_naiv_H0 [ s ] = test_naiv_H0$p . value
# matching ra t e at f i n a l a n a l y s i s
matching_rate_naiv [ s ] = length ( rr2$ index . treated ) /n
rm( rr2 , glm . fitted2 , fit2 )
#####################################################################
# resamping approach o f matching ra t e at in te r im ana l y s i s
#####################################################################
# inte r im ana l y s i s
matching_rate_boot = rep (NA , boot )
f o r (b in 1 : boot ) {
# sample data f o r matching ( groups o f equal s i z e )
data_matching = as . data . frame (
data [ c ( sample ( 1 : n , c e i l i n g (n_interim_group0 [ i ] ) , r e p l a c e=F ) ,
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(n_group0+1) : ( n_group0+c e i l i n g (n_interim [ i ] ) ) ) , ] )
# model f o r propens i ty s co r e
fit3 <− glm ( group ~ diab + NIHSS_Aufnahme + age ,
data = data_matching ,
f ami ly = " binomial " )
glm . fitted3 <− l og ( fit3$ f i t t e d / (1 − fit3$ f i t t e d ) )
# propens i ty s co r e matching
rr3 <− Match ( Tr = data_matching$group , X = glm . fitted3 ,
r e p l a c e = F , M = k , ties = F , caliper = ca )
# McNemar Test f o r H1 ( d i f f e r e n c e e x i s t s )
test_interim_H1 = mcnemar . test ( matrix ( c (
sum( i f e l s e ( data_matching$NIHSS_dif_H1 [ rr3$ index . c on t r o l ]<1 &
data_matching$NIHSS_dif_H1 [ rr3$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H1 [ rr3$ index . c on t r o l ]>0 &
data_matching$NIHSS_dif_H1 [ rr3$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H1 [ rr3$ index . c on t r o l ]<1 &
data_matching$NIHSS_dif_H1 [ rr3$ index . treated ] >0 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H1 [ rr3$ index . c on t r o l ]>0 &
data_matching$NIHSS_dif_H1 [ rr3$ index . treated ] >0 ,1 ,0) ) ) ,
nrow=2) ,
correct=F )
# McNemar Test f o r H0 (no d i f f e r e n c e e x i s t s )
test_interim_H0 = mcnemar . test ( matrix ( c (
sum( i f e l s e ( data_matching$NIHSS_dif_H0 [ rr3$ index . c on t r o l ]<1 &
data_matching$NIHSS_dif_H0 [ rr3$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H0 [ rr3$ index . c on t r o l ]>0 &
data_matching$NIHSS_dif_H0 [ rr3$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H0 [ rr3$ index . c on t r o l ]<1 &
data_matching$NIHSS_dif_H0 [ rr3$ index . treated ] >0 ,1 ,0) ) ,
sum( i f e l s e ( data_matching$NIHSS_dif_H0 [ rr3$ index . c on t r o l ]>0 &
data_matching$NIHSS_dif_H0 [ rr3$ index . treated ] >0 ,1 ,0) ) ) ,
nrow=2) ,
correct=F )
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p_value_interim_H0 [ s ] = test_interim_H0$p . value
p_value_interim_H1 [ s ] = test_interim_H1$p . value
# matching ra t e
matching_rate_boot [ b ] = (n_interim [ i]−rr3$ndrops ) /n_interim [ i ]
}
# mean/sd o f resampled matching r a t e s at in te r im ana l y s i s
matching_rate [ s ] = mean( matching_rate_boot )
matching_rate_sd [ s ] = sd ( matching_rate_boot )
# Lower CI l im i t to c a l c u l a t e the number o f pa t i en t s a dd i t i o n a l l y needed
f o r f i n a l a n a l y s i s
CI_lowerLimit = matching_rate [ s ] −
qnorm(q_CI ) ∗ s q r t ( ( matching_rate [ s ] ∗(1−matching_rate [ s ] ) ) /n )
n_CI [ s ] = c e i l i n g (n/CI_lowerLimit − n_interim [ i ] )
rm( rr3 , glm . fitted3 , fit3 )
# r e c r u i t miss ing data f o r CI method
data_a l l_CI = as . data . frame (
data [ c ( 1 : n , (n_group0+1) : ( n_group0+n_interim [ i ] +n_CI [ s ] ) ) , ]
)
############################################
# f i n a l a n a l y s i s
# Propens i ty Score matching with complete data
fit4 <− glm ( group ~ NIHSS_Aufnahme + age + diab ,
data = data_a l l_CI ,
f ami ly = " binomial " )
glm . fitted4 <− l og ( fit4$ f i t t e d / (1 − fit4$ f i t t e d ) )
rr4 <− Match ( Tr = data_a l l_CI$group , X = glm . fitted4 ,
r e p l a c e = F , M = k , ties = F , caliper = ca )
# McNemar Test f o r H1 ( d i f f e r e n c e e x i s t s )
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test_CI_H1 = mcnemar . test ( matrix ( c (
sum( i f e l s e ( data_a l l_CI$NIHSS_dif_H1 [ rr4$ index . c on t r o l ]<1 &
data_a l l_CI$NIHSS_dif_H1 [ rr4$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_CI$NIHSS_dif_H1 [ rr4$ index . c on t r o l ]>0 &
data_a l l_CI$NIHSS_dif_H1 [ rr4$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_CI$NIHSS_dif_H1 [ rr4$ index . c on t r o l ]<1 &
data_a l l_CI$NIHSS_dif_H1 [ rr4$ index . treated ] >0 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_CI$NIHSS_dif_H1 [ rr4$ index . c on t r o l ]>0 &
data_a l l_CI$NIHSS_dif_H1 [ rr4$ index . treated ] >0 ,1 ,0) ) ) ,
nrow=2) ,
correct=F )
# McNemar Test f o r H0 ( no d i f f e r e n c e e x i s t s )
test_CI_H0 = mcnemar . test ( matrix ( c (
sum( i f e l s e ( data_a l l_CI$NIHSS_dif_H0 [ rr4$ index . c on t r o l ]<1 &
data_a l l_CI$NIHSS_dif_H0 [ rr4$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_CI$NIHSS_dif_H0 [ rr4$ index . c on t r o l ]>0 &
data_a l l_CI$NIHSS_dif_H0 [ rr4$ index . treated ] <1 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_CI$NIHSS_dif_H0 [ rr4$ index . c on t r o l ]<1 &
data_a l l_CI$NIHSS_dif_H0 [ rr4$ index . treated ] >0 ,1 ,0) ) ,
sum( i f e l s e ( data_a l l_CI$NIHSS_dif_H0 [ rr4$ index . c on t r o l ]>0 &
data_a l l_CI$NIHSS_dif_H0 [ rr4$ index . treated ] >0 ,1 ,0) ) ) ,
nrow=2) ,
correct=F )
# save p−va lue s o f f i n a l a n a l y s i s
p_value_CI_H0 [ s ] = test_CI_H0$p . value
p_value_CI_H1 [ s ] = test_CI_H1$p . value
# matching ra t e o f f i n a l a n a l y s i s
matching_rate_CI [ s ] = length ( rr4$ index . treated ) /n
rm( rr4 , glm . fitted4 , fit4 )
############################################
# save r e s u l t s
i f (s==n_sim ) {
results [ [ i ] ] = l i s t (
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p_value_interim_H0 = p_value_interim_H0 ,
p_value_interim_H1 = p_value_interim_H1 ,
p_value_interim_H0_naiv = p_value_interim_H0_naiv ,
p_value_interim_H1_naiv = p_value_interim_H1_naiv ,
matching_rate = matching_rate ,
matching_rate_sd = matching_rate_sd ,
matching_rate_interim_naiv = matching_rate_interim_naiv ,
matching_rate_interim_CI = CI_lowerLimit ,
n_naiv = n_add_naiv+n_interim [ i ] ,
p_value_naiv_H0 = p_value_naiv_H0 ,
p_value_naiv_H1 = p_value_naiv_H1 ,
matching_rate_naiv = matching_rate_naiv ,
n_CI = n_CI+n_interim [ i ] ,
p_value_CI_H0 = p_value_CI_H0 ,






return ( results )
}
C.2 Generation of Evidence - Iterative Matching Procedure
The following R functions include the data generating process (data_fct), the function per-
forming the iterative matching (iterative_matching_fct), and one shell function (Simulation)
applying the data function and the iterative matching procedure function.
#########################################################################
# Functions f o r s imu la t i on o f i t e r a t i v e matching procedure
# F i r s t func t i on : data gene ra t i on
# Second func t i on : i t e r a t i v e matching procedure
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# Third func t i on : s imu la t i on func t i on ( us ing 1 s t and 2nd func t i on )
#########################################################################
# func t i on f o r data gene ra t i on
data_fct <− f unc t i on (
# con t r o l data
# binary confounder 1 , 2 ( here : FLT3 , Zyto high ) j o i n t d i s t r i b u t i o n
# vector : no/no , no/yes , yes /no , yes / yes
binary_proportions_con t r o l = c ( . 4 8 , . 3 2 , . 1 8 , . 0 2 ) ,
binary_proportions_intervention = c ( . 4 8 , . 3 2 , . 1 8 , . 0 2 ) ,
# cont inuous confounder normally d i s t r i b u t e d
cont_mean_con t r o l = 55 ,
cont_sd_con t r o l = 15 ,
cont_mean_intervention = 55 ,
cont_sd_intervention = 15 ,
# outcome model c o e f f i c i e n t s
outcome_intercept = 2 ,
outcome_binary1 = −.2 ,
outcome_binary2 = −.5 ,
outcome_cont = − .05 ,
outcome_in t e r a c t i o n = 0 ,
outcome_intervention=log ( 0 . 7 / 0 . 3 ) ,
# sample s i z e
n_con t r o l = 1000 ,
n_intervention = 100 ,
# random number seed
seed=1234
) {
r e qu i r e ( boot )
s e t . seed ( seed )
# t o t a l number o f ob s e rva t i on s
n = sum(n_contro l , n_intervention )
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# i n i t i a l i z i n g data t ab l e s
data_con t r o l = matrix (NA , nco l =5, nrow = n_con t r o l )
data_intervention = matrix (NA , nco l =5, nrow = n_intervention )
# group va r i ab l e
data_con t r o l [ , 1 ] = rep (0 , n_con t r o l )
data_intervention [ , 1 ] = rep (1 , n_intervention )
# binary v a r i a b l e s in c on t r o l group
data_con t r o l [ , 2 ] <− sample ( c (0 , 1 ) , n_contro l , r ep l a c e=T ,
prob=c (sum( binary_proportions_con t r o l [ 1 : 2 ] ) ,
sum( binary_proportions_con t r o l [ 3 : 4 ] ) ) )
tmp_rows_con t r o l <− which ( data_con t r o l [ , 2]==0)
data_con t r o l [ tmp_rows_contro l , 3 ] <− sample (
c (0 , 1 ) , l ength ( tmp_rows_con t r o l ) , r ep l a c e=T ,
prob=c ( binary_proportions_con t r o l [ 1 ] , binary_proportions_con t r o l [ 2 ] ) )
data_con t r o l [−tmp_rows_contro l , 3 ] <− sample (
c (0 , 1 ) , n_contro l−l ength ( tmp_rows_con t r o l ) , r ep l a c e=T ,
prob=c ( binary_proportions_con t r o l [ 3 ] , binary_proportions_con t r o l [ 4 ] ) )
rm( "tmp_rows_con t r o l " )
# binary v a r i a b l e s in i n t e r v en t i on group
data_intervention [ , 2 ] <− sample (
c (0 , 1 ) , n_intervention , r e p l a c e=T ,
prob=c (sum( binary_proportions_intervention [ 1 : 2 ] ) ,
sum( binary_proportions_intervention [ 3 : 4 ] ) ) )
tmp_rows_intervention <− which ( data_intervention [ , 2]==0)
data_intervention [ tmp_rows_intervention , 3 ] <− sample (
c (0 , 1 ) , l ength ( tmp_rows_intervention ) , r ep l a c e=T ,
prob=c ( binary_proportions_intervention [ 1 ] ,
binary_proportions_intervention [ 2 ] ) )
data_intervention [−tmp_rows_intervention , 3 ] <− sample (
c (0 , 1 ) , n_intervention−l ength ( tmp_rows_intervention ) , r ep l a c e=T ,
prob=c ( binary_proportions_intervention [ 3 ] ,
binary_proportions_intervention [ 4 ] ) )
rm( "tmp_rows_in t e r v en t i on " )
# cont inuous va r i ab l e
data_con t r o l [ , 4 ] <− rnorm (n_contro l , cont_mean_contro l , cont_sd_con t r o l )
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data_intervention [ , 4 ] <− rnorm (n_intervention , cont_mean_intervention ,
cont_sd_intervention )
data <− rbind ( data_contro l , data_intervention )
# outcome gene ra t i on
data [ , 5 ] <− rbinom (n , 1 , inv . logit ( outcome_intercept +
outcome_intervention∗data [ , 1 ]+
outcome_in t e r a c t i o n ∗data [ , 1 ] ∗data [ , 4 ]+
outcome_binary1 ∗ data [ , 2 ] +
outcome_binary2 ∗ data [ , 3 ] +
outcome_cont ∗ data [ , 4 ] ) )
colnames ( data ) <− c ( " group " , " b inary1 " , " b inary2 " , " cont " , " outcome " )
data <− as . data . frame ( data )
re turn ( data )
}
#####################################################################
# func t i on f o r i t e r a t i v e matching procedure
iterative_matching_fct <− f unc t i on (
# sample s i z e
n_con t r o l = 1000 ,
n_interim_intervention = 50 ,
# data ( c on t r o l group = 0 , i n t e r v en t i on group = 1) ordered by group
data=NULL ,
# column o f binary va r i ab l e 1
binary_co l_1 = 2 ,
# column o f binary va r i ab l e 2
binary_co l_2 = 3 ,
# column o f cont inuous va r i ab l e
cont_co l = 4 ,
# column f o r group va r i ab l e
group_co l = 1 ,
# c a l i p e r f o r propens i ty s co r e matching
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ca = 0 .2 ,
# maximum number o f matching par tne r s
k = 10 ,
# to l e r an c e f o r matching ra t e
tolerance = 0 .1 ,
# random number seed
seed
) {
r e qu i r e ( Matching )
r e qu i r e ( boot )
s e t . seed ( seed )
matching_rate <− rep (NA , k )
matching_pa i r s <− l i s t ( )
# matching data
data_con t r o l <− data [ which ( data$group==0) , ]
data_intervention <− data [ which ( data$group==1) , ]
data_matching <− as . data . frame ( rbind ( data_contro l ,
data_intervention [ 1 : n_interim_intervention , ] ) )
# Propens i ty Score matching
# 1 :1
fit <− glm ( group ~ . ,
data = data_matching ,
f ami ly = " binomial " )
glm . f i t t e d <− l og ( fit$ f i t t e d / (1 − fit$ f i t t e d ) )
rr <− Match ( Tr = data_matching$group , X = glm . f i t t e d ,
r ep l a c e = F , M = 1 , ties = F , caliper = ca )
matching_rate [ 1 ] <− (n_interim_intervention−rr$ndrops ) /n_interim_intervention
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matching_pa i r s [ [ 1 ] ] <− cbind ( rr$ index . treated ,
rr$ index . c on t r o l )
mr_actual <− matching_rate [ 1 ]
k_final <− 0
# 1 : k matching
f o r (l in 2 : k ) {
i f ( ( n_con t r o l / 2) >= ( ( k+1)∗n_interim_intervention ) ) {
i f ( ( matching_rate [1]− tolerance ) <= mr_actual ) {
k_final <− k_final + 1
fit <− glm ( group ~ . ,
data = data_matching ,
f ami ly = " binomial " )
glm . f i t t e d <− l og ( fit$ f i t t e d / (1 − fit$ f i t t e d ) )
rr <− Match ( Tr = data_matching$group , X = glm . f i t t e d ,
r ep l a c e = F , M = l , ties = F , caliper = ca )
matching_rate [ l ] <− (n_interim_intervention−rr$ndrops ) /
n_interim_intervention
matching_pa i r s [ [ l ] ] <− cbind ( rr$ index . treated ,
rr$ index . c on t r o l )




matching_pa i r s_final <− matching_pa i r s [ [ k_final ] ]
# save r e s u l t s
results <− l i s t ( matching_rate = matching_rate ,
matching_pa i r s = matching_pai r s ,
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matching_pa i r s_final = matching_pa i r s_final ,
k_final = k_final )
re turn ( results )
}
#####################################################################
# func t i on f o r s imu la t ing i t e r a t i v e matching procedure
Simulation <− f unc t i on (
# con t r o l data
# binary covar 1 , 2 ( here : FLT3 , Zyto high )
# no/no , no/yes , yes /no , yes / yes
binary_proportions_con t r o l = c ( . 4 8 , . 3 2 , . 1 8 , . 0 2 ) ,
# cont . covar normally d i s t r i b u t e d
cont_mean_con t r o l = 55 ,
cont_sd_con t r o l = 15 ,
# in t e r v en t i on data
# binary covar 1 , 2 ( here : FLT3 , Zyto high )
binary_proportions_intervention = c ( . 4 8 , . 3 2 , . 1 8 , . 0 2 ) ,
# cont . covar normally d i s t r i b u t e d
cont_mean_intervention = 55 ,
cont_sd_intervention = 15 ,
# outcome model
outcome_intercept = 2 ,
outcome_binary1 = −.2 ,
outcome_binary2 = −.5 ,
outcome_cont = −.05 ,
outcome_in t e r a c t i o n = 0 ,
outcome_intervention=log ( 0 . 7 / 0 . 3 ) ,
# sample s i z e in con t r o l group
n_con t r o l = 1000 ,
# maximal number o f i n t e r v en t i on pa t i en t s
n_intervention_max = 100 ,
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# sample s i z e at in te r im ana l y s i s ( i n t e r v en t i on pa t i en t s )
n_interim_intervention = 25 ,
# planned sample s i z e f o r f i n a l a n a l y s i s
n_intervention_plan = 50 ,
# column f o r group va r i ab l e
group_co l = 1 ,
# column o f binary va r i ab l e 1
binary_co l_1 = 2 ,
# column o f binary va r i ab l e 2
binary_co l_2 = 3 ,
# column o f cont inuous va r i ab l e
cont_co l = 4 ,
# column f o r outcome va r i ab l e
out_co l = 5 ,
# c a l i p e r f o r propens i ty s co r e matching
ca = 0 .2 ,
# maximum number o f matching par tne r s
k = 10 ,
# to l e r an c e f o r matching ra t e
tolerance = 0 .1 ,
# Number o f s imu la t i on runs
s=1,
# random number seed
seed=1234
) {
source ( " data_f c t .R" )
source ( " i t e r a t i v e_matching_f c t .R" )
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matching_result_interim <− l i s t ( )
f o r (i in 1 : s ) {
# data gene ra t i on
data <− data_fct (
# binary ba s e l i n e v a r i a b l e s ( j o i n t d i s t r i b u t i o n )
binary_proportions_con t r o l = binary_proportions_contro l ,
binary_proportions_intervention = binary_proportions_intervention ,
# cont inuous confounder normally d i s t r i b u t e d
cont_mean_con t r o l = cont_mean_contro l ,
cont_sd_con t r o l = cont_sd_contro l ,
cont_mean_intervention = cont_mean_intervention ,
cont_sd_intervention = cont_sd_intervention ,
# c o e f f i c i e n t s f o r outcome model
outcome_intercept = outcome_intercept ,
outcome_binary1 = outcome_binary1 ,
outcome_binary2 = outcome_binary2 ,
outcome_cont = outcome_cont ,
outcome_in t e r a c t i o n = outcome_in t e r a c t i on ,
outcome_intervention = outcome_intervention ,
# sample s i z e s
n_intervention = n_intervention_max ,
n_con t r o l = n_contro l ,
# random number seed
seed = seed+i )
# I t e r a t i v e matching procedure at in te r im ana l y s i s us ing the be f o r e
generated data s e t
matching_result_interim [ [ i ] ] <− iterative_matching_fct (
# sample s i z e s
n_con t r o l = n_contro l ,
n_interim_intervention = n_interim_intervention ,
data = data ,
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# columns f o r b a s e l i n e v a r i a b l e s in data s e t
binary_co l_1 = binary_co l_1 ,
binary_co l_2 = binary_co l_2 ,
cont_co l = cont_col ,
group_co l = group_col ,
# c a l i p e r width f o r propens i ty s co r e matching
ca = ca ,
# maximum number o f matching par tne r s
k = k ,
# to l e r an c e f o r matching ra t e
tolerance=tolerance ,
# seed
seed = seed+i )
}
re turn ( matching_result_interim )
}
C.3 Synthesis of Evidence
This section contains selected function of the method comparison. first the shell function of
the method comparison is given (indComp), followed by functions conducting the indirect
comparison by Bucher (Bucher_fct) and MAIC (MAIC_fct).
###############################################################################
# Function to conduct the method comparison f o r i n d i r e c t comparisons
# con s i d e r i ng the method o f Bucher and
# the matching adjusted i n d i r e c t comparison (MAIC)
# The s h e l l f unc t i on i s f o r a time−to−event endpoints because i t i n c l ud e s
# the data gene ra t i on proces ( indComp)
# Functions f o r the i n d i r e c t comparison are independent prom the endpoint
###############################################################################
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# The f o l l ow i ng func t i on s are needed : sampleSizeTtE − sample s i z e c a l c u l a t i o n
# patChar_f c t − ba s e l i n e c h a r a c t e r i s t i c s
# surv_times − s u r v i v a l t imes
# directComp − d i r e c t comparison
# aggData − c a l c u l a t e s aggregated data
# Bucher_f c t − i n d i r e c t comparison
# MAIC_f c t − i n d i r e c t comparison
###############################################################################
indComp <− f unc t i on (
# Input f o r sampleSizeTtE func t i on
# Direc t Comparison AB
# s ign i f iCBnce l e v e l
alpha_n_AB = 0.05 ,
# power
beta_AB = 0 .2 ,
# propot ion o f samples in c on t r o l group
v_AB = 0 .5 ,
# hazard r a t i o under a l t e r n a t i v e hypothes i s ( not l og HR)
hr_AB ,
# p r obab i l i t y f o r event
phi_AB ,
## Direc t Comparison CB
# s i g n i f i c a n c e l e v e l
alpha_n_CB = 0.05 ,
# power
beta_CB = 0 .2 ,
# propot ion o f samples in c on t r o l group
v_CB = 0 .5 ,
# hazard r a t i o under a l t e r n a t i v e hypothes i s ( not l og HR)
hr_CB ,
# p r obab i l i t y f o r event
phi_CB ,
## Direc t Comparison AB
# Input f o r patChar_f c t func t i on :
# names o f pa t i en t c h a r a c t e r i s t i c v a r i a b l e s ( cha rac t e r vec to r )
varnames_AB ,
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# type o f pa t i en t c h a r a c t e r i s t i c s
# 0 − cont
# 1 − c a t e r g o r i c a l ( k=2)
vartypes_AB ,
# vecto r o f means f o r cont v a r i a b l e s or r e f e r e n c e cat f o r c a t e g o r i c a l
v a r i a b l e s
mu_AB ,
# sd f o r cont Var iab les , e l s e NA
sd_AB ,
# Covariance matrix f o r pa t i en t v a r i a b l e s
C_AB ,
# l i s t conta in ing p r o b a b i l i t i e s f o r c a t e g o r i c a l va r i ab l e s , i f 2 c a t e g o r i e s
only the p r obab i l i t y f o r c a t e g o r i e " 1 "
prob_AB ,
## Direc t Comparison CB
# Input f o r patChar_f c t func t i on :
# names o f pa t i en t c h a r a c t e r i s t i c v a r i a b l e s ( cha rac t e r vec to r )
varnames_CB ,
# type o f pa t i en t c h a r a c t e r i s t i c s
# 0 − cont
# 1 − c a t e r g o r i c a l ( k=2)
# 2 − c a t e r g o r i c a l (k>2)
vartypes_CB ,
# vecto r o f means f o r cont v a r i a b l e s or r e f e r e n c e cat f o r c a t e g o r i c a l
v a r i a b l e s
mu_CB ,
# sd f o r cont Var iab les , e l s e NA
sd_CB ,
# Covariance matrix f o r pa t i en t v a r i a b l e s
C_CB ,
# l i s t conta in ing p r o b a b i l i t i e s f o r c a t e g o r i c a l va r i ab l e s , i f 2 c a t e g o r i e s
only the p r obab i l i t y f o r c a t e g o r i e " 1 "
prob_CB ,
# Direc t Comparison AB
# Input f o r surv_times func t i on
lambda_mort_AB ,
nue_mort_AB ,





# Direc t Comparison CB







# Input f o r directComp func t i on
# method f o r handl ing t i e s ( as in coxph )
method = " bres low " ,
# robust=T −−> using robust var i ance e s t imator
robust = TRUE ,
# Input f o r MAIC_f c t func t i on
# s i g n i f i c a n c e l e v e l
alpha = .05 ,
# pr in t e f f e c t i v e sample s i z e a dd i t i o n a l l y to r e s u l t s o f i n d i r e c t comparison
p r in t_ES = TRUE
) {
# load func t i on s
source ( ’ SampleSizeTtE .R ’ )
source ( ’ PatCharFct .R ’ )
source ( ’ Surv_data .R ’ )
source ( ’ directComp .R ’ )
source ( ’ aggregatedData .R ’ )
source ( ’ Bucher .R ’ )
source ( ’MAIC.R ’ )
# l i s t o f r e s u l t s
results = l i s t ( )
# Sample s i z e f o r t r i a l AB
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sampleSize_AB <− sampleSizeTtE ( alpha = alpha_n_AB ,
# power
beta = beta_AB ,
# propot ion o f samples in c on t r o l group
v = v_AB ,
# hazard r a t i o under a l t e r n a t i v e hypothes i s (
not l og HR)
hr = hr_AB ,
# p r obab i l i t y f o r event
phi = phi_AB )
# Sample s i z e f o r t r i a l CB
sampleSize_CB <− sampleSizeTtE ( alpha = alpha_n_CB ,
# power
beta = beta_CB ,
# propot ion o f samples in c on t r o l group
v = v_CB ,
# hazard r a t i o under a l t e r n a t i v e hypothes i s (
not l og HR)
hr = hr_CB ,
# p r obab i l i t y f o r event
phi = phi_CB )
# Pat ient c h a r a c t e r i s t i c s f o r t r i a l AB
Pat_AB = patChar_fct ( n_exp=sampleSize_AB [ 2 ] ,
# number o f pa t i e n t s in c on t r o l arm
n_cont=sampleSize_AB [ 1 ] ,
# names o f pa t i en t c h a r a c t e r i s t i c v a r i a b l e s ( cha rac t e r
vec to r )
varnames=varnames_AB ,
# type o f pa t i en t c h a r a c t e r i s t i c s
vartypes=vartypes_AB ,
# vecto r o f means f o r cont v a r i a b l e s or r e f e r e n c e cat
f o r c a t e g o r i c a l v a r i a b l e s
mu=mu_AB ,
# sd f o r cont Var iab les , e l s e NA
sd=sd_AB ,
# Covariance matrix f o r pa t i en t v a r i a b l e s
C=C_AB ,
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# l i s t conta in ing p r o b a b i l i t i e s f o r c a t e g o r i c a l
va r i ab l e s , i f 2 c a t e g o r i e s only the p r obab i l i t y f o r
c a t e g o r i e " 1 "
prob = prob_AB )
# Pat ient c h a r a c t e r i s t i c s f o r t r i a l AB
Pat_CB = patChar_fct ( n_exp=sampleSize_CB [ 2 ] ,
# number o f pa t i e n t s in c on t r o l arm
n_cont=sampleSize_CB [ 1 ] ,
# names o f pa t i en t c h a r a c t e r i s t i c v a r i a b l e s ( cha rac t e r
vec to r )
varnames=varnames_CB ,
# type o f pa t i en t c h a r a c t e r i s t i c s
vartypes=vartypes_CB ,
# vecto r o f means f o r cont v a r i a b l e s or r e f e r e n c e cat
f o r c a t e g o r i c a l v a r i a b l e s
mu=mu_CB ,
# sd f o r cont Var iab les , e l s e NA
sd=sd_CB ,
# Covariance matrix f o r pa t i en t v a r i a b l e s
C=C_CB ,
# l i s t conta in ing p r o b a b i l i t i e s f o r c a t e g o r i c a l
va r i ab l e s , i f 2 c a t e g o r i e s only the p r obab i l i t y f o r
c a t e g o r i e " 1 "
prob = prob_CB )
# Surv iva l t imes f o r t r i a l AB







# Surv iva l t imes f o r t r i a l CB
Data_CB = surv_times ( data=Pat_CB ,
lambda_mort=lambda_mort_CB ,
nue_mort=nue_mort_CB ,





# Direc t comparison f o r t r i a l AB
results$directAB = directComp (
# data with c ova r i a t e s and su r v i v a l in fo rmat ion
data = Data_AB ,
# method f o r handl ing t i e s ( as in coxph )
method = method ,
# robust=T −−> using robust var i ance e s t imator
robust = robust
)
# Direc t comparison f o r t r i a l CB
results$directCB = directComp (
# data with c ova r i a t e s and su r v i v a l in fo rmat ion
data = Data_CB ,
# method f o r handl ing t i e s ( as in coxph )
method = method ,
# robust=T −−> using robust var i ance e s t imator
robust = robust
)
# aggregated data o f t r i a l AB
results$AGGR_AB = aggData ( varnames = varnames_AB ,
vartypes = vartypes_AB ,
data = Data_AB )
# aggregated data o f t r i a l CB
results$AGGR_CB = aggData ( varnames = varnames_CB ,
vartypes = vartypes_CB ,
data = Data_CB )
# i n d i r e c t comparison accord ing to Bucher
results$Bucher <− Bucher_fct ( results$directAB$logTE_AB ,
results$directCB$logTE_CB ,
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results$directAB$SElogTE_AB ,
results$directCB$SElogTE_CB )
# i n d i r e c t comparison us ing MAIC
results$MAIC <− MAIC_fct ( IPD_data = Data_AB ,
# aggregated data (mean ba s e l i n e va lue s )
aggr_data = results$AGGR_CB ,
# r e s u l t s o f aggregated t r i a l
results_aggr = results$directCB ,
# s i g n i f i c a n c e l e v e l
alpha = alpha ,
# robust var iance method
robust = robust ,
# pr in t e f f e c t i v e sample s i z e a dd i t i o n a l l y to r e s u l t s
o f i n d i r e c t comparison
p r in t_ES = pr in t_ES )
re turn ( results )
}
#######################################################################
# Function to conduct an i n d i r e c t comparison by the method o f Bucher
#######################################################################
Bucher_fct <− f unc t i on (
# r e s u l t s o f d i r e c t comparisons
# comparison between treatments A and B (AB) , C and B (CB)
# the logar i thm of the treatment e f f e c t ( odds r a t i o (OR) /hazard r a t i o (HR) )
logTE_AB ,
logTE_CB ,
# and the standard e r r o r o f the l og treatment e f f e c t
SElogTE_AB ,
SElogTE_CB ,
# s i g n i f i c a n c e l e v e l ( f o r c a l c u l a t i o n o f con f id ence i n t e r v a l )
alpha = .05
) {
# log es t imate (OR/HR) o f the i n d i r e c t comparison
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logTE <− logTE_AB − logTE_CB
# var iance o f d i r e c t comparisons
Var_AB <− SElogTE_AB^2
Var_CB <− SElogTE_AB^2
# var iance o f i n d i r e c t comparison
Var_logTE <− Var_AB + Var_CB
# con f idence i n t e r v a l l f o r i n d i r e c t l og Odds Ratio or Hazard Ratio ( Estimate )
logCI <− logTE + c (−1 ,1) ∗ qnorm(1−alpha/ 2) ∗ s q r t ( Var_logTE )
# save i n d i r e c t treatment e f f e c t (OR/HR) and the corre spond ing 95% CI
result_indComp <− exp ( c ( logTE , logCI ) )
names ( result_indComp ) <− c ( " exp ( co e f ) " , " lowerCI " , " upperCI " )
re turn ( result_indComp )
}
#######################################################################
# Function to conduct an i n d i r e c t comparison by the
# matching adjusted i n d i r e c t comparison (MAIC)
#######################################################################
MAIC_fct <− f unc t i on (
# ind i v i dua l pa t i en t data (IPD)
IPD_data ,
# aggregated data (mean ba s e l i n e values , i n c l ud ing propor t i ons f o r
c a t e g o r i c a l v a r i a b l e s )
aggr_data ,
# r e s u l t s o f aggregated t r i a l ( treatment e f f e c t and the corre spond ing 95%
con f idence i n t e r v a l )
results_aggr ,
# s i g n i f i c a n c e l e v e l
alpha = .05 ,
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# robust var iance method ( us ing a sandwich es t imator to c a l c u l a t e the
var iance o f the es t imate obtained by MAIC)
robust = TRUE ,
# pr in t e f f e c t i v e sample s i z e a dd i t i o n a l l y to r e s u l t s o f i n d i r e c t comparison
p r in t_ES = TRUE ,
# vecto r with names o f va r i ab l e s , which are not used f o r matching
prog_var
) {
# i d e n t i f y va r i ab l e names used f o r matching
names_match <− names ( aggr_data )
names_match <− names_match [ which ( ! ( names_match %in% prog_var ) ) ]
# exc lude v a r i a b l e s which are not needed f o r matching
IPD_data_matching <− IPD_data [ , names_match ]
# cente r the IPD by the mean ba s e l i n e c h a r a c t e r i s t i c s o f the aggregated data
IPD_centered <− t ( t ( IPD_data_matching )−aggr_data [ names_match ] )
k <− nco l ( IPD_centered )
# func t i on to opt imize
fct <− f unc t i on ( beta , X ) {
Xmatrix <− as . matrix (X )
sum( exp ( Xmatrix %∗% beta ) )
}
# opt imi se betas in func t i on " f c t "
# Broyden−Fletcher−Goldfarb−Shanno (BFGS) method , non−l i n e a r opt imiza t i on
# i n i t i a l vec to r o f weights : a l l 0
beta_hat <− optim ( rep (0 , k ) , fct , method="BFGS" , X=IPD_centered ) $par
# c a l c u l a t e weights
weights <− exp ( as . matrix ( IPD_centered ) %∗% beta_hat )
# f i t weighted r e g r e s s i o n model ( cox/ l o g i s t i c )
results_IPD <− directComp_adj ( IPD_data ,
weights=weights ,
robust=robust )
# f i n a l comparison us ing Bucher Method
result_indComp <− Bucher_fct ( logTE_AB = results_IPD$logTE ,
logTE_CB = results_aggr$logTE ,
SElogTE_AB = results_IPD$selogTE ,
SElogTE_CB = results_aggr$selogTE )
i f ( p r i n t_ES ) {
# c a l c u l a t e e f f e c t i v e sample s i z e (ESS)
n <− nrow ( IPD_data )
n_effective <− (sum( weights ) ) ^2 / (sum( weights ^2) )
samplesize <− c (n , n_effective )
names ( samplesize ) <− c ( "n␣IPD" , "n␣ e f f e c t i v e " )
# return r e s u l t s o f i n d i r e c t comparison and ESS
return ( l i s t ( result_indComp = result_indComp ,
sampleSize = samplesize ) )
} e l s e {
# return r e s u l t s o f i n d i r e c t comparison
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